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ABSTRACT 
Nuo Xu: Optimizing and understanding checkpoint inhibition therapy and chimeric antigen 
receptor therapy against breast cancer 
(Under the direction of Jonathan S. Serody) 
 
Cancer immunotherapies, which include chimeric antigen receptor therapy (CAR-T) and 
immune checkpoint inhibition therapy (ICI), have revolutionized the field of cancer therapy.  
Those therapies modulate the immune system to recognize and target cancer cells. Despite the 
success of immunotherapy, a large majority of cancer patients do not respond to these 
immunotherapies. The goal of my research is to understand the mechanisms that cause resistance 
to immunotherapy and utilize novel combinatorial approaches to enhance current 
immunotherapy. 
 
We developed strategies to enhance the activity of CAR T cells against solid tumors by 
utilizing a mouse model of breast cancer.  We found that CAR T cells generated from Th/Tc17 
cells had improved persistence in the TME.  Administration of the STING agonist DMXAA 
greatly enhanced tumor control and was associated with Th/Tc17 CAR T cell persistence and 
recruitment into the TME. Additionally, DMXAA strongly modulated the immunosuppressive 
TME through alterations in the balance of immune-stimulatory and suppressive myeloid cells.  
Sustained long term tumor regression was accomplished with the addition of anti-PD-1 and anti-
GR-1 mAb to Th/Tc17 CAR T cell therapy.  This study provides a new understanding of the 
approaches needed to enhance adoptive T cell therapy in solid tumors.
 iv 
Another focus of my research is to further understand the mechanism by which ICI therapy 
boosts the anti-tumor response. To do this, we engineered a novel mammary mouse tumor that is 
sensitive to immune checkpoint therapy. Using this model, we uncovered that ICI therapy 
induced T follicular helper cell activation of B cells to facilitate the anti-tumor response. We also 
showed that B cell activation of T cells and the generation of antibody are key to the 
immunotherapy response. This work uncovers new components of the response to immune 
checkpoint inhibitors. 
 
In conclusion, this work has provided insight into mechanisms that can enhance the anti-tumor 
response of immunotherapies in breast cancer. These strategies, either through harnessing the 
activity of B cells or by providing STING agonists, have the potential to translate into the clinic 

















To my parents, Dr. Xu Jifeng and Dr. Zhao Wenxia, 
 






















My journey to PhD is both a tough and rewarding process. But it is because those people who 
care and believe me, support me to overcome all challenges during graduate school, especially 
during the last year with pressures from both the pandemic and the government. 
 
Among those people that support me, I want to first thank Dr. Jonathan Serody who helped me 
through the whole graduate study. You guided me from a beginner, who did not know the three 
signals for T cell activation, till now an immunologist. You allowed me to independently 
discover my interest in tumor immunotherapy, and also provided priceless advice on my projects 
whenever I encountered difficulties.  Also, I want to thank my committee members who gave me 
suggestion during my committee meeting, especially the first couple ones when none of my 
experiment worked. In addition, I want to thank current and alumni members from Serody lab, 
including Sonia, Malini and Alex, who helped me on my project and the writing of the 
dissertation as well as others who provided useful guidance during my research. Besides, 
members from the neighboring labs (Chuang, Peishun, Zengli and Dan), you shared me with 
your experiences inside and outside academia so I can become an eligible researcher now. 
 
Secondly, I want to thank my friends, Dr. Li Qian and Jiandong Liu, who taught me countless 
research and life experience during my first year lab rotation, and Shengjie, Shengwei, Wei, 
Xuhui and Yuanfan who helped me for my academic and life decision, also Jitong, Gang, Yiwen, 
 vii 
Paul, Qishun, Cheng, Yiqing, Yunyan, Hadeng and other friends on volleyball, basketball courts 
or in front of video game when I need to escape from the busy graduate study. 
 
Last but not the least, I want to thank family. My parents. Your achievements spurred me 
becoming a scientist. You trust me, no matter I am at low or high tide of my life. My 
grandmother, who understand me for not being able to go back to China to see her often during 
my graduate study. I want to specially thank Chuxuan, my girlfriend who supported me during 
this year of pandemic and all challenges we have faced, which makes me believe we can also 






























TABLE OF CONTENTS 
 
LIST OF TABLES ..........................................................................................................................x 
LIST OF FIGURES........................................................................................................................xi 
LIST OF ABBREVIATIONS........................................................................................................xv 
CHAPTER I. INTRODUCTION ...……...………………………......…………………..………..1 
Tumor Immunology ...…………...………………………………...…………..……...…..1 
T cell-based tumor immunotherapy ……………………………………………………….5 
Breast cancer ...……………………………………………………………………...…...10 
Chimeric antigen receptor T cells therapy (CAR-T) ...…………....………………...…..14  
Immune checkpoint inhibitor (ICI) therapy …………………………………...………...29  
Conclusion ...……………………………………………………………………….........39 
Figures ...……………………….......……………………………………………….........40 
CHAPTER II. SINGLE CELL SEQUENCING REVEALS A CRITICAL ROLE FOR T  
CELL TRAFFICKING AND MODULATION OF THE TUMOR MICROENVIRONMENT  
BY A STING AGONIST IN THE EFFICACY OF CAR T CELLS IN LOCALLY  








CHAPTER III. B CELLS AND T FOLLICULAR HELPER CELLS MEDIATE RESPONSE TO 
CHECKPOINT INHIBITORS IN HIGH MUTATION BURDEN MOUSE MODELS OF 





Tables and figures .......................………….....…………...…....……..….…………….112 
Methods .....................……………………………………...…....……..……………….142 




LIST OF TABLES 
 
Table 1. Response to combination immunotherapy. ......……………..…………...…………....112 























LIST OF FIGURES 
 
Figure 1.1: The suppressive tumor microenvironment with critical factors that contribute to  
the anti-inflammatory environment. ............................................................................…….........40 
 
Figure 1.2: T cells recognize and kill tumor cells through T cell receptor or chimeric antigen 
receptor. .....................................……………………………………………………………...…41 
 
Figure 1.3: The intracellular and extracellular of CAR construct and the evolution from  
first generation of CAR (T-bodies) to third generation of CAR construct. ....................................42 
 
Figure 1.4: The function of cGAS-STING that initiate the immune response. ............................43 
 
Figure 2.1: Th/Tc17 CAR-T cells exhibit enhanced early control of tumor growth over 7/15 
CAR-Ts due to enhanced persistence in the tumor. ................................................…..….…..….57 
 
Figure 2.2:  Tumor control by Th/Tc17 CAR-T cells is enhanced by DMXAA injection due  
to altered composition of tumor infiltrating immune cells. …........................................……......59 
 
Figure 2.3:  DMXAA treatment enhances the number and cytotoxicity of Tc17 CAR-T cells  
in the TME, though they eventually become exhausted. ...................................……………..….61 
 
Figure 2.4:  DMXAA reduces the accumulation of suppressive macrophages and enhances  
the trafficking of T cells in the TME, but this effect is eventually lost due to the return of 
immunosuppressive cells. .........................................................………………………………....64 
 
Figure 2.5:  DMXAA is required for tumor remission after Th/Tc17 CAR-T, DMXAA,  
anti-PD-1 and anti-Gr1 treatment. ....................................................………………………..…..67 
 
Figure 2.6:  Depletion of myeloid cells with anti-Gr1 during Th/Tc17 CAR+D+aP regimen  
leads to cytokine release-like syndrome. .......................................................……………..…….69 
 
Figure 2.7:  IL-7/15 cultured LH28BBz or LHBBz CAR-T cells fail to control in vitro or in  




Figure 2.8:  7/15 CAR-Ts fail to control NT2 tumor growth in vivo compared to Th/Tc17  
CAR-Ts. ............................................………………………………………….....…………..….73 
 
Figure 2.9: DMXAA treatment induces global changes in immune cells of the TME 7 days  
After therapy. .........................................………………………………......………….…………75 
 
Figure 2.10: Th/Tc17 CAR-Ts, but not Tc17 CAR-Ts alone, control tumor growth in the 
presence of DMXAA. ...................................................................................................................76 
 
Figure. 2.11:  DMXAA treatment enhances the number and cytotoxicity of Th17 CAR-T  
cells in the TME. .......................................................................……………....…………………77 
 
Figure 2.12:  DMXAA treatment enhances anti-tumor function of Th/Tc17 CAR-T cells in  
an IFN-γ-dependent manner. ............................................................................………………....79 
 
Figure 2.13:  T cell exhaustion limits the cumulative beneficial effect of DMXAA on  
Th/Tc17 CAR-T therapy. .............................…………….....…………………………………....80 
 
Figure. 2.14: Macrophages and myeloid cells are reduced upon DMXAA treatment, but  
later replaced by suppressive myeloid cells. ………....…………………....………………...…..82 
 
Figure 2.15:  Anti-PD-1 and anti-GR-1 mAb does not increase therapeutic benefit of 7/15  
CAR-T cells with DMXAA. ......………………………………………..………………...……..84 
 
Figure 2.16:  Differences in proliferative capacity and generation of central memory in 
Th17/Tc17 CAR-Ts. ........................................……………………..…………………………...85 
 
Figure. 2.17:  Model of the Activity of CAR T cells against Breast Cancer. ...............................87 
 
Figure 3.1: Intrinsic tumor and immune cell gene expression features in mouse mammary  
tumor models. ....................................................................…………….………………...……113 
 
Figure 3.2: Intentional elevation of tumor mutation burden sensitizes tumors to  




Figure 3.3: Signature testing on human studies. ………………………….………………........116 
 
Figure 3.4: Features of response to anti-PD1/anti-CTLA4 therapy in murine tumors. ..............118 
 
Figure 3.5: Single cell RNA-seq of KPB25Luv tumors with or without  
anti-PD1/anti-CTLA4 therapy. ...................................................................................................120 
 
Figure 3.6: Immune cell depletion of key immune cell populations during immune  
checkpoint therapy. .....................................................................................................................122 
 
Figure 3.7: Testing B Cell Activation and IgG Functionality during immune checkpoint 
therapy. ........................................................................................................................................124 
 
Figure 3.8: Somatic mutation burden and response to immune checkpoint therapy in mouse 
models of triple negative breast cancer. ......................................................................................127 
 
Figure 3.9: In vitro characterization of mouse tumor-derived cell lines mutagenized by  
Apobec3 or by exposure to short-wave ultra violet radiation. ....................................................129 
 
Figure 3.10: Supervised analysis of anti-PD1/anti-CTLA4 therapy sensitive and resistant  
mouse mammary tumors. ............................................................................................................131 
 
Figure 3.11: Validation of immune cell signatures and demonstration of key immune  
features for individual tumor cell lines. ......................................................................................133 
 
Figure 3.12: Single cell RNA-seq of T11-Apobec tumors with or without  
anti-PD1/anti-CTLA4 therapy. ...................................................................................................135 
 
Figure 3.13: Flow cytometry analysis of targeted immune cell depletion in tumors and  
spleens in tumor bearing mice receiving anti-PD1/anti-CTLA4 therapy. ..................................138 
 

































LIST OF ABBREVIATIONS 
 
APC Antigen presenting cell 
  
Batf3 basic leucine zipper transcriptional factor ATF-like 3 
  
BCR B cell receptor  
  




CRS Cytokine release syndrome 
  
CTLA-4 Cytolytic T lymphocyte antigen 4 
  
ER Estrogen receptor 
  
GEMM genetically engineered mouse model 
  
HER2 Human epidermal growth factor receptor 2  
  
ICI Immune checkpoint inhibitor therapy  
  
IDO Indoleamine 2,3-dioxygenase 
  
ITIM immunoreceptor tyrosine-based inhibition motif  
  
Lag3 Lymphocyte activation gene 3  
  
mAb Monoclonal antibody  
  
MDSC Myeloid-derived suppressive cells 
  
MMTV mouse mammary tumor virus  
  
NLR NOD-like receptor 
  




Program death receptor 1 
  
PGE2 Prostaglandin E2  
  
PR Progesterone receptor 
 
 xvi 
scFv single-chain variable fragment  
  
scRNA-seq Single cell RNA sequencing 
  
STING The stimulator of interferon genes pathway  
  
Tcm Central memory T cell  
  
Tfh Follicular helper T cell  
  
TILs Tumor infiltrating lymphocytes 
  
TITs Tumor infiltrating T cells 
  
TLR Toll-like receptor 
  
TCR T cell receptor 
  
TMB Tumor mutation burden  
  
TME Tumor microenvironment 
  
TNBC Triple-negative breast cancer 
  
Treg Regulatory T cell 
  





CHAPTER I. INTRODUCTION 
 
Tumor immunology 
The immune system functions to protect the host against foreign pathogens. In order for the 
immune system to function, it must be able to distinguish “self” from “non-self” molecules[1, 2].  
Malignant cells arise from an accumulation of mutations in oncogenes and tumor suppressor 
genes that alter normal mechanisms limiting cellular proliferation[3].  These mutations lead to 
the generation of novel peptides that can be recognized by the immune system as, “non-self”[4].  
During the early part of this century, scientists proposed that the immune system plays a crucial 
role in the anti-tumor response by recognizing differences between healthy “self” cells and 
malignant “non-self” cells[1, 5].  Since then, there has been increasing new evidence 
demonstrating the critical role of the immune response against tumors.  
 
1.1 The innate and adaptive immune systems in the tumor microenvironment (TME) 
Immune cells closely interact with tumor cells in the TME. The TME refers to the tumor and 
its’ surrounding environment, which includes blood and lymphatic vessels, stromal cells, 
extracellular matrix, and immune cells.  The TME plays a key role in limiting the ability of anti-
tumor immune cells to migrate into and proliferate at the tumor site[6, 7].  Besides tumor cells, 
the majority of cells in the TME are tumor stromal cells, which includes tumor associated 
epithelial cells and fibroblasts.  These cells can promote tumor metastasis via the formation of 
blood vessels and can diminish the function and migration of immune cells in the TME[8-10].  
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Immune cells play a complicated role in tumor biology. Both the innate and adaptive immune 
system are important components of the TME.  The innate immune system is the first line of 
defense against foreign pathogens and induces a non-specific and rapid response against 
stimulus.  One key component of innate immune cells is antigen presenting cells (APC) that can 
initiate the immune response.  The activation of APCs is through the binding of pattern 
recognition receptors on/in APCs, such as toll-like receptors (TLR) to extracellular stimulus for 
the detection of extracellular danger, or NOD-like receptors (NLR) to intracellular stimulus for 
intracellular infections[11].  Another critical innate immune population, natural killer cells, can 
directly kill target cells by producing lytic proteins such as granzyme, perforin, or cytokines like 
TNF.  Importantly, innate immune cells activate the adaptive immune system in a specific way.  
APCs process proteins into small peptides that are presented on the surface of those cells by class 
I and class II MHC proteins.  These peptide/MHC complexes are recognized by CD8+ and 
CD4+ T cells[12].  However, T cell activation requires two additional signals: co-stimulation of 
the T cell from the engagement of protein ligands such as CD80/86 on the APC with CD28 a 
receptor expressed by T cells and the interaction of cytokines generated by APCs with cytokine 
receptors on the T cell[13, 14].  These cytokines are critically important for the polarization of 
the T cell response toward anti-tumor Th1 cells or a pro-tumorigenic Tregs[15, 16].  APCs and 
CD4+ T cells play a critical role in the activation of B cells where they generate cytokines such 
as IL-21 and interact through the CD40/CD40-ligand pathway to promote the germinal center 
reaction, B cell memory and the generation high avidity antibodies by plasma cells[17, 18].  
 
There are multiple different subsets of T cells, which can be classified into cytotoxic CD8+ T 
cells and helper CD4+ T cells.  Activated cytotoxic CD8+ T cells mediate tumor cell lysis 
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through the release of cytolytic granules, containing the pore-forming protein, perforin, and 
granzymes which mediate cellular apoptosis[19]. In addition to CD8+ T cells, CD4+ helper T 
cells are also involved in the anti-tumor response through production of cytokines that shape the 
pro-inflammatory environment to enhance the function of tumor-specific T cells[20, 21].  CD4+ 
helper T cells are also important for the survival of CD8+ T cells[22, 23].  However, there are 
also subpopulations of T and B lymphocytes that suppress the immune response against cancer.  
For example, T cells that express the forkhead box transcription factor (FoxP3), termed 
regulatory T cells (Tregs), suppress the adaptive immune response[24].  Similar populations of B 
cells that express IL-10 and/or IL-35 are termed regulatory B cells (Bregs) and also function to 
suppress the anti-tumor immune response[25, 26]. 
 
1.2 Suppressive mechanisms of the TME to inhibit the anti-tumor immune response  
The balance between the anti-tumor effector and inhibitory immune response in the TME is 
critical to tumor progression and metastasis.  A key hallmark of cancer progression is their 
ability to evade or resist immune surveillance[27].  Suppressive innate and adaptive immune 
cells can modify the TME to form a unique anti-inflammatory environment that abrogates the 
anti-tumor response[28, 29] (Figure 1.1). 
 
In conditions that favor the elimination of tumors, the release of tumor antigen first alerts the 
immune system through the activation of innate immune cells.  Tumor antigens are generated 
from the unstable tumor genome due to the accumulation of mutations and can typically be 
separated into the following: 1) neoantigens, which arise from genomic mutations that alter the 
protein sequence or structure, resulting in antigens that are “foreign” to the immune system[30], 
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and 2) tumor associated antigens, which can be normal (unmutated) proteins that are either 
overexpressed or abnormally expressed after embryonic development[4, 31].  Tumor antigens 
are released into TME, and captured by APCs (in most cases DC cells), followed by the 
phagocytosis of tumor antigens by APCs.  The APCs process the antigen and load the antigenic 
peptide onto major histocompatibility complex (MHC) molecules, and then display the 
peptide/MHC molecule complex on the cell surface.  T cells with a T cell receptor (TCR) 
specific for the peptide/MHC complex will recognize the complex, and the binding results in T 
cell activation, proliferation and differentiation of T cells specific for these tumor antigens[32].  
 
Previous work has indicated that chronic inflammation as found in the TME is associated with 
cellular, metabolic and pathway changes that are critical to the induction of an 
immunosuppressive TME[33, 34].  Treg cells are programmed to limit the expansion of T cells 
that have escaped central deletion in the thymus.  Treg cells limit the expansion and function of 
adaptive immune cells in part by having stronger interactions with APCs[35-37].  Additionally, 
Tregs, tumor cells and stroma recruit immature myeloid cells to the TME[38-40].  The immature 
myeloid cells have been characterized as myeloid derived suppressor cells (MDSCs).  MDSCs 
are bone marrow derived myeloid cells that are generated during chronic inflammation found in 
the TME.  MDSCs suppress the adaptive immune response through a number of mechanisms 
such as the generation of arginase, increased expression of reactive oxygen species and nitric 
oxide, and the generation of PGE2, Cox2 and cytokines such as IL-10[41, 42].  Additionally, as 
chronic inflammation is critical for the generation of MDSCs, they are often increased in number 




Another characterized population of immunosuppressive myeloid cells found in the TME are 
M2-like or alternatively activated macrophages.  Macrophages can exist on a continuum from 
M1-like that generate IL-12, and IFN-γ, to M2-like that generate IL-10, and have increased 
expression of the scavenger mannose and galactose E and C-type receptors[44-46].  Both of 
these populations (and intermediate entities) are found in the TME with the ratio of 
suppressive/activating macrophages important to the immunosuppressive TME.   
 
The discovery of the anti-inflammatory network in the TME has allowed for the design of 
therapeutics that disrupt the immune-regulatory network in the TME.  Methods to stimulate the 
host’s immune response against tumors in the TME, termed tumor immunotherapy, has 
revolutionized tumor treatment and provides effective treatment for a subset of cancer 
patients[47]. 
 
T cell-based tumor immunotherapy 
Tumor immunotherapy utilizes antibodies, cytokines, or small molecules that activate specific 
pathways in innate or adaptive immune cells to target tumor cells.  The field of tumor 
immunotherapy began in the late 19th century when Dr. William B. Coley at New York Hospital 
treated tumor patients by directly injecting a mixture of killed bacteria, termed Coley’s toxins, 
into the tumor site[48].  This bold treatment induced tumor regression in some patients[49].  
However, the idea of harnessing the body’s immune system to fight against cancer lay dormant 
for the next several decades, in part, due to the development of radiotherapy and chemotherapy. 
Advancements in the fields of immunology and biotechnology has again placed tumor 
immunotherapy at the forefront as a viable option to treat cancer.  To date, there are hundreds of 
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tumor immunotherapies in clinical trials[50, 51].  The majority of these treatments attempt to 
activate tumor infiltrating T cells (TITs) that are dysfunctional in the TME, either by directly or 
indirectly targeting immune cells in the TME to boost anti-tumor activity[51].  
 
2.1 The TME inhibits TITs activity against tumors 
Under physiological conditions, the immune system is activated and can recognize and 
respond to a “foreign” pathogen.  Once the pathogen is cleared, a strong immune response 
against the pathogen is no longer needed and inhibitory signals ensue, which results in the 
dampening of the immune response, leading to immune homeostasis.  This does not occur in 
chronic infections where the initial immune response is insufficient to clear the pathogen.  Over 
time, the robustness of the immune response decreases which is associated with the upregulation 
of proteins on adaptive immune cells that limit their function and the recruitment, expansion, and 
persistence of immunosuppressive cells.  In a similar vein, the inability of the immune response 
to eradicate cancer leads to the development of an inhibitory TME[52-54].  A critical effector 
arm of the anti-tumor immune response that is suppressed in the TME is mediated by tumor 
infiltrating lymphocytes (TILs)[55] (Figure 1.1).  TILs are adaptive immune cells specific for 
tumor cells and are found within or around tumor. There are a multitude of adaptive immune 
cells that make up the TIL population.  This includes cytolytic CD8+ T cells, Th1 T cells that 
generate the proinflammatory cytokine IFN-γ, memory B cells that activate T cells, generate 
cytokines and lead to the generation of plasma cells and cells with more ambivalent function 
such as Th/Tc17 cells[56-59].  In addition to acting within the TME, T cells can circulate into 
peripheral tissues and develop into long-lived memory T cells to prevent tumor relapse after the 
clearance of primary tumors[60-62].  TILs are critical to the immune response to cancer, and in 
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the early 2000s, studies found that the presence of TILs was associated with a favorable 
prognosis in cancer patients[63-65].  
 
Recent studies evaluating the activity of TILs have focused on TITs [66].  The activation of T 
cells requires multiple well-described processes.  The engagement of the TCR on the T cell to 
MHC/peptide complex on targeted cells is signal 1. MHC plays a major role in initialing the 
response of T cells.  There are two classes of MHC molecules, class I MHC (MHCI), expressed 
on all nucleated cells [67]and II MHC (MHCII), mainly expressed constitutively on professional 
APCs, including DCs, macrophages and B cells[68].  MHCI can load intracellular antigen to 
activate CD8 T cells, while MHCII binds to phagocytosed extracellular antigen and present it to 
activate CD4 T cells.  Notably, professional APCs, for example, DCs, can also uptake and 
process exogenous antigen to present antigen to stimulate CD8 T cells, named cross-
presentation.  Cross-presentation is a key process during tumor antigen recognition, and basic 
leucine zipper transcriptional factor ATF-like 3 (batf3) expressing CD103 positive DCs are 
critical to the function of cross priming cytolytic CD8 T cells against tumor cells[69].  Signal 1 
alone is not sufficient to activate T cells.  Activation of the T cell via peptide/MHC binding to 
the TCR in the absence of co-stimulation results in T cell anergy in part due to the lack of 
generation and response to cytokines critical for T cell expansion[70].  T cell activation requires 
co-stimulation of the T cell by APCs, which is signal 2. Co-stimulation occurs through the 
interaction between co-stimulatory receptors expressed on the T cell surface, such as CD28 or 4-
1BB, with their ligands on APCs, which includes CD80/86 or 4-1BBL[71, 72].  In addition to 
signal 2, cytokines provide a third signal which allows for differentiation of CD4+ T cells and 
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the expansion of CD8+ T cells[13].  The combination of these three signals results in the 
activation, differentiation, and expansion of antigen specific T cells.  
 
Over time, T cell activation in the immunosuppressive TME is diminished in part through the 
disruption of tumor antigen processing and the recruitment of immunosuppressive cells that 
produce immunosuppressive proteins such as TGF-β and/or IL-10 to limit the function of T cells 
in the TME.  A robust CD8+ T cell response includes the expansion of activated T cells and 
recognition of target cells through the interaction of TCR on T cells and peptide/MHC molecules 
on target cells, which results in the killing of target cells.  However, in the suppressive TME, 
APCs lose the ability to prime tumor specific T cells in the TME[73].  Studies have found that 
DCs in the TME have decreased expression of MHC molecules as well as genes associated with 
antigen processing, such as ER-resident aminopeptidases[74].  Furthermore, DCs downregulate 
expression of CD80/86 and fail to co-stimulate T cells through interaction with CD28 on T 
cells[75].  Finally, DCs lack the ability to produce cytokines necessary to support the activity of 
cytolytic T cells. Instead, DCs develop into a suppressive phenotype as indicated by the secretion 
of anti-inflammatory cytokines such as IL-10[76].  
 
In addition to inhibiting T cell activation, the effector function of activated T cells is also 
suppressed in the TME.  The anti-tumor function of T cells requires an optimal environment that 
provides nutrients and cytokines necessary to support T cell effector function.  However, 
immunosuppressive cells and pathways in the TME limit T cell effector function.  The TME has 
a relatively hypoxic and acidic environment that limits the effector activity of activated T 
cells[77].  T lymphocytes after activation utilize glucose rather than oxidative phosphorylation 
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for energy[78].  Due to intense competition with tumors cells for glucose uptake, the metabolic 
profile in the TME may limit T cell proliferation[79].  In addition, the presence in the TME of 
anti-inflammatory cytokines, including IL-10 or TGF-β, and suppressive proteins, such as 
indoleamine 2,3-dioxygenase (IDO) and prostaglandin E2 (PGE2), strongly restrict the activity 
of T cells[77, 79].  
 
Furthermore, the sustained interaction between tumor specific T cells with tumor and myeloid 
cells in the TME can drive these T cells to become dysfunctional, which is manifested by 
decreased proliferation and effector function[80].  Mechanistically, T cell exhaustion has been 
characterized predominantly for CD8+ T cells in the setting of chronic viral infection.  This 
process leads to increasing loss of effector function by these cells with cytolytic activity lost first 
then cytokine production and finally T cell proliferation[81, 82].  There are a substantial number 
of proteins that inhibit T cell function in the TME.  Two of these pathways, are CTLA-4 and PD-
1/PD-L1.  These pathways inhibit T cell activity by blocking (1) cell proliferation via the 
induction of cell cycle arrest (mechanism for CTLA-4) [83]or (2) phosphatase activity of TCR 
downstream signaling motif (mechanism for PD-1/PD-L1 interaction)[84, 85].  Both of these 
pathways have been clinically targeted through the generation of monoclonal antibodies specific 
for these proteins.  
 
The intervention of the processes mentioned above has been the main purpose for T cell-based 
immunotherapy in efforts to restore the activity of TITs against tumor cells. Although 
approaches vary, they can be classified as 1) targeting the negative regulatory factors on T cells 
such as checkpoint inhibitor therapy, 2) the adoptive transfer of T cells that are specific for tumor 
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cells such as chimeric antigen T cells therapy, or 3) modulation of the immune pathway to 
enhance the function of T cells against tumor cells. Recent evidence from preclinical and clinical 
trials have shown multiple different approaches may be required for anti-tumor clinical efficacy, 
since the mechanisms of tumor immune evasion can be complicated. Further understanding of 
these treatments will allow for better therapeutics to eliminate the tumor. 
 
Breast cancer 
3.1 Breast cancer subtypes and treatment 
Breast cancer is the most frequent malignancy in women and is the second leading cause of 
cancer deaths among women in the United States[86].  The prognosis and treatment of breast 
cancer depends upon a variety of factors including the age of the patient, the tumor stage, and 
most importantly, the molecular subtype of the tumor.  Based on the expression of hormone 
receptors, breast cancer can be categorized into 4 subtypes: estrogen receptor (ER+), 
progesterone receptor (PR+), human epidermal growth factor receptor 2 (HER2)-enriched and 
triple-negative breast cancer (TNBC)[87].  Breast tumors that express ER and/or PR comprise 
approximately 60% of all diagnosed breast cancer cases.  Patients with ER or PR tumors have a 
better overall survival in part due to tumor intrinsic characteristics and in part due to improved 
therapy targeting ER/PR[88].  
 
HER2 breast cancer overexpresses the proto-oncogene HER2/neu and accounts for 20%-30% 
of total breast cancer patients.  Patients whose tumors overexpress HER-2/neu have more 
aggressive disease progression than other subtypes of breast cancer[89].  Recent therapies 
targeting HER2, such as trastuzumab, have successfully improved the overall outcome for 
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HER2+ breast cancer patients.  However, patients can develop resistance to HER2 targeted 
therapies, which creates challenges in treating HER2 breast cancer patients.  The mechanism for 
HER2 resistance is still under investigation.  One current theory is that the activation of 
downstream signaling pathways independent of HER2 receptor is responsible for resistance to 
HER2 specific therapies[90, 91].  Thus, instead of interrupting the HER2 signaling pathway, 
directly targeting HER2/neu on tumor cells may improve the outcome of these patients.  This can 
be performed by the generation of chimeric antigen receptor modified T cells (CAR-T cells) 
specific for HER-2/neu.  However, CAR-T cell therapy against HER2+ tumors have 
demonstrated minimal efficacy in clinical trials[92]; therefore, further investigation is required in 
efforts to modify and enhance the therapeutic effect of an immunotherapy targeting HER2 
cancer. 
 
The final subtype, TNBC, lacks expression of estrogen, progesterone, and HER2 receptors and 
has the worst clinical prognosis of all the subtypes[88].  Since TNBC lacks these receptors, 
hormone and HER2-targeted therapies are ineffective.  TNBC is the most heavily immune 
infiltrated of the different types of breast cancer[93].  As a result, ICI has also been proposed to 
treat patients with TNBC.  Further studies are required to enhance the effectiveness of 
immunotherapies for TNBC patients.  
 
3.2 Mouse models of breast cancer  
Currently, there are multiple mouse models of breast cancer, including 1) xenografts of either 
human cancer cell lines or patients-derived tumor samples into immunocompromised mice as 
well as 2) genetically engineered mouse models (GEMMs)[94].  Although xenograft models 
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allow for the study of human tumors, these models have limitations.  First, human tumors are 
typically established heterotopically but not orthotopically. The abnormal location of the tumor 
may alter the TME, and confound data generated in the model.  Secondly, since these mouse 
models require the use of immunocompromised mice.  Depending on the model, these mice lack 
(1) human adaptive immune cells; (2) human innate immune cells (3) human stroma, and human 
endothelium unless these are specifically infused into the mouse model.  Generation of adaptive 
immune cells is more complicated as the thymus is critical to the selection of T cells from the 
bone marrow.  Thus, the absence of a human thymus greatly limits the expansion of human T 
cells.  As B cells require T cell help to respond to the majority of antigens, the absence of T cells 
greatly limits the expansion and function of human B cells.  The absence of a robust TME in 
these models is a significant factor in the limited utility of these models to predict clinical 
responses to immunotherapy[95].  Finally, while researchers can transfer human T cells into 
immunocompromised mice to study T cell-based immunotherapies, the persistence, metabolism 
and proliferation kinetics of T cells are altered in the manipulated environment[96].    
 
In contrast to xenograft mouse models, GEMMs provide a physiological immunocompetent 
environment to study breast cancer.  While tumors from GEMMs are derived from a murine 
host, these mouse tumor models have similar gene expression profiles to human cancer and 
develop a TME similar to that found in humans[97].  Therefore, GEMMs provide both tumor 
intrinsic and extrinsic factors that are relevant to clinical tumors.  One commonly used model is 
the NT2 tumor, which is derived from FVB/N-Tg(MMTVneu) mouse.  In this mouse model, the 
expression of the rat proto-oncogene Neu, a rat homolog to human HER2, is driven by the mouse 
mammary tumor virus (MMTV) promoter resulting in Neu overexpression in mammary tissues 
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leading to spontaneous tumors[98].  From these spontaneous tumors, the Jaffe laboratory 
generated a cell line NT2, that can be orthotopically utilized for immunotherapy studies.  One 
interesting feature of the NT2 mouse is that the tumor can be developed in transgenic FVB/N-
Tg(MMTVneu) mice but is eliminated in non-transgenic wild-type FVB mice.  This is because 
Neu is also expressed in the thymus of the transgenic mice.  As a result, high affinity Neu-
specific T cells are deleted in the thymus by negative selection.  As a consequence, Neu-specific 
T cells in FVB-N-TG(MMtVneu) mice are low avidity T cells similar to those found in humans.  
This characteristic renders NT2 a relevant tumor model to study human cancer where the 
tumorigenesis can be partially due to the development of tolerance against tumor antigens.  
 
A mouse model that provides clinical relevance to human TNBC is the T11 tumor.  T11 
mammary gland tumors develop through the deletion of the tumor suppressor gene p53, and this 
tumor displays molecular and histological patterns similar to human claudin-low tumors (a 
subtype of TNBC), including aggressive tumor progression and the absence of ER, PR and Her2 
expression[99].  Moreover, our group has shown that the TME of mice with T11 tumors 
recapitulates the TME in humans with claudin-low tumors including the presence of Tregs, 
MDSCs as well as activated and exhausted T cells and B cells[100].   
 
In summary, GEMMs are valuable tools for preclinical cancer therapy research.  The use of 
GEMMs for breast cancer enables researchers to study the intricacies of the TME and the 
influence of the TME on different immunotherapy methods.  The understanding of the 
interaction between TME and T cell-based immunotherapy can lead to the design of novel 
therapies with advance efficacy in treating breast cancer.   
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Chimeric antigen receptor T cells therapy (CAR-T) 
The development of T cells take place in thymus, where negative selection results in the death 
of T cells expressing a TCR with high affinity toward self-antigens[101].  Negative selection 
mediates central tolerance of T cells to limit the development of autoimmunity.  As a result of 
this process, T cells that recognize overexpressed tumor antigens typically have low affinity 
TCRs with low avidity for interactions with peptide/MHC.  These T cells are limited in the 
ability to generate a rapid, robust response critical for the anti-tumor immune response.  To 
overcome this limitation, investigators have generated T cells with (1) higher affinity/avidity by 
cloning higher affinity TCR into T cells [102]or (2) used T cells that recognize tumor antigens 
independent of the TCR.  One approach to the latter is to generate the binding moiety of an 
antibody and link this to the signaling function of a T cell (Figure 1.2).  These are termed 
chimeric antigen receptors (CARs)[103]. CARs can be engineered into T cells that are isolated 
from patients and infused back for in vivo efficacy. This therapy is termed CAR-T cell therapy, 
and has several features[104].            
1. CAR-T cell therapy does not require the presence of tumor specific T cells, which may be 
limiting in some cancer patients.  
2. The activity of CAR-T cells against tumor cells bypasses the requirement for antigen 
presentation during T cell priming, limiting the ability of established tumors to evade immune 
recognition.  





CAR-T cell therapy has demonstrated striking success in treating hematopoietic cancers.  For 
example, an early study indicated that anti-CD 19 CAR-T cells, which target CD19 expression 
leukemia or lymphoma, led to tumor remission in more than 80% of patients with acute 
lymphoblastic leukemia[105, 106].  However, CAR-T cell therapy against solid tumors has 
limited therapeutic efficacy[107], and this has not changed despite the use of different CAR 
constructs or the treatment of various different types of tumor. 
 
4.1 The design of CAR construct 
CAR T cells were first designed by Dr. Zelig Eshhar, who termed the cells “T-bodies”, and 
showed great efficacy when targeting in vitro tumors[108].  The “T-bodies” construct is also 
considered to make up first generation CAR-T cells.  The first generation of CAR construct 
utilized the intracellular motif from CD3 zeta chain to simulate the phosphorylation signals from 
the TCR complex that initiates T cell activation[109].  Later, scientists optimized the design by 
the incorporation of co-stimulatory motif into the signal portion of the “T-bodies”, and which led 
to the development of second-generation CAR-T cells[110].  Recently, the further addition of co-
stimulatory motif into the second-generation CAR construct has been introduced and named 
third generation of CAR-T cells[111] (Figure 1.3).  In clinical studies, the first generation of 
CAR-T cells shows limited therapeutic advantage in clinical studies due to poor persistence in 
vivo, while the second-generation CAR-T cells showed great anti-tumor activity in vivo for most 
patients with CD19-expressing tumors[112]. 
Currently, CAR contain an extracellular domain that can bind to protein expressed on tumor 
cell surface, and an intracellular domain that initiates a stimulatory cascade within the T cell.  In 
addition, the extracellular and intracellular motif are connected with a linker and a 
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transmembrane region, where the linker provides the flexibility of extracellular binding motif 
and the transmembrane domain enables the assemble of CAR construct to cell membrane.  
Typically, the extracellular domain is derived from the single-chain variable fragment (scFv) 
region of an antibody that specifically binds to an antigen expressed on the tumor cell 
surface[113].  The engagement of tumor antigen by CAR-T cells through scFv binding leads to 
the activation of effector functions through the phosphorylation of intracellular motifs.  
 
An interesting aspect of CAR-T is the selection of different co-stimulatory domain enables 
CAR-T cells with different activity.  To date, the intracellular co-stimulatory motifs of CD28, 4-
1BB, ICOS or OX40, have been used to generate CAR-T cells with distinct effector 
phenotypes[112, 113].  For example, CAR constructs containing ICOS domains have been 
shown to polarize activated CAR-T cells towards a Th17 phenotype[114].  The most widely 
studied CAR-T constructs have been engineered to express the costimulatory domains of CD28 
or 4-1BB.  In general, CAR-T cells that expressed the CD28 endodomain have enhanced 
cytotoxicity while CAR T cells that express the 4-1BB endodomain are associated with increased 
persistence.  A recent study demonstrated that CAR-T cells expressing 4-1BB endodomain have 
enhanced fatty acid oxidation and generation of functional mitochondria which correlated with 
increased expansion, while CAR-T cells expressing CD28 have increased aerobic glycolysis to 
support the cytolytic activity of T cells[115].  Another study evaluated the downstream 
biochemical processes after activation of by either 4-1BB or CD28[116].  These data 
demonstrated differences in the recruitment of either LCK by CD28 endodomain or THEMIS-
SHP1 complex by 4-1BB for phosphorylation or dephosphorylation of CD3, resulting in the 
differential magnitude of CAR-T tonic activity and survival.   
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4.2 CAR-T treatment shows great anti-tumor efficacy against hematopoietic tumor in clinic 
Second generation CAR-T cells equipped with either CD28 or 4-1BB co-stimulatory domains 
have shown success when targeting hematopoietic tumors, with the most encouraging results 
coming from studies utilizing anti-CD19 CAR-T cell therapy against B cell malignancies. CD19 
is an ideal target that is expressed on most hematopoietic tumors, including leukemia and 
lymphoma, but not on other normal tissue other than B cells[117].  Clinically, patients that 
respond to anti-CD19 CAR-T treatments experienced profound tumor remission, but may also 
undergo a significant B cell aplasia, which can be managed by immunoglobulin 
replenishment[118].  The first clinical trial using anti-CD19 CAR-T against B cell acute 
lymphoblastic leukemia was done in the US in 2011 and reported an 80% response rate, with 
90% of patients achieving complete remission[119].  The initial encouraging result motivated the 
development and commercialization of CD19 CAR-T cell therapy against a variety of B cells 
related cancer, and in 2017 FDA approved the use of CD19 CAR-T against B cells leukemia and 
lymphoma. 
 
4.3 CAR-T efficacy against solid tumor is limited 
Compared to the clinical success of CAR-T cell therapy in resolving hematopoietic 
malignancy, CAR-T cells have shown limited efficacy when used to treat patients with solid 
tumors.  Though CAR constructs designed to target discrete solid tumor surface antigens 
demonstrate in vitro tumor killing activity during co-culture of CAR-T cells and tumor cells, 
success in human trials has been disappointing.  Clinical studies have revealed at least three 
primary underlying causes of the poor performance of CAR-T cell therapy[120]: 
1. Antigen selection 
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2. Impaired CAR T cell persistence  
3.  Immunosuppressive TME that restrain CAR-T cell activity against tumor cells. 
 
The antigen selection challenge results from the fact that there is a paucity of tumor-specific 
antigens for the overwhelming majority of solid tumors.  As a result, CAR-T cells may also 
engage normal cells and cause toxicity to the host.  Besides, there are at least two additional 
critical features of solid tumors that differentiate them from hematopoietic malignancies 
currently targeted by CAR-T cells.  1. T cells constitutively traffic to lymph nodes and bone 
marrow, which are the location for leukemia, lymphoma or myeloma development.  Similar 
trafficking does not occur for the overwhelming majority of solid tumors[121, 122].  2. The TME 
of solid tumors is highly immunosuppressive, which limits the persistence and expansion of 
CAR T cells. Thus, my dissertation focuses on improving CAR-T performance in solid tumors 
by enhancing CAR-T cell persistence and altering the immunosuppressive TME for enhanced 
CAR-T trafficking and activity.  
 
4.3.1 Persistence defect 
Clinical studies have revealed that the therapeutic benefit of CAR-T cell therapy is strongly 
associated with the persistence of CAR-T cells in the host[123].  When analyzing patients with B 
cell leukemia or lymphoma receiving CAR T cells with a 4-1BB endodomain, the overall 
response is strongly correlated with longitudinal CAR T cell persistence[124, 125].  However, 
when using CAR-T cells to target solid tumors, limited persistence of CAR-T cells in solid tumor 
patients after CAR-T infusion was shown, which correlated with the limited therapeutic benefit 
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of this therapy[92].  The persistence defect of CAR-T in solid tumor patients results in part from 
the immunosuppressive nature of TME and the poor CAR-T cell trafficking into the TME.        
 
To enhance CAR-T cell persistence, strategy/approaches have been adopted to utilize T cells 
with improved persistence and migration.  Central memory T cells (Tcm), especially stem 
memory T cells (Tscm), are long-lived T cells with enhanced cytotoxicity against tumor cells in 
vivo[126, 127].  These memory T cells are characterized by a gene expression profile similar to 
stem cells, with increased expression of the WNT-β-catenin and mTOR pathways, resulting in 
decreased apoptosis and increased expansion[128, 129].  Both xenograft animal models and 
clinical observations have shown a positive correlation of the presence of tumor-specific Tcm 
and enhanced anti-tumor activity in vivo.  As a result, Tcm are ideal candidates for CAR-T cell 
therapy with enhanced persistence.  However, this rare T cell population is difficult to obtain in 
large scale for the manufacture of CAR-T cells.  Thus, strategies have been adopted to enrich 
CAR-T cells with enhanced memory phenotype during ex-vivo culture or after infusion into 
patients.  Augmentation of Tcm CAR-T cells can be achieved by optimizing the CAR design or 
the manufacture process during the culture of CAR-T cells.  
 
4.3.1.1 Selection of CAR constructs 
Both the extracellular and intracellular domains of CAR constructs can affect the persistence 
of CAR-T cells.  The CAR extracellular domain can be recognized by the host immune system.  
This can lead to the development of an anti-CAR response by the host, leading to the elimination 
of CAR-T cells[130].  The intracellular costimulatory domain of the CAR construct, can affect 
the generation of effector and/or memory CAR-T cells.  For example, animal model studies have 
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shown that CAR T cells engineered with a 4-1BB co-stimulatory endodomain enhanced CAR-T 
cell proliferation and persistence after infusion.  CAR-T cells with a 4-1BB costimulatory 
endodomain were characterized with a metabolism profile similar to memory T cells, including 
enhanced respiratory capacity which could support the increased proliferation of these cells[115].  
In addition to 4-1BB engineering, selection of MyD60/CD40 or ICOS as co-stimulatory motifs 
has been linked with the polarization of CAR-T cells into a memory T cells in vivo upon 
activation[114, 131] However, most of the evidences showing the correlation of boosting CAR-T 
cells persistence by switching co-stimulatory domain of CAR construct and advanced tumor 
growth control are using CD19 targeting CAR-T cells against hemopoietic tumor models. As a 
result, whether the strategy to augment CAR-T cell persistence can be translated into solid tumor 
remains undetermined.  
 
4.3.1.2 Modifying cell engineering process 
Another factor that impacts greatly on the memory profile of CAR T cells is the ex vivo 
expansion protocol necessary to generate sufficient number of CAR-T cells for clinical therapy.  
Initial studies that focused on greatly enhancing effector function from ex vivo CAR- T cell 
cultures led to the generation of products with very poor in vivo persistence.  Thus, ex-vivo 
culture/expansion has been altered to culture CAR-T cell products in cytokines that enhance T 
cell persistence such as IL-7 and IL-15 instead of IL-2[132].  This approach has been shown to 






4.3.1.3 The selection of T cell could enhance persistence of CAR-T cell therapy 
Over the past decade, work from a number of groups has demonstrated that previous held 
beliefs regarding the fixed nature of effector T cells was incorrect.  T cells are plastic with the 
ability of these cells to alter transcriptional programs to generate different canonical populations 
of T cells[133, 134]. 
 
Studies have shown that CD4+ T cells that generate IL-17A and express the transcription 
factor RORC have increased plasticity, which is associated with the ability to generate increased 
numbers of Tscm cells from this population[135, 136].  IL-17-secreting CD4+ T cells (Th17 
cells) and their CD8+ counterpart (Tc17 cells) persist longer in vivo in part mediated by the 
presence of cells that adopt a stem cell phenotype[137].  Th17 and Tc17 cells express higher 
level of tcf7 and lef1, which are key transcription factors involved in the Wnt-β-catenin signaling 
pathway, a pathway associated with stem cell function[136, 138].  These cells have increased 
expression of genes upstream of the expression of bcl2, an anti-apoptotic protein. These cells 
have a unique metabolic profile similar to Tcm, and give rise to an effector Th1/Tc1 phenotype 
that is has significant pro-inflammatory activity in vivo[57, 139].  Previous studies demonstrated 
enhanced in vivo anti-tumor activity of TCR transgenic Th17 cells against TRP-1+ melanoma, 
which was associated with superior in vivo persistence[140].  Another study showed that the 
incorporation of ICOS as the endodomain of CAR-T cells polarized CAR-T cells into a Th17 
status, resulting in an advanced tumor growth control in immune-compromised hosts[114], again 
associated with greater in vivo persistence.  
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Th/Tc17CAR-T cells have not been evaluated in solid tumor models.  Thus, it is not clear if 
these cells can overcome the challenges that have limited the efficacy of other CAR-T cell 
products when treating solid tumors.  
 
4.4 TME suppress the anti-tumor activity of CAR-T cells  
The strong immunosuppressive TME is a significant barrier for CAR-T cell therapy.   The 
TME serves as both a physical barrier to hinder the trafficking of CAR-T cells into the 
environment, and a hostile environment to the function and persistence of those cells.  
Understanding approaches to modify the TME is critical to the improved use of CAR-T cells in 
solid tumors.  
 
4.4.1 Barrier for CAR-T trafficking 
The migration of CAR-T cells into the tumor is a prerequisite for their effector function.  
Unlike leukemia and lymphoma where CAR-T cells can traffic constitutively through a 
physiological circulation, T cells do not typically traffic to tissues where solid tumors are found.  
As a result, many solid tumors feature an immune “cold” environment, a hallmark of poor T cell 
infiltration.  Enhancing the ability of CAR-T cells to traffic into these tumors is a goal for 
adoptive cellular therapy of solid tumors.  The migration of T cells into inflammatory sites 
requires a set of well-organized events, including rolling, adhesion, extravasation and 
chemotaxis.  These complex steps are regulated by mechanisms involving in the interaction 
between T cells and endothelial cells on blood vessels[122].  Chemokines in the local 
environment and their matched chemokine receptors expressed on T cells, such as CXCL9/10 
and their interacting receptor, CXCR3 expressed on T cells play an important role[141].  In cold 
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tumors recruitment of cytotoxic T cells is limited in part by the poor function of neovascular 
blood vessels in the TME, which limits attachment of T cells to epithelium and the production of 
chemokines critical for anti-tumor T cell infiltration.  Treatments targeting vascular endothelial 
growth factors (VEGF), its receptor (VEGFR) or CD160 on tumor blood vessels stabilize the 
architecture of tumor blood vessels and exhibit superior tumor growth control when combined 
with immune-modulatory therapy[142].  Interestingly, the redirection of CAR-T cells against 
angiogenesis factor or tumor stroma facilitated the collapse of the TME and the trafficking of 
CAR-T cells into the TME.  Targeting VEGFR-2 cells on tumor blood vessel by CAR-T cells 
showed an enhanced anti-tumor efficacy[143].  Another study showed that engineering CAR-T 
to secrete heparinase to digest extracellular matrix from tumor stroma improved CAR-T 
migration into tumors, which was associated with enhanced anti-tumor activity[144]. 
 
Taken together, multiple different studies have shown that the generation of a “warm” tumor 
is associated with the increased expression of chemokines that attract tumor specific T cells, such 
as CCL5, CXCL9, CXCL10 and CXCL11[145-147].  As a result, the incorporation of 
chemokines into TME or CAR-T cells could enhance the trafficking of CAR-T into the tumor 
site.  For example, CXCL11 has been engineered into anti-mesothelin CAR-T cells or delivered 
into the TME directly and resulted in enhanced CAR-T infiltration[148].  Another study revealed 
increased CAR-T accumulation at the tumor site after engineering CAR-T cells to express 
CCL19 and IL-7 in an animal lung carcinoma model[149].  Engineering CAR-T-bearing cells to 
express chemokine receptor has been shown to enhance the control of tumor growth, as 
demonstrated in models of CCR2 expression anti-GD2 or anti-mesothelin CAR-T cells against 
neuroblastoma or malignant pleural mesotheliomas, respectively[150, 151]. 
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While CAR-T cell trafficking remains a critical issue for optimizing CAR-T cell therapy it is 
not clear if improving this without altering the immunosuppressive TME of solid tumor is 
sufficient to improve anti-tumor therapy.  Thus, approaches to alter the immunosuppressive TME 
may be critical to the optimal use of adoptive cellular therapy.   
 
4.4.2 Barriers for CAR-T function 
4.4.2.1 Suppressive factors in TME limited CAR-T activity 
In addition to the obstacles that prevent a robust CAR-T cells trafficking into the TME, the 
presence of immunosuppressive immune cells in the TME is another critical challenge that 
dampens the effector function of CAR-T cells against tumor cells.  The presence of inhibitory 
cells, including suppressive myeloid derived cells (MDSCs) tumor associated macrophages 
(TAM, M2 macrophages typically as anti-inflammatory phenotype), Tregs, and also stromal tumor 
cells such as cancer associated fibroblasts, limits CAR-T function in part by producing 
suppressive cytokines[121].  The inhibitory cytokines (such as TGFβ or IL-10) promote the 
development of immunosuppressive immune cells that block the robust interaction between 
effector T cells and APCs.  In addition, immunosuppressive cells secrete proteins that negatively 
affect the activity of effector function of T cells, including prostaglandin E2/cyclooxygenase-2 
(PGE2/COX2) that inhibits the phosphorylation of STAT3, adenosine which inhibits effector T 
cell activity through the production of cyclic AMP, and/or indoleamine 2,3-dioxygenase (IDO) 
that stimulates the production of kynurenine which limits the survival of T cells[77].  All of these 
processes lead to the diminished activity of T cells. Strategies targeting aforementioned 
suppressive factors have been adopted to potentiate the anti-tumor activity of CAR-T cells.  For 
example, the downregulation of IDO by miR-153 has showed an enhancement of CAR-T activity 
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against colon cancer in a xenograft tumor model[152], and using A2AR antagonists to inhibit 
adenosine on CAR-T cells improved the anti-tumor efficacy of CAR-T cells in a solid tumor pre-
clinical animal model[153].  
 
Although targeting each individual suppressive molecule may yield clinical benefit, the 
complicated suppressive TME may not be reverted by blocking a particular pathway.  Thus, 
strategies to more globally reprogram the TME to pro-inflammatory environment have been 
investigated.  One strategy is to have CAR-T cells express additional cytokines, such as IL-12.  
This approach, can enhance the polarization of M1-like macrophages and lead to the expansion 
of Th1/Tc1 T cells[154].  In fact, polarization of inflammatory macrophages promoted tumor 
rejection as seen in in multiple different pre-clinical tumor models.  For example, Toll like 
receptor agonists that enhance the generation of M1-like macrophages have a synergistic effect 
with IFN treatment to induce anti-tumor activity in a murine lung carcinoma model[155].  In 
another study using CD40 agonist for inflammatory macrophage transition, the authors reported 
enhanced anti-tumor efficacy using approaches to target CSF-1R, which is found on M2-like 
macrophages[156].  This process worked by enhancing T cell anti-tumor function.  Immature 
myeloid cells termed MDSCs found in the TME have also been shown to impair immune 
function.  Depletion of MDSCs augmented CAR-T function against primary sarcoma and liver 
metastatic colon tumors[157, 158].  While these approaches have shown some promise, in 
general, these approaches are not associated with tumor clearance rates that approach 100%.   





4.4.2.2 Targeting immune pathway can overcome suppressive TME 
Activation of T cells is mediated by APCs.  In tumor setting, the stimulator of interferon genes 
pathway (STING pathway) in APCs has been shown to be a pivotal component that links innate 
immune cells with the adaptive immune response[159].  STING is an intracellular sensor that 
recognizes cytosolic DNA to prevent danger from infections via the induction of type I 
interferons[160] (Figure 1.4).  Recent studies have suggested a critical role of STING pathway in 
detecting tumor antigen in the TME (“sensing” tumors).  Dying tumor cells may release their 
DNA into the TME, which, when taken up by APCs, activates the STING pathway.  The 
resulting activation of dendritic cells or inflammatory macrophages can prime tumor-specific T 
cells and guide the migration of those cytolytic T cells into the TME through chemokine 
production[159, 161].  The activation of STING pathway has been found to mediate profound 
anti-tumor activity in murine tumors, including B16 melanoma, CT26 colon, and 4T1 breast 
carcinomas, and tumor remission was strongly associated with the trafficking of functional anti-
tumor CD8 T cells into the TME[162].  DMXAA is a compound that was initially evaluated for 
its ability to alter tumor vasculature and enhance anti-tumor chemotherapy[163].  Later work 
demonstrated that DMXAA functions predominantly by specifically activating the murine 
STING pathway[162, 164, 165].  The failure of DMXAA clinically was due to its lack of activity 
to activate human STING.  Studies showed that by activating the STING pathway, exposure to 
DMXAA led to the activation of NF-κB, a master transcription factor regulating inflammatory 
events in innate immune cells[164].  In addition to direct stimulation of the STING pathway, 
DNA damage indirectly activates the STING pathway.  A recent report has shown that targeting 
the DNA damage response triggers the activation of STING pathway in TME, leading to the 
recruitment of cytolytic T cells in otherwise “cold” TME, which can then response to immune 
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checkpoint inhibition therapy[166].  However, whether STING activation can potentiate CAR-T 
function and yield clinical benefits remains untested. 
 
Although the manipulation of the suppressive TME could provide synergic activity with CAR-
T cells against tumors, sustained CAR-T activation has been shown to induce CAR-T cell 
“exhaustion” which is associated with impaired function of these cells. 
 
4.4.2.3 Overcome exhaustion defect can rescue CAR-T activity in TME 
As indicated previously, there are multiple different immune checkpoint that inhibit the 
effector function of adaptive immune cells.  Of these, the PD-1/PD-L1/2 pathway has been 
shown to play a critical role in the persistent function of effector T cells.  Once activated CAR-T 
cells are subject to the same exhaustion processes found in endogenous T cells.  Thus, the 
expression of PD-L1/2 in the TME and the increased expression of PD-1 on activated CAR T 
cells can lead to diminished effector function of CAR-T cells longitudinally[167].  Thus, even if 
CAR-T cells can traffic, persist and expand in the TME, cell intrinsic approaches limit the 
efficacy of this approach.  
  
4.5 Adverse side effect of CAR-T cell therapy 
Multiple studies have demonstrated that CAR-T cells targeting CD19 and BCMA have 
substantial clinical efficacy[119, 168].  These studies also demonstrated significant side-effects 
in patients receiving CAR-T cell therapy.  One of the most common is the cytokine release 
syndrome (CRS) [169].  This is a supraphysiological response to immune therapy that activates 
the adaptive and innate immune systems.  This process leads to activation of T cells, 
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macrophages and endothelial cells.  Specific cytokines contribute to the pathophysiology of this 
process[170]. Notably, CRS is not uniquely in CAR-T cell therapy, as bispecific antibody 
treatment and haploidentical stem cell transplant induces CRS[171, 172].  CRS is characterized 
by a rapid upregulation of pro-inflammatory cytokines in the host after receiving CAR-T cell 
therapy.  Currently, CRS has been seen in clinic from anti-CD19 and anti-BCMA CAR-T 
treatment in hematopoietic patients, where patients received the best therapeutic efficacy by 
CAR-T[169].  Interestingly, clinic observations for anti-CD19 CAR-T treatment demonstrated a 
positive correlation between the anti-tumor activity of CAR-T cells and CRS severity[173], 
suggesting that the clinical benefit of CAR-T cells may be linked to their toxicity. 
 
Early studies demonstrated significant increases in IL-6, GM-CSF, CCL3, IFN-γ and IL-1β in 
patients with CRS[170]. However, clinically, IL-6 blockade can alleviate CRS while leaving 
CAR-T efficacy intact, suggesting that the cytokines that mediate CRS are not critical to the 
expansion or function of CAR-T cells.  Recent studies in a pre-clinical animal model showed that 
the secretion of IL-1β and IL-6 from host myeloid cells was critical for the development of 
CRS[174].  The authors further show that the secretion of CRS associated-cytokines was 
mediated specifically by tumor-associated macrophages in the TME, and modulation or blockade 
of IL-6 or IL-1β signaling mitigated symptoms of CRS.  The role of myeloid cells in CRS was 
supported by another study, where CRS was induced in a pre-clinical tumor model by bi-specific 
antibody targeting.  The authors found that the CRS developed upon the activation of monocytes 
by T cell derived TNF after stimulated by bi-specific antibody treatment[175].  Though these 
studies help to address some questions about the role of CAR-T cells in CRS, little is known 
about their specific impact on CRS in patients bearing solid tumors.  Clinically, CRS is rarely 
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seen in patients receiving CAR-T for the treatment of solid tumors.  The mechanism for the lack 
of CRS in solid tumors models is not clear and may be in part due to limited CAR-T cell efficacy 
and expansion, the immunosuppressive TME differences in tumor targets or some combination 
of these.  Thus, whether CRS does occur in the setting of profound anti-tumor activity using 
CAR-T cells to treat solid tumors requires further investigations. 
 
Immune checkpoint inhibitor (ICI) therapy  
Chronic antigenic stimulation of tumor specific T cells contributes to T cell dysfunction, 
termed exhaustion.  Exhausted tumor specific T cells exhibit reduced proliferation and effector 
function against tumor cells.  Studies have found that expression of different negative regulatory 
receptors, also known as checkpoint inhibitory receptors, on the cell surface of activated T cells, 
contributes to T cell exhaustion[80].  The anti-tumor activity of these dysfunctional T cells can 
be restored via disruption of the interaction between these inhibitory receptors and their ligands 
by monoclonal antibodies, termed immune checkpoint inhibitor therapy (ICI).  ICI has been 
successful in achieving tumor remission in a subset of patients, and the goal is to increase the 
efficacy of ICI to successfully treat a larger number of cancer patients[176].   
 
To date, there are three immune checkpoint inhibitors that have been discovered and more are 
under investigation.  The first immune checkpoint inhibitor to show efficacy in the clinic is a 
monoclonal antibody (mAb) that targets the inhibitory receptor cytolytic T lymphocyte antigen 4 
(CTLA-4).  The mAb ipilimumab, which blocks CTLA-4 signaling, has led to profound benefits 
in patients with melanoma.  The study of blocking CTLA-4 as an effective ICI spurred the 
discovery of more checkpoint inhibitory receptors expressed on T cells, including Program death 
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receptor 1 (PD-1), lymphocyte activation gene 3 (Lag-3), and CD160 and the ligand for PD-1, 
PD-L1 that is expressed by tumor and myeloid cells.  Monoclonal Ab therapy directed against 
the above-mentioned checkpoint inhibitory receptors was promising in preclinical animal studies 
as well as clinical trials for melanoma, lung cancer, head and neck carcinoma and other type of 
cancers[176].  Of these receptors, blocking PD-1 signaling provides the most promising results 
by enhancing the immune response against several types of cancer, and this treatment directed 
against PD-1 has fewer side effects compared to therapy targeting CTLA-4, which may in part be 
due to the critical function of CTLA-4 on Tregs[177].  The success of ICI has encouraged the field 
of immunotherapy, and in 2018, Nobel Prize in Medicine was awarded to Dr. James P. Allison 
and Dr. Tasuku Honjo for the discovery of the immune checkpoint blockade therapies against 
CTLA-4 and PD-1.  However, despite the therapeutic effect of ICI, the response rate of ICI only 
ranges from 20-40% across different tumor types[178]; therefore, there is an increased need to 
understand ICI in efforts to modify the therapy so it can benefit patients that currently fail to 
respond to the therapy.  Different checkpoint receptor adopts discrete mechanism to induce T 
cell exhaustion, and the outcome of blockade therapies also varies among different receptors. 
 
5.1 CTLA-4 blockade treatment  
CTLA-4, also known as CD152, is a co-inhibitory molecule that is upregulated on activated 
conventional T cells and is constitutively expressed on Tregs.  CTLA-4 is localized intracellularly 
in Golgi vesicles until T cell activation.  Upon T cell activation, CTLA-4 is expressed on the cell 
surface[179].  CTLA-4 binds to CD80 and CD86 on APCs with higher affinity and avidity than 
CD28. The increased affinity for CD80/86 enhances the ability of CTLA-4 to inhibit T cell 
activation[180]. Moreover, a recent study suggests that CTLA-4 signaling may downregulate 
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expression of CD80/86 on APCs by endocytosis, limiting the availability of CD80/86 on APCs 
to activate T cells[181].  
 
Dr. James Allison’s laboratory was the first to treat tumors by using monoclonal antibodies to 
block CTLA-4 in mouse tumor models.  From that work a mAb specific for human CTLA-4, 
ipilimumab, was developed[182].  The treatment of metastatic melanoma patients with 
ipilimumab, a human IgG1 mAb that blocks CTLA-4 activity, improved progression free and 
overall survival of those patients when compared to other standard therapies. Ipilimumab 
doubled the one-year durable survival benefit (from 45.6% to 25.3%) in those patients with 
melanoma[183].  However, ipilimumab can induce side effects in patients.  The severity of the 
toxicity due to anti-CTLA-4 treatment varies among patients and ranges from skin rashes, 
diarrhea, hepatitis, colitis, hypophysis, and pneumonitis[177, 184]. In some cases, the adverse 
side effects required the cessation of treatment.  Additionally, the response rate of anti-CTLA-4 
antibody to cancers other than melanoma was modest.  
 
Studies have focused on investigating the mechanism of anti-CTLA-4 blockade, and the role 
of this antibody in inhibiting Treg numbers and/or function[185].  The function of anti-CTLA-4 
that recognizes human CTLA-4 is complicated.  CTLA-4 is constitutively expressed on Tregs and 
there is conflicting data on the ability of ipilimumab to deplete specific populations of Tregs[186].  






5.2 PD-1 blockade treatment  
The promising therapeutic outcome of anti-CTLA-4 mAb therapy led to the discovery of other 
checkpoint inhibitory receptors.  PD-1, originally evaluated in a screen for proteins critical for 
the induction of cell death in T cells, was later actually shown to be critical as another negative 
regulator of adaptive immunity[187].  PD-1 is expressed after T cell activation and inhibits T cell 
function[188].  PD-1 interacts with its ligands, PD-L1 or PD-L2, which are expressed on a 
variety of cells, including hematopoietic cells, and tumor cells.  The engagement of PD-1 leads 
to the phosphorylation of immunoreceptor tyrosine-based inhibition motif (ITIM) on the 
intracellular tail of PD-1, which induces a downstream signaling cascade acting through the 
activity of specific phosphatases that leads to dephosphorylation of critical proteins downstream 
of TCR/CD28-dependent T cell activation[85, 189].  This process can lead to T cell dysfunction 
as indicated by reduced cytokine production and decreased expression of effector T cell-related 
genes, such as T-bet, as well as T cell survival-related genes.     
 
Blocking the PD-1/PD-L1 interaction using mAb therapy has revealed a significant 
therapeutic benefit for patients with multiple types of cancer.  The first large scale trial with anti-
PD-1mAb therapy using nivolumab (a human IgG4 monoclonal antibody) demonstrated a two-
year durable response rate in patients with melanoma, and the outcome was strikingly better than 
the use of conventional chemotherapy[190, 191].  Nivolumab treatment also resulted in 
decreased toxicity as compared to conventional therapy[192].  These promising results led to the 
approval of nivolumab as the first line of treatment for melanoma in Japan and the United States.  
Clinical trials for the treatment of patients with non–small cell lung cancer, renal cell carcinoma, 
and B and T Hodgkin’s lymphoma with anti-PD-1 mAb treatment showed enhanced clinical 
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benefit, with improvements in overall and progression free survival compared to conventional 
therapy[193].  In addition to blocking PD-1, blocking the ligand PD-L1 using anti-PD-L1 mAb 
was also effective against various cancers, including bladder, head and neck, and renal cell 
cancer[194, 195].  
 
Recent clinical studies have shown that anti-PD-1/PD-L1 mAb treatment led to improved 
clinical benefit in patients compared to anti-CTLA-4 mAb treatment.  The blockade of anti-PD-1 
or PD-L1 had a higher response rate (44%) compared to anti-CTLA-4 mAb treatment (16%) in 
melanoma patients, and treatment against PD-1/PD-L1 signaling resulted in decreased toxicity as 
compared to anti-CTLA-4 mAb treatment[177].  Moreover, anti-PD-1 mAb treatment was 
therapeutically beneficial for patients that developed resistance to anti-CTLA-4 mAb 
therapy[196].  The most encouraging results are from clinical trials combining both anti-PD-1 
mAb and anti-CTLA-4 mAb treatments.  This combination therapy led to improvements in 
progression-free and overall survival in melanoma patients comparison to patients who received 
single checkpoint inhibitor therapy[184]. The clinical efficacy of combining anti-PD-1 mAb and 
anti-CTLA-4 mAb treatment for tumors other than melanoma is currently under investigation. 
 
Although ICI can lead to tumor regression in some patients, not all patients receive therapeutic 
benefits from this therapy.  Therefore, a better understanding of the mechanisms by which ICI 
works is needed to predict which patients will respond to ICI.  Over the next section, I will 





5.3 Predicting ICI Response based on tumor mutation burden (TMB)        
According to the analysis of ICI clinical trials, hypotheses have been proposed to explain the 
different response rates across tumor types or different patients.  Deep sequencing of tumor 
genomes from patients identified a strong positive correlation between TMB and the response to 
ICI[178].  Patients with higher than 100 mutations in their tumor were more likely to respond to 
ICI therapy, and conversely, cancer patients with a low TMB are less likely to respond to ICIs.  
Therefore, TMB has been proposed as a model to predict response rates to ICIs; however, this 
model is not universal as some cancers with high TMB do not respond to ICI therapy.  The 
explanation posited between the linkage of high TMB and improved response rates is the 
correlation between TMB and the generation of tumor neoantigens derived from these 
mutations[178, 197]. 
 
5.4 ICI response and T cell activity    
The presence of functional TILs is another factor contributing towards the response to ICIs.  
Immunohistochemical staining, a method to identify molecular markers on cells via antibodies 
binding antigens, is useful to phenotype cells in tumor biopsies before and after ICI therapy, and 
allows further investigation of changes in the TME before and after therapy.  By using the 
method, studies have found that the spatial distribution of TILs is important in determining the 
response to ICI in patients.  
 
5.4.1 Spatial distribution of TILs and the ICI response 
The TME can be divided into three groups based on the presence or absence of TILs[198, 
199].  The first group is known as immune-inflamed and is characterized by increased infiltration 
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of TILs that express PD-1.  The immune-inflamed TME has robust infiltration of tumor specific 
T cells, but it also contains inhibitory immune cells, such as Tregs and suppressive myeloid cells, 
which limit the function of T cells.  Another group is termed immune-excluded and is 
characterized by the absence of TILs in the tumor; however, TILs are present along the margins 
of the tumor.  In the immune-excluded condition, the sequester of TILs restricts the interaction of 
TILs with tumor cells, and contributes to the poor anti-tumor activity of TILs.  The final group 
known as an immune-desert lacks T cell infiltration in all locations of the tumor suggesting a 
lack of priming of tumor specific T cells.  
 
The classification of TME according to spatial distribution of T cells not only aids in the 
prediction of the response to ICI but also guides the design for combinatorial approaches to 
enhance the therapeutic efficacy of ICI.  For example, the immune-desert TME is resistant to ICI 
due to the absence of T cells within the tumor.  The induction of an ICI response requires a 
modification to the TME to coordinate T cell recruitment to the tumor.  Recent studies showed 
that targeting the DNA damage pathway can activate the STING pathway in non-small cell lung 
cancer cells (NSCLC)[166].  The activation of STING turned a NSCLC model that was 
originally resistant to ICI, to sensitive for anti-PD-L1 Ab therapy.  The authors further showed 
that the transition is achieved by the augment of PD-L1 expression on tumor cells and the 
production of chemokines, including CXCL10 and CCL5, that are critical for the recruitment of 
tumor specific T cells into the TME upon STING activation.  
 
Clinical studies have shown that ICI is efficacious in a TME that already has T cell infiltration 
(immune-inflamed or immune-excluded)[199].  Some cases suggest that the immune-excluded 
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TME may have a better response to ICI than immune-inflamed as the anti-tumor activity of TILs 
in the immune-inflamed model are dampened by suppressive immune cells rather than through 
exhaustion of T cells.  For example, immunohistochemical studies have found that TILs present 
in the margins (immune-excluded) have enhanced expression of PD-1, and the tumor cells have 
increased PD-L1 expression[200].  As a result, the TILs found in the margins are more sensitive 
to ICI, and immune excluded tumors exhibit an enhanced therapeutic response rate to anti-PD1 
therapy as compared to tumors where the majority of TILs infiltrate into the tumor core.  In this 
case, the activity of TILs in the core is suppressed due to suppressive immune cells in the TME.  
 
5.4.2 The functional phenotype of TILs determines the ICI response    
The ability versus the inability of exhausted TILs in the TME core to retain cytolytic activity 
against tumor cells may be linked to the functional phenotype of these TILs.  As a result, the 
functional phenotype of TILs is another factor to consider for the response of ICI.  Gene analysis 
studies showed that the expression of cytolytic genes, such as perforin 1 and granzyme, is 
predictive for the presence of cytolytic TILs that can respond to ICI therapy[201, 202].  Apart 
from the cytolytic gene signature, the use of PD-1 expression on CD8 TILs as a predictive 
marker has also gained attention.  A study involving non-small cell lung cancer suggests that 
CD8 TILs with the highest PD-1 expression are metabolically and functionally different from 
PD-1-low and PD-1-negative TILs[203].  These PD-1 high CD8 TILs express higher level of 
genes associated with cell division and uptake of glucose.  This phenotype is consistent with 
activated T cells that have undergone clonal expansion upon antigen stimulation.  The authors 
further found that the exhaustion of those TILs may partially result from vulnerable 
mitochondrial function, and the robust cytolytic activity and normal metabolism of those TILs 
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can be overcome during ex-vivo culture.  By contrast, a melanoma study demonstrated that CD8 
TILs with intermediate PD-1 expression and the expression of tcf, a gene associated with effector 
T cell activity, can induce persistent anti-tumor activity upon anti-PD-1 treatment[204]; 
however, PD-1 high-expressing CD8 TILs display markers of terminal exhaustion and do not 
respond to anti-PD-1 therapy due to limited cytotoxic function and persistence.  This discrepancy 
showed the complicated nature of PD-1 expression on CD8 TILs in regards to anti-tumor 
function, and further investigation of PD-1 signaling on TILs is ongoing to better understand the 
function of PD-1 expression on CD8+ T cells in the TME. 
 
Unlike CD8 TILs, very little is known about CD4 T cells during ICI therapy.  Functionally, 
CD4 TILs can be classified into conventional CD4 TILs (CD4+ Foxp3-) and Treg TILs (CD4+ 
Foxp3+).  Current evidence shows that the presence of Tregs, which inhibit the anti-tumor immune 
response, are a major hindrance for successful ICI treatment.  CTLA-4 plays a critical role in the 
ability of Tregs to be suppressive[205].  The expression of CTLA-4 on Tregs can mediate the 
removal of co-stimulatory receptors (CD80/86) on APCs and limit the activity of tumor targeting 
T cells[181].  Therefore, anti-CTLA-4 Ab therapy is associated with a decrease in Treg 
infiltration in mice and inhibits tumor growth, although a decreased of Treg influx has not been 
observed in human clinical trials[186].  Similarly, a study using anti-PD-1 mAb therapy suggests 
that Tregs are a major challenge in a breast cancer model that are resistant to ICI, and the deletion 
of Tregs restored the sensitivity of cytolytic function of CD8 TILs to ICI treatment[100]. 
Currently, the study of conventional CD4 TILs during ICI treatment is growing, especially 




Tfh cells are a group of CD4 T cells that after activation, will migrate to the follicle of 
secondary or tertiary lymphoid organ/structure, where they can educate geminal center B cells to 
undergo somatic hypermutation, affinity maturation and class switching[206].  Tfh cells express 
PD-1 at high level, CXCR5, and bcl-6, which are critical for maintaining the cells in the 
follicular zone in the germinal center response.  CXCR5 facilitates the migration of Tfh cells to 
B cells critical for the germinal center reaction[207].  Studies have shown that bcl-6 is a key 
transcription factor that initiates Tfh differentiation[208].  Functionally, Tfh cells provides co-
stimulation and cytokines (IL-21) to B cells in the geminal center, resulting in class-switch 
recombination, affinity maturation and somatic mutation on B cells[209, 210].  The evidence of 
the activity of Tfh during tumor immunotherapy is emerging, and somewhat contradictory.  One 
study showed that a group of conventional CD4 TILs during ICI treatment featured high PD-1 
expression and displayed a unique Tfh-like phenotype[211].  Interestingly, the Tfh-like 
subpopulation is reduced after anti-PD-1 Ab and anti-CTLA-4 Ab treatment, and the loss of this 
cell population was associated with tumor growth control upon ICI therapy.  However, in another 
study involving non-ICI therapy, the authors found that the presence of Tfh cells and B cells are 
negatively correlated with tumor progression in patients with colorectal cancer[212].  
Considering the critical role of Tfh in the recruitment and functional support of B cells, the role 
of B cells during ICI treatment requires further investigation. 
 
5.5 B cell Response to ICI Therapy 
B cells are a component of the adaptive immune system and function in humoral immunity by 
secreting antibodies against antigens.  B cells can also present antigens and secrete cytokines. 
The role of B cells during ICI therapy is not fully understood.  Studies show that B cells play a 
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suppressive role against the activity of TILs by either expressing PD-L1, which facilitates the 
exhaustion of T cells, or through obtaining a regulatory B cell phenotype[213, 214].  However, 
recent evidence suggests that B cells may be critical for anti-tumor activity during ICI therapy.  
In one study, B cells expressing high levels of PD-1 responded to anti-PD-1 treatment by 
enhancing proliferation and secreting pro-inflammatory cytokines, independent of T cells[215]. 
Recent evidence also links the activity of B cells with a positive prognostic outcome in ICI 
clinical trials in multiple different types of cancer.  B cells found in tertiary lymphoid structures 
within the tumor and the accumulation of B cells in the TME was associated with an improved 
outcome after ICI treatment in patients with melanoma and sarcoma[216, 217].  Despite recent 
evidences suggesting a role for B cells in the anti-tumor immune response after ICI treatment, 
many fundamental questions still remain regarding the function of B cells in the anti-tumor 
response.  What is the function of B cells during ICI?  Do B cells secret antibodies targeting 
tumor cells or function as stimulatory APCs for tumor specific T cells, or by secreting cytokines 
participating in shaping the pro-inflammatory TME?  The answer of those questions may provide 
novel parameters for the prediction of ICI outcome by incorporating B cell signature, and new 
potential targets for B cells to enhance the therapeutic effect of ICI.  
 
Conclusion 
The goal of my dissertation is to use GEMMs to understand and improve current 
immunotherapies against breast cancer.  I focus on two current areas of intense investigation: 
optimizing CAR-T cell therapy against breast cancer by targeting the proto-oncogene Her2/neu 
in an immunocompetent mouse model and approaches to enhance and better understand the 





Figure 1.1. The suppressive tumor microenvironment with critical factors that contribute to the 



























Figure 1.3. The intracellular and extracellular of CAR construct (A) and the evolution from first 
generation of CAR (T-bodies) to third generation of CAR construct, whose differences are the 











Figure 1.4. The function of cGAS-STING that initiate the immune response. DNA from infection 
microorganisms or dying tumors can be uptake by the innate immune cells and binds to cGAS, 
which lead to the generation of cyclic GMP–AMP (cGAMP). cGAMP can bind and activate 
STING pathway after translocation from the ER to the Golgi. In Golgi, cGAMP-STING complex 
attracts kinases including TANK-binding kinase 1 (TBK1) and IκB kinase (IKK), which further 
phosphorylating interferon regulatory factor 3 (IRF3) and the nuclear factor-κB (NF-κB), 
respectively. Phosphorylated IRF3 will translocate to the nucleus and activate the expression of 
type I interferons such as interferon-β (IFNβ), while activated NF-κB will translocate to the 





CHAPTER II. SINGLE CELL SEQUENCING REVEALS A CRITICAL ROLE FOR T 
CELL TRAFFICKING AND MODULATION OF THE TUMOR 
MICROENVIRONMENT BY A STING AGONIST IN THE EFFICACY OF CAR T 
CELLS IN LOCALLY ADVANCED BREAST CANCER 1 
 
Introduction 
Chimeric antigen receptor (CAR) T cells have substantial activity against CD19-expressing B 
cell malignancies in humans[218] [219].  These receptors fuse the single-chain variable fragment 
(scFv) of an antibody specific to a tumor target with the signaling molecules of an effector T cell.  
This provides these cells with the specificity of an antibody and the effector function of T cells 
[220, 221]. 
 
Treatment of patients with solid tumors using CAR T cell therapy, however, has been less 
successful [222, 223].  Potential barriers to CAR T cell efficacy against solid tumors include the 
suboptimal migration and persistence of CAR-T cells in the tumor microenvironment (TME), 
impaired function mediated by the immunosuppressive TME, and CAR T cell exhaustion.  
Previous work from our group and others has shown that Th17 and Tc17 cells have enhanced  
persistence in solid tumors as compared to conventional Th1 cells [224, 225].  Whether CAR T 
cells generated from Th/Tc17 cells are capable of persisting in the immunosuppressive TME of 
solid tumors remains unclear.  
 
1 This chapter contains a manuscript that has been peer reviewed by Journal of Experimental Medicine (JEM). 
Currently the manuscript is under revision for the publication by JEM. I am the only first author in this manuscript. I 
and Dr. Jonathan Serody designed the study. I performed all experiments and wrote the manuscript under the 




Development of an Orthotopic Immune Competent Model to Evaluate CAR T cell Therapy 
Given the need to understand mechanistically how to enhance CAR T cell function in solid 
tumors, we developed second and third generation murine CAR constructs targeting the proto-
oncogene Neu (Figure 2.1A and Figure 2.7A).  Second generation CAR T cells were generated 
using the co-stimulatory domains from either CD28 (termed LH28z) or CD137 (4-1BB termed 
LHBBZ).  Third generation CAR T cells were generated using both CD28 and CD137 signaling 
endodomains (LH28BBZ).  Neu-specific CAR T cells were transduced and expanded with IL-7 
and IL-15 (7/15 CAR T cells) (Figure 2.1B, Figure 2.7B) at an equal ratio of CD4+ to CD8+ T 
cells (Figure 2.7C).  These cells were functional in vitro as they killed Neu-expressing target 
cells (Figure 2.1C and Figure 2.7D) and released pro-inflammatory cytokines only in response to 
Neu+ tumor cells (Figure 2.1D).  However, we consistently found that the transduction efficiency 
of the LHBBz construct was inferior to LH28z or LH28BBBz constructs (Figure 2.7B).  
Furthermore, both in vitro (Figure 2.7C) and in vivo experiments (Figure 2.7D) showed inferior 
antitumor activity of LH28BBz and LHBBz CAR T cells as compared to LH28z CAR T cells.  
Given these findings, we focused on enhancing the function of LH28z CAR T cells for the 
remainder of this work. 
 
We evaluated the antitumor effects of CAR T cells in an orthotopic murine breast tumor 
model of locally advanced disease in immunocompetent mice (Figure 2.8A).  Despite their in 
vitro cytolytic function, LH28z 7/15 CAR T cells were not able to control tumor growth in vivo 
(Figure 2.1E), even if hosts were lymphodepleted using irradiation prior to CAR T cell infusion 
(Figure 2.8B).  Combination of 7/15 LH28z CAR T cells with an anti-PD-1 mAb did not 
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improve the outcome (Figure 2.8C) indicating that blocking the PD-1/PDL-1 pathway is 
insufficient for tumor control by 7/15 LH28z CAR T cells.  Furthermore, very few CAR T cells 
were detected in the TME 5 days post treatment (Figure 2.8D), suggesting that the limited 
efficacy of 7/15 LH28z CAR T therapy was at least partly due to poor trafficking and persistence 
of CAR T cells in the TME.   
 
Th/Tc 17 CAR T cells have enhanced in vivo persistence 
Th17 cells and their counterpart Tc17 cells (CD8+ T cells that express IL-17A) have longer 
persistence in the TME, in part due to their better survival in vivo.  To evaluate if Th/Tc17 CAR 
T cells had better migration and/or persistence, we generated LH28z Th/Tc17 CAR T cells 
(termed Th/Tc17 CAR T cells).  We compared these cells with 7/15 CAR T cells.  Transduction 
efficacy (Figure 2.1F) and killing activity in vitro (Figure 2.1G) were comparable.  Th/Tc17 
CAR T cells released IL-17A and TNF, while 7/15 CAR T cells expressed IFN-γ and TNF when 
co-cultured with Neu+ tumor cells in vitro (Figure 2.1H).  
 
We next compared the in vivo antitumor effects of Th/Tc17 CAR T cells and 7/15 CAR T 
cells.  Th/Tc17 CAR T cells were superior to 7/15 CAR T cells in controlling tumor growth up to 
day 5 post-infusion (Figure 2.1I).  To identify mechanisms associated with the improved early 
efficacy of Th/Tc17 CAR T cells, we isolated tumor-infiltrating lymphocytes (TILs) from the 
TME and assessed their phenotype 5 days after therapy.  There was a significant increase in both 
CD4+ and CD8+ CAR T cells in the tumor and CD4+ CAR-T cells in the spleen of mice 
receiving Th/Tc17 CAR T cells compared to the recipients of 7/15 CAR T cells (Figure 2.1J and 
Figure 2.8E).  However, Th/Tc17 CAR T cells were only modestly increased in the TME, which 
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may in part explain the lack of long-term tumor control.  Thus, Th/Tc17 CAR T cells exhibit 
modestly improved migration/persistence to the TME and improved early tumor control, but this 
did not lead to a long-term anti-tumor response.   
 
The STING Agonist DMXAA Greatly Enhances CAR T Efficacy 
Given the short-term efficacy of Th/Tc17 CAR T cells in vivo, we sought an approach that 
would further enhance the migration and persistence of CAR T cells in the TME.  Recent studies 
have shown a critical role for the STING pathway in generating “warm” tumors in the setting of 
checkpoint inhibitor therapy[166].  Thus, we evaluated the activity of the STING agonist, 
DMXAA, in combination with CAR-T cells.  Mice were injected with NT2 tumors, and when 
tumors reached approximately 50 mm2, mice were given 7/15 or Th/Tc17 CAR T cells with 
DMXAA, which was given at a site remote from the tumor.  Interestingly, DMXAA enhanced 
the persistence of 7/15 CAR T cells in the TME (Figure 2.2A).  However, this was a modest 
increase in comparison to the increase when combined with Th/Tc17 CAR T cells.  Thus, we 
focused on Th/Tc17 CAR T cells.  The administration of DMXAA prior to Th/Tc17 CAR-T cell 
infusion, significantly improved anti-tumor efficacy (Figure 2B) and overall survival (Figure 
2.2C) compared to mock transduced T cells or Th/Tc17 CAR-T cells alone.   
 
We performed single cell transcriptome sequencing (scRNA-seq) on CD45+ cells isolated 
from the TME of mice that received Th/Tc17 CAR-T with or without DMXAA.  These 
evaluations were performed on day 7 post CAR T cell therapy, a time point where we observed 
the greatest tumor control, and at day 10 when tumors began to regrow (Figure 2.2D).  Based on 
gene expression profiles, we identified three immune cell populations in the TME in mice 
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receiving Th/Tc17 CAR T cells with or without DMXAA (Figure 2.9A).  Specifically, at day 7 
post-therapy, we identified clusters of T cells, macrophages and a second myeloid cell cluster 
that each showed differential gene expression profiles in the presence or absence of DMXAA 
treatment (Figure 2.2E).  In addition, we noted an increase in T cells and a decrease in a sub-
cluster of myeloid cells in the TME on day 7 post CAR T cell therapy (Figure 2.9B).   
 
The most noticeable difference in the TME in mice receiving DMXAA was a substantial 
increase in CAR T cells compared to animals given Th/Tc17 CAR T cells without DMXAA 
(Figure 2.3A).  CD8+ CAR T cells infiltrating the TME exhibited two different phenotypes.  A 
subset expressed the transcription factor RORC and the cytokine IL17A (Figure 2.3B, D) 
consistent with Tc17 cells.  Interestingly, DMXAA treatment enhanced the accumulation of T 
cells that co-expressed the transcription factor TBX21, the pro-inflammatory cytokine IFNG, the 
interferon-inducible chemokine receptor CXCR3, and CCR5 a trafficking receptor found on 
Th1/Tc1 cells (Figure 2.3C-D).  This expression pattern is consistent with the presence of pro-
inflammatory Tc1 cells converted from Tc17 cells in the presence of DMXAA.  To confirm the 
increase in CAR T cells in mice receiving DMXAA, flow cytometry was performed to detect 
CAR T cells in the TME.  DMXAA treatment greatly increased the percentage and number of 
CAR T cells in the TME (Figure 2.3E).  In addition, we found a strong association between the 
number of CD8+ CAR T cells in the TME and tumor size in mice receiving DMXAA (Figure 
2.3F).   
 
A combination of Tc17 and Th17 cells were necessary for anti-tumor efficacy using DMXAA 
as Tc17 cells alone were not effective in tumor control (Figure 2.10).  To evaluate the effect of 
 
 49 
DMXAA on CD4+ T cells, we performed scRNA-seq of CD4+ CAR T cells with or without 
DMXAA treatment (Figure 2.11A).  Like the findings with CD8+ T cells, there was an increase 
in CAR T cells expressing canonical genes for the Th17 phenotype (RORC) and genes for a 
cytolytic Th17/Th1 phenotype (TBX21 and IRF4).  We also found an increase in the expression 
of IFNG and chemokine receptor genes found on Th1 cells (CXCR3 and CCR5) (Figure 2.11B-
D).  We confirmed our single cell data using flow cytometry, which demonstrated an increase in 
the number and percentage of CD4+ CAR T cells in the presence of DMXAA.  This increase 
was associated with control of tumor growth (Figure 2.11F).  To further validate our single cell 
transcriptome data, we performed bulk qPCR array evaluation of the TME.  We found increased 
expression of genes associated with the Th1 and Th17 pathways in mice receiving Th/Tc17 CAR 
T cells and DMXAA treatment (Figure 2.12A-B).  Finally, we demonstrated a critical role for 
IFN-γ expression by demonstrating the loss of activity of Th/Tc17 CAR T cell therapy plus 
DMXAA in mice that received anti-IFN-γ mAb (Figure 2.12C).  Thus, DMXAA therapy was 
associated with a change in the phenotype of Th/Tc17 CAR T cells to a pro-inflammatory dual 
Th17-Th1/Tc17-Tc1 phenotype, which is critical for tumor control.   
 
CAR T cell Exhaustion Limits in vivo Efficacy 
LH28z Th/Tc17 CAR T cell therapy given with DMXAA controlled tumor growth for 
approximately 10 days but did not eradicate the tumor.  To investigate the cause of loss of 
activity of LH28z Th/Tc17 CAR T cells with DMXAA, we compared scRNA-seq of the TME at 
days 7 and 10 post CAR T cell therapy.  As early as day 7 post LH28z Tc/Th17 CAR T cell 
infusion, we found increased expression of PDCD1 (PD-1), LAG3, CD160 and TOX by CAR T 
cells with decreased expression of TCF7 (Figure 2.3G-I, Figure 2.13A).  To confirm the single 
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cell data, flow analysis was performed on CAR T cells in the TME.  There was a significant 
increase in PD-1-expressing CD4+ and CD8+ T cells at day 7 after Tc/Th17 LH28z CAR T cell 
treatment compared to mock transduced CAR T cells (Figure 2.13B).  We found increased 
expression of S100A8 and S100A9[226, 227], which together generate the protein calprotectin, 
that has been shown to induce T cell apoptosis (Figure 2.13C-D).  Additionally, we found an 
increase in CXCL2, which has been associated with the recruitment of suppressive myeloid cells 
into the TME (Figure 2.3J). 
 
Alteration of Myeloid Cells in the TME is Associated with the Function of DMXAA 
DMXAA can modify the function of innate immune cells[159, 160].  Thus, we evaluated the 
effects of the STING agonist on myeloid cells in the TME.  Significant differences were found in 
the presence of M1-like and M2-like macrophages, inflammatory-like myeloid cells (iMCs) and 
myeloid derived suppressor-like cells (MDSC) in mice treated with and without DMXAA 
(Figure. 2.4A-B).  There was a marked decrease in the presence of M2-like macrophages 
expressing RENTLA, MMRC1, FOLR2, and IL10 in the TME after treatment with DMXAA 
(Figure 2.4C and Figure. 2.14A-B).  This was associated with increased expression of genes 
associated with M1-like macrophages including NOS2 and INHBA.  M1-like macrophages had 
increased expression of chemokines such as CXCL9, CXCL10 and CCL5, which have been 
shown to recruit Th1/Tc1 T cells by binding to CXCR3 and CCR5-expressing cells (Figure 2.4D, 
and Figure. 2.14A-B).  Consistent with the increased expression of IFNG in the presence of 
DMXAA, macrophages had increased expression of CD274 (PD-L1)[228] (Figure 2.14C).  To 
demonstrate a critical role in the recruitment of CAR T cells to the TME by macrophages, 
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liposome clodronate was used to deplete these cells.  Macrophage depletion reversed the efficacy 
of DMXAA over the first week of Th/Tc17 CAR T cell therapy (Figure 2.4E).  
A second cluster of myeloid cells was found after treatment with DMXAA with greatly 
enhanced expression of the transcription factor BATF2[229], the chemokine ligands CXCL10 
and CCL5, and downstream genes related to inflammatory function, including SOCS1, NOS2 
and IL12A (Figure 2.4F-I, Figure 2.14D-E).  Additionally, there was reduced expression of 
APOE, PTGS2 and AREG, and (Figsure 2.14F-G) a gene expression profile consistent with 
MDSC-like cells.  Thus, DMXAA was able to modulate the expression of genes associated with 
enhanced anti-tumor efficacy and to decrease the presence of pro-tumorigenic myeloid cells. 
 
To characterize the TME immediately prior to tumor growth, we evaluated myeloid cell 
subsets at day 10 post Th/Tc17 CAR T cell infusion with DMXAA.  As shown in Figure 2.4, 
(panels J to M), there was a significant change in the TME over this four-day period with a 
marked increase in the presence of MDSC-like cells expressing PTGS2 (Cox2), AREG, and 
APOE (Figure 2.14H).  There was a significant decrease in the presence of BATF2-expressing 
myeloid cells (Figure 2.4L-M).  Thus, the diminished function of LH28z Th/Tc17 CAR T cells 
plus DMXAA was strongly associated with the re-establishment of an immunosuppressive TME. 
 
Targeting CAR T cell Exhaustion and Immature Myeloid Cells enhanced CAR Efficacy 
Given our data regarding the expression of PD-1 on CAR T cells and the marked changes in 
the immunosuppressive nature of the TME, we evaluated whether targeting these pathways could 
enhance the long-term efficacy of LH28z Th/Tc17 CAR T cells plus DMXAA.  To this end, we 
treated mice with LH28z Th/Tc17 CAR T cells plus DMXAA along with anti-PD-1 and anti-
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GR-1 mAb therapy (Figure 2.5A).  This approach led to significantly improved overall survival 
and control of tumor growth compared to mice that received CAR T cell therapy with DMXAA 
and either anti-PD-1 or anti-GR-1 mAb therapy (Figure 2.5B-D).  However, substantial anti-
tumor activity was found only in mice that received CAR T cells plus DMXAA with either anti-
PD-1 or anti-GR-1 mAb therapy (Figure 2.5B-C).  There was no anti-tumor activity in mice that 
did not receive CAR T cells or DMXAA (Figure 2.5B-C).  Importantly, optimal tumor control 
required CAR T cell therapy with DMXAA and anti-PD-1 and anti-GR-1 mAbs (Figure 2.5D). 
 
To evaluate whether combination therapy with DMXAA, anti-PD-1 and anti-GR-1 mAbs 
could also enhance the anti-tumor activity of 7/15 CAR T cells, we compared tumor growth in 
mice receiving anti-GR-1 and anti-PD-1 mAb with DMXAA and given either 7/15 or Th/Tc17 
CAR T cells.  Much greater anti-tumor activity was found with the administration of Th/Tc17 
CAR T cells compared to 7/15 CAR T cells when combined with DMXX and anti-PD-1 and 
anti-GR-1 mAbs (Figure 2.15A-B).  Even in the absence of anti-PD-1 and anti-GR-1 therapy, 
there was an increase in CAR T cells in the TME (Figure 2.2A), compared to the spleen (Figure 
2.15C) in mice receiving Th/Tc17 CAR T cells compared to 7/15 CAR-T cells.  There was much 
greater proliferation of CD4+ CAR T cells in mice receiving Th/Tc17 compared to 7/15 CAR T 
cells (Figure 2.16A).  For CD8+ CAR T cells, we found a significant increase in the number of 
CD8+ Tcm CAR T cells from day 7 until day 12 post-infusion in the TME of mice receiving 
Th/Tc17 as compared to 7/15 CAR T cells, which were predominantly effector memory T cells 
at day 7 (Figure 2.16B-C).  Differences in the number of effector vs. central memory CAR T 
cells were supported by the increased number of Th/Tc17 CAR T cells with a precursor effector 




In conclusion, sustained tumor regression caused by Th/Tc17 CAR-T cells was associated 
with enhanced proliferation and expansion of central memory T cells. 
 
Efficacy associated with Cytokine-like Release Syndrome 
Treatment of mice with Th/Tc17 CAR T cells, DMXAA, and anti-PD-1 and anti-GR-1 mAbs 
led to significant tumor control with the majority of mice tumor-free 30 days post treatment.  
However, we found a small subset of mice that received this combination therapy exhibited 
significant weight loss and hunching consistent with a cytokine-release like syndrome (Figure 
2.6A).  This was correlated with increased mortality in these mice (Figure 2.6B).  Treatment 
efficacy correlated with the development of this syndrome (Figure 2.6C).  To determine a cause 
for the increased toxicity in these mice, we evaluated cytokine levels from the serum of mice 
receiving Th/Tc17 CAR with DMXAA and anti-PD-1 +/- anti-GR-1 mAb treatment.  Significant 
increases in CCL2, G-CSF and IL-6 were found in mice given anti-GR-1 mAb compared to mice 
that did not receive anti-GR-1 treatment (Figure 2.6D).  Mice receiving Th/Tc17 CAR T cells 
with DMXAA, anti-PD-1 and anti-GR-1 mAbs, were then treated with an anti-IL-6 antibody, 
which has demonstrated efficacy in the treatment of CRS in human subjects receiving CAR T 
cells[174, 175].  Mice were given anti-IL6 antibody at day 5 at the onset of weight loss in 
animals treated with combination therapy (Figure 2.6B).  As shown (Figure 2.6E-G), treatment 
with anti-IL-6 mAb was associated with improved survival in mice receiving combination 






Although CAR T cells targeting CD19 have been successful in treating patients with B cell 
malignancies, the clinical activity of CAR T cells in patients with solid tumors has been modest.  
Using a rational and sequential approach, we have implemented a combinatorial immunotherapy 
strategy based on CAR T cells polarized to a Th/Tc17 phenotype, anti-PD1 mAb, STING agonist 
DMXAA and anti-GR-1 mAb that leads to tumor eradication in an immunocompetent syngeneic 
model of breast cancer.  The most compelling finding was the ability of DMXAA, given at a site 
remote of the tumor, to promote CAR T cell recruitment and persistence at the tumor site.  To 
our knowledge, these data are the first to demonstrate the function of a STING agonist in altering 
the trafficking properties of adoptive T cellular products. Furthermore, this activity did not 
require intratumoral injection of the STING agonist.   
 
A critical aspect of effective CAR T cell therapy is the ability of the transferred cells to traffic 
to tumor sites.  CAR T cells expanded ex vivo and infused intravenously in patients home 
physiologically to secondary lymphoid organs such as the bone marrow and lymph nodes, which 
explains in part the robust antitumor effects of CAR T cells observed in patients with leukemia, 
lymphoma and multiple myeloma [230].  In contrast, T cells do not constitutively traffic to breast 
tissue.  Th/Tc17 cells have enhanced biodistribution to peripheral tissues as compared to Th1 
cells, and this may explain in part our observation that Th/Th17 CAR T cells showed superior 
persistence in the tumor compared to IL7/15 CAR T cells (Figure 2.2 and Figure 2.7).  To further 
increase CAR T cell accumulation in solid tumors, engineering processes have been exploited 
using tumor-associated chemokine gradients or by modifying the stiffness of the extracellular 
matrix[144, 149, 150].  Here, we report that the STING agonist DMXAA promoted CAR T cell 
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persistence within the TME.  DMXAA treatment led to increased expression of CXCL9 and 
CXCL10 by myeloid cells within the TME.  These chemokines recruit CXCR3-expressing 
Th/Tc1 T cells.  Correlating with this finding, DMXAA treatment was associated with a marked 
increase in the number of CAR T cells through day 10 post-therapy.  Interestingly, these CAR T 
cells had an altered phenotype as they did not generate IFN-γ prior to infusion but expressed 
IFNG, TBX21, and CXCR3 post-therapy with DMXAA.  T cells expressing IL-17A and IFN-γ 
have been found in other models to induce significant tissue pathology[231, 232].  Our data 
using anti-IFN-γ, which led to a complete loss of the activity of these CAR T cells in vivo, would 
support a critical role for the conversion of Th/Tc17 CAR T cells to a Th/Tc1 phenotype in their 
anti-tumor activity in vivo.   
 
The immunocompetent mouse model we developed allowed us to assess how the myeloid 
tumor compartment affected the antitumor activity of CAR T cells.  We demonstrate that the 
persistence of Th/Tc17 CAR T cells in the TME was associated with enhanced expression of 
genes associated with M1-like macrophages and a marked loss of genes associated with M2-like 
macrophages and MDSC-like cells.  The decrease in BATF2-expressing iMCs was associated 
with the inability of CAR T cells to control tumor growth.  Thus, these data suggest that 
enhancing CAR T cell trafficking and persistence without altering the immunosuppressive TME 
is unlikely to lead to significant sustained anti-tumor effects in solid tumors.   
 
Th/Tc17 CAR T cell persistence within the TME, which is promoted by the pro-inflammatory 
myeloid switch caused by a STING agonist, does not prevent exhaustion of CAR T cells, which 
requires checkpoint blockade to sustain CAR T cell mediated tumor control.  Moreover, a rapid 
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influx of immunosuppressive monocytic MDSCs within the TME was also observed and 
associated with diminished control of tumor growth.  Previous work had shown that CAR T cells 
specific for CEA were inhibited by liver myeloid derived suppressor cells when given via the 
portal vein to mice with liver metastasis[158].  Here, we found that depletion of MDSC-like cells 
in combination with CAR T cells, STING agonist and PD-1 blockade allowed sustained 
regression of the tumor.  We however observed that the optimal combination also led to the 
development of rapid cachexia consistent with a cytokine release syndrome.  Recent work has 
highlighted the critical role of myeloid cells in the pathogenesis of cytokine release 
syndrome[233-235].  Our data suggest that MDSCs, and perhaps other immunosuppressive 
myeloid cells, limit the anti-tumor efficacy of CAR T cells but also attenuate the severity of the 
inflammatory reaction.  Fully licensing CAR T cells by depleting MDSCs exacerbated a cytokine 
release syndrome, which responded to IL-6 blockade as observed in patients receiving CAR T 
cells targeting CD19.   
 
In summary (Figure 2.17), we have found that suboptimal trafficking and 
persistence/expansion of CAR T cells greatly limits their antitumor activity in an orthotopic 
model of locally advanced breast cancer.  The STING agonist, DMXAA, greatly enhanced the 
trafficking and persistence of CAR T cells especially when Th/Tc17 cells were used to generate 
CAR T cells.  These data suggest a viable strategy for boosting CAR T activity in solid tumors as 
STING agonists are in clinical trials for the treatment of patients with cancer[160], there are 
multiple ongoing clinical trials using approaches to inhibit MDSCs for patients with malignant 
disease[236] and there are clinical trials currently evaluating the combination of CAR T cells 







SP VL GS VH Hinge+ CD8a CD28 CD3z
Figure.1
Hinge+







Mock Ts 7/15 CAR-Ts
E.
C.

















































































Co-culture cytokines secrection 




Mock Ts Th/Tc17 CAR-Ts
CD4 CD8
CAR







































































































Figure 2.1:  Th/Tc17 CAR-T cells exhibit enhanced early control of tumor growth over 7/15 
CAR-Ts due to enhanced persistence in the tumor. 
A, Schematic of the LH28z CAR cassette encoding the scFv (7.16.4), hinge and transmembrane 
domain from CD8, and intracellular domains from CD28 and CD3ζ. B, Expression of CAR-T 
receptor on transduced murine 7/15 CD4+ (left) and CD8+ (right) T cells. C, Representative flow 
cytometry histograms depicting viability of Neu+ NT2 tumor cells in vitro after 3 days of co-
culture with 7/15 CAR-Ts. Tumor cells were pre-labeled with CFSE and plated prior to the 
addition of CAR-Ts at a 1:1 ratio with tumor cells. D, Intracellular staining illustrating IFN-g and 
TNF production by 7/15 CAR-Ts after co-culture with Neu+ cells or Neu- 3T3 cells at a 2:1 ratio. 
E, Tumor area change (tumor area prior to therapy subtracted from area following therapy) was 
determined and compared in FVB-neu mice that received 7/15 CAR-Ts or mock transduced T 
cells (Mock Ts). F, Expression of CAR-T receptor on transduced Th17 (left) or Tc17 (right) 
cells. G, In vitro killing of NT2 tumor cells by 7/15 CAR-T and Th/Tc17 CAR-T cells following 
overnight culture. H, Histogram flow plots of IL-17A, TNF and IFN-g secretion by Th/Tc17 
CAR-T and 7/15 CAR-T compared to mock T cells after co-culture with Neu+ cells at 3:1 ratio 
for 6 hours. I, Tumor area change was calculated and compared in FVB-neu mice that received 
Th/Tc17 CAR-Ts or 7/15 CAR-Ts. J, Detection of CD4 and CD8 CAR-Ts in spleen or tumor by 
flow cytometry 5d after injection of 7/15 CAR-Ts or Th/Tc17 CAR-Ts. Data from B-D are 
shown as mean ± s.d. (n = 3) and e represents 7 mice per group. Data from F-H shown as mean ± 
s.d. (n=3). Data from I represent 7-8 mice per group, J represent 5 mice per group. * P <0.05, ** 
P <0.01, significance was determined by Student’s t-test or two-way ANOVA when comparing 
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Figure 2.2:  Tumor control by Th/Tc17 CAR-T cells is enhanced by DMXAA injection due 
to altered composition of tumor infiltrating immune cells.  
NT2 tumors were orthotopically injected into murine mammary pads. 21 days later 500 μg of 
DMXAA was injected at a site distal to the tumor site, followed by injection of 3x106 mock-T 
cells 7/15 CAR-T or Th/Tc17 CAR-T cells (CD4:CD8 at ~1:1 ratio).  
A, Representative flow cytometry histograms of CAR-Ts detection at in the TME (left) and 
summary of accumulation of CAR-T cells (right). B, Change in tumor area was measured over 7 
days after treatment. C, Kaplan-Meier survival curve for the treatment cohorts. End point criteria 
for sacrifice was a tumor area of 200 mm2or greater. D, Tumor area change 14 days after 
indicated therapy. E, t-SNE analysis of pooled single cell sequencing data generated from tumor 
infiltrating CD45+ immune cells 7 days after receiving Th/Tc17 CAR-Ts in the presence or 
absence of DMXAA. Data were analyzed by unsupervised clustering and populations determined 
by expression of key markers, including Cd3e (T cells), Adgre1 (macrophage) and Itgam and/or 
Itgax (myeloid cells). Right panel shows further classification of sub-population between 
DMXAA treatment (+DMXAA) and non DMXAA treated (-DMXAA) mice. The gating from 
the flow cytometry histograms was performed using FMO for each individual experiment.  B-D 
shows 5-10 mice. E shows 3 mice in each treatment group. * P <0.05, ** P <0.01, *** P <0.001 
significance was determined by Student’s t-test or two-way ANOVA when comparing tumor 
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Figure 2.3:  DMXAA treatment enhances the number and cytotoxicity of Tc17 CAR-T cells 
in the TME, though they eventually become exhausted. 
A, T cell populations were subdivided based on expression of Cd8 and Cd44 (activated CD8 T 
cells), Cd44 (naïve T cells), Cd4 and Foxp3 (regulatory T cells, Treg). CD8 T cells were 
compared between the +DMXAA and –DMXAA treatment groups, and each sub-population was 
examined further as described below. 
 B, t-SNE plots of CD8 T cells for Tc17 related genes (C) t-SNE plots of CD8 T cells for Tc1 
related genes. D, Violin plots depicting the distribution and change in expression of genes 
identified in B and C. E, Validation of single-cell sequencing data using flow cytometry to detect 
CD8 CAR-T cells. Representative flow plots (left), frequency (middle) and number (right) of 
CD8 CAR-T cells. F, Analysis of the correlation between tumor growth change and absolute cell 
number of CAR-expressing CD8 T cells/ cm2 tumor. G, Activated or exhausted T cell cluster 
was selected from unsupervised clustering result of tumor infiltrating immune cells from 7 days 
and 10 days after Th/Tc17 CAR+DMXAA therapy and is shown as a t-SNE plot. H, t-SNE plot 
(left) and Violin plot (right) of T cells for genes that are associated with T cells exhaustion. I, t-
SNE plot (left) and Violin plot (right) of T cells for genes that are associated with T cells effector 
function. J, t-SNE plot (left) and Violin plot (right) of T cells for genes that are associated with 
chemokine secretion. *indicates Q<0.05 in the change of percentage expression cells and fold 
change is larger than 2. # indicates Q<0.05 in the change of cell number. Q value is determined 
by gene specific analysis (GSA) from Partek flow workstation.  * or # indicates change is 
significant higher for +DMXAA VS -DMXAA or 7 Days VS 10 Days and * or # indicates the 
change is significant higher for -DMXAA VS + DMXAA or 10 Day VS 7 Days. Single cell 
 
 63 
sequencing data represent 2-3 mice/treatment group and flow cytometric analysis is pooled from 











































































7Days 10Days apoe, ptgs2, areg batf2
batf2 ptgs2 batf2
7 Days after therapy






































7 Days 10 Days 7 Days 10 Days
 
 65 
Figure 2.4:  DMXAA reduces the accumulation of suppressive macrophages and enhances 
the trafficking of T cells in the TME, but this effect is eventually lost due to the return of 
immunosuppressive cells. 
A, t-SNE plot of macrophage populations identified by unsupervised clustering (Figure 2) were 
selected and classified as M1- or M2-like and compared between mice receiving therapy with or 
without DMXAA treatment. B, Heat map of genes identified in A exhibiting a greater than 2-
fold change in expression following DMXAA treatment with a significant difference of P < 0.05 
(determined by GSA analysis). C, t-SNE plot (left) and violin plots (right) showing expression of 
M2-related genes. D, t-SNE plot (left) and violin plots (right) showing expression of M1-related 
genes. E, Tumor area prior to and after 7 days treatment with Th/Tc17 CAR-T and DMXAA 
therapy in the following injection of clodronate or control liposomes (n=5 mice per group). F, t-
SNE plot of myeloid populations identified by unsupervised clustering (Figure 2) were selected 
and classified as inflammatory myeloid cells or suppressive myeloid cells and compared between 
mice in the presence or absence DMXAA treatment. G, Heat map of genes identified in F 
exhibiting a greater than 2-fold change in expression following DMXAA treatment with a 
significant difference of P < 0.05 (determined by GSA analysis). H, t-SNE plot depicting genes 
preferentially expressed in inflammatory myeloid cells. I, Violin plots showing distribution and 
change in expression of genes highlighted in H. Myeloid cells from unsupervised clustering 7 
days and 10 days after therapy were selected. J, t-SNE plot of myeloid cells between 7 days and 
10 days after therapy. K, Heat map of pro-inflammatory or suppressive genes that exhibit a 
greater than 2-fold change in expression following DMXAA treatment with a significant 
difference of P < 0.05. L, t-SNE plot of myeloid cells illustrating genes associated with the 
inflammatory and suppressive functions of myeloid cells. M, Violin plots showing distribution 
 
 66 
and change of indicated gene expression in L. *indicates P<0.05. Significance was determined 
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Figure 2.5:  DMXAA is required for tumor remission after Th/Tc17 CAR-T, DMXAA, 
anti-PD-1 and anti-Gr1 treatment. 
Animals received injections of anti-PD-1 (200μg/mouse) and anti-Gr1 (300μg/mouse) twice 
weekly, beginning a day after CAR-T injection in additional to therapy described in Figure 2 
(Th/Tc17 CAR+D+aP+aG).  A, Schematic describing therapy schedule. B, Summary of tumor 
growth (in area) in the first 3 weeks after CAR-T therapy. C, Change in tumor area was assessed 
7 days after administration of Th/Tc CAR + triple therapy or in the absence of DMXAA, anti-
PD-1, anti-Gr-1 or CAR-T cells (mock T cells to model the absence of CAR-T cells). D, Kaplan-
Meier survival curve indicating mortality over 100 days for the four treatment groups. Each 
group includes 9-12 mice pooled from a minimum of two independent experiments. * P <0.05, 
** P <0.01, *** P <0.001, **** P <0.0001, significance was determined by Student’s t-test or 
two-way ANOVA when comparing tumor growth change between groups or log-rank Mantel–
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Figure 2.6:  Depletion of myeloid cells with anti-Gr1 during Th/Tc17 CAR+D+aP regimen 
leads to cytokine release-like syndrome.  
Mice received Th/Tc17 CAR+D+P with or without twice weekly anti-Gr-1 injections after CAR-
T therapy. A, Quantification of weight loss as percentage of total change in body weight 
following Th/Tc17 CAR+D+P or Th/Tc17 CAR+D+aP+aG treatment (n = 6 mice/group). B. 
Kaplan-Meier survival curve indicating mortality over 20 days in the presence or absence of anti-
Gr-1 treatment. C, Change in tumor area 7 days after Th/Tc17 CAR+D+P or Th/Tc17 
CAR+D+aP+aG treatment in mice that survived but lost more than 10% of their initial weigh 
(CRS-like) compared to mice that eventually died from CRS-like symptoms (severe CRS-like) 
(n=4-6 mice/group). D, Serum cytokine levels of CCL2, mG-CSF and IL-6 measured 5 days 
after therapy (n=4 mice per group). E, Quantification of weight loss as percentage of total 
change in body weight following Th/Tc17 CAR+D+aP+aG+aIL-6 or Th/Tc17 CAR+D+aP+aG 
treatment (n = 7 mice/group). F, Kaplan-Meier survival curve indicating mortality over 20 days 
in the presence or absence of anti-IL-6 mAb treatment. G, Tumor growth change at 14 days after 
the therapy in the presence or absence of anti-Gr-1 and/or anti-IL-6 mAb. Data are shown as 
mean ± s.d. * P <0.05, ** P <0.01, *** P <0.0001, significance was determined by Student’s t-
test, Mann-Whitney test when comparing serum cytokine, and log-rank Mantel–Cox test when 






















Figure 2.7:  IL-7/15 cultured LH28BBz or LHBBz CAR-T cells fail to control in vitro or in 
vivo tumor growth control compared to LH28z CAR-T cells 
A, Schematic of the different CAR cassettes encoding the scFv (7.16.4), hinge and 
transmembrane domain from CD8, and intracellular domains from CD3ζ, 4-1BB and/or CD28. 
B, Expression of CAR-T receptor on IL-7/15 cultured LH28BBz or LHBBz CAR-T cells 
compared to LH28z CAR-T cells. C, Ratio of CD4+:CD8+ CAR T cells after 6 days of expansion 
with IL-7 and IL-15. D, NT2 cells were co-cultured with different ratios of indicated CAR-T 
cells for 6 hours, and tumor cell ATP activity was measured. Tumor ATP level indicating death 
of tumor cells was characterized at different ratios of mock-T cells, LH28z or LH28BBz CAR-T 
cells. E, Tumor area change was calculated following the administration of IL-7/15 cultured 
LHBBz or LH28z CAR-Ts (3x106 CAR-T cells intravenously at 1:1 CD4+:CD8+ ratio) into 
tumor bearing mice when the tumor size reached 50mm2. Data in c are shown as mean ± s.d. (n= 

















Figure 2.8:  7/15 CAR-Ts fail to control NT2 tumor growth in vivo compared to Th/Tc17 
CAR-Ts.  
A, Schematic of the tumor model in which 5x104 NT2 tumor cells were injected orthotopically 
into the mammary fat pad at day -21. Mice received 3x106 CAR-T cells intravenously at 1:1 
CD4+:CD8+ ratio at day 0 when the tumor size reached 50mm2. B, Tumor area change was 
calculated following injection of 7/15 CAR-T prior to lymphopenia induced by 5Gy total body 
irradiation. C, Tumor area change was calculated following the administration of anti-PD-1 (200 
μg/mouse) twice a week following 7/15 CAR-Ts injection. D, Representative flow cytometry 
histograms show detection of CAR-T cells within the tumor 5 days after 7/15 CAR-Ts infusion. 
E, Representative flow plots showing detection of CAR-T cells within the tumor or spleen 5 days 








Figure 2.9: DMXAA treatment induces global changes in immune cells of the TME 7 days 
after therapy.  
A, Immune cells were analyzed using unsupervised clustering and populations were determined 
by expression of key markers, including Cd3e (T cells), Itgam+ Adgre1+ (macrophage) and 
Itgam+ Adgre1- (myeloid cells). B, Comparison of frequency of indicated cell populations 
between +DMXAA and –DMXAA treated animals. * P <0.05, significance was determined by 









Figure 2.10: Th/Tc17 CAR-Ts, but not Tc17 CAR-Ts alone, control tumor growth in the 
presence of DMXAA.  
Tumor infiltrating T cells were isolated 7 days after therapy and CAR expression was determined 
by flow cytometry. A, Determination of change in tumor area 7 days after injection of Tc17 or 
Th/Tc17 CAR-Ts (n= 5-8 mice per group). B, Assessment of intratumoral CD8+ CAR-T cells 
was performed 7 days after therapy. C-D, Frequency and absolute number of CD8+ CAR-T cells 
per mm2 tumor 7 days after therapy (n= 3-9 mice per group). Data shown as mean ± s.d. * P 










Figure. 2.11:  DMXAA treatment enhances the number and cytotoxicity of Th17 CAR-T 
cells in the TME.  
A, CD4+ T cells were subdivided based on absence of Cd44 (naïve T cells), expression of Cd4 
and Cd44 (activated CD4 T cells), Cd4 and Foxp3 (Treg). CD4+ T cells were compared between 
the +DMXAA and –DMXAA treatment groups, and each sub-population was examined further 
as described below. B, t-SNE plot of CD4+ T cells for Th17 related genes. C, t-SNE plot of 
CD4+ T cells for Th17/Th1 related genes. D, Violin plot shows the distribution and change of 
indicated gene expression in B and C. E, Validation of single cell data using flow cytometry to 
detect CD4+ CAR-T cells. F, Analysis of the correlation between tumor growth change and 
absolute cell number of CAR-expressing CD4 T cells/ cm2 tumor. *indicates Q<0.05 in the 
change of percentage expression cells and fold change is greater than 2. # indicates Q<0.05 in the 
change of cell number. Q value is determined by gene specific analysis (GSA) from Partek flow 
workstation.  * or # indicates change is significant higher for +DMXAA VS -DMXAA. Single 
cell sequencing data represent 3 mice/treatment group and flow cytometric analysis is pooled 













Figure 2.12:  DMXAA treatment enhances anti-tumor function of Th/Tc17 CAR-T cells in 
an IFN-γ-dependent manner.  
Mice received Th/Tc17 CAR-Ts in the presence or absence of DMXAA therapy. 7 days later, 
RNA from tumors was isolated and analyzed by microarray for Th17/Th1 response A, Heat map 
depicts genes where fold change was significant with a 3-fold increase. Each column represents 
an individual mouse B, Quantification of significant changes (P<0.05) in TME for Th17 or Th1 
response following DMXAA treatment. C, Mice were treated intraperitoneally with anti-IFN-γ 
(250 μg/mouse) twice a week after Th/Tc17 CAR-Ts therapy. Tumor growth was measured for 2 
weeks after therapy. Significance was determined by Student’s t-test. Data from C is from two 











Figure 2.13:  T cell exhaustion limits the cumulative beneficial effect of DMXAA on 
Th/Tc17 CAR-T therapy. 
T cell cluster selected by Cd3e expression from unsupervised clustering of tumor infiltrating 
immune cells from 7 days and 10 days after Th/Tc17 CAR+D therapy.  
A, t-SNE plot (left) and violin plot of T cells for genes that are associated with T cells 
exhaustion. B, Validation of PD-1 expression using flow-based method to detect high levels of 
PD-1 expression on T cells from mice receiving Th/Tc17 CAR-T or mock-T cell therapy. 
Representative flow cytometry histograms (left), the percentage of CAR-T (right) within the 
CD4 or CD8 T cells group (n=4/group). C, t-SNE plot of T cells for genes associated with T cell 
apoptosis. D, Violin plot shows the distribution and change of indicated gene expression in C. 
*indicates Q<0.05 in the change of percentage expression cells and fold change is greater than 2. 
# indicates Q<0.05 in the change of cell number. * or # indicates the change is significant for day 
10 vs. day 7. Q value is determined by gene specific analysis (GSA) from Partek flow 















Figure. 2.14: Macrophages and myeloid cells are reduced upon DMXAA treatment, but 
later replaced by suppressive myeloid cells. 
Myeloid cells from day 7 are selected as in Figure 3F.  
A, t-SNE plot on M1-like (left) and M2-like (right) related genes. B, Violin plot shows the 
distribution and change of indicated gene expression in A. C, t-SNE and violin plot of cd274 
(PD-L1). D, t-SNE plot on genes expressed in inflammatory-like myeloid cells. E, Violin plot 
shows the distribution and change of indicated gene expression in D. F, t-SNE plot of genes 
expressed in myeloid-like suppressor cells. G, Violin plot shows the distribution and change of 
indicated gene expression in F. Myeloid cells from day 7 and day 10 are selected as in Figure 3J.  
H, t-SNE plot (left) and violin plot (right) of myeloid cells for genes associated with myeloid-

















Figure 2.15:  Anti-PD-1 and anti-GR-1 mAb does not increase therapeutic benefit of 7/15 
CAR-T cells with DMXAA. 
Mice are treated with anti-GR-1, anti-PD-1, DMXAA and Th/Tc17 CAR-Ts, 7/15 CAR-Ts or 
mock-Ts as described in Figure 5A. A, Tumor growth in individual mice receiving therapy (n = 
5-11 mice per group in E-F). B, Kaplan-Meier survival curve. C, Summary of CAR-T cell 
accumulation in the spleen. Data shown as mean ± s.d. * P <0.05, ** P <0.01, *** P <0.001, 
**** P <0.0001, significance was determined by Student’s t-test or two-way ANOVA when 

















Figure 2.16:  Differences in proliferative capacity and generation of central memory in 
Th17/Tc17 CAR-Ts.  
Mice received 7/15 CAR+D+aP or Th/Tc17 CAR+D+aP treatment. T cells were isolated from 
the tumor 7 days after therapy and characterized by flow cytometry. A, Representative plot (left) 
and summary graph (right) of Ki67 expression from CD4+CAR-T cells with 6-9 mice per group. 
B-C, Assessment of the memory phenotype of CD8+ CAR-T cells from the tumor at 7 or 12 days 
after 7/15 CAR+D+aP or Th/Tc17 CAR+D+aP treatment (n = 3-5 mice per group). D, 
Comparison of memory precursor effector cells of CD8+ CAR-T cells within the tumor 7 days 
after 7/15 CAR+D+aP or Th/Tc17 CAR+D+aP treatment (n = 4 mice per group shown). Data  











Figure. 2.17:  Model of the Activity of CAR T cells against Breast Cancer.  
The use of Th/Tc17 CAR-T cells with enhanced proliferation and memory status (intrinsic 
modification) along with DMXAA to enhance trafficking and reduce immumosuppression in the 
TME (extrinsic modification) are critical for the effective anti-tumor response of CAR-T cells 
against breast cancer (left). CAR-T exhaustion (intrinsic resistance) and reversion back to an 
immunosuppressive TME state (extrinsic resistance) are associated with loss of CAR T cell 
function (middle). The addition of anti-PD-1 to overcome exhaustion (intrinsic modification) and 
the depletion of suppressive myeloid cells with anti-Gr-1 (extrinsic modification) lead to 







Tumor cell culture. 3T3 cell lines were obtained from the ATCC and cultured in DMEM 
(Gibco) supplemented with 10% fetal bovine serum (FBS; Gemini), and 1% Pen/Strep 
(Invitrogen).  3T3-Neu and NT2 tumor have been previously described[98].  3T3-Neu cultures 
were made as described and cultured with the addition of 0.3 μM methotrexate.  NT2 (Passage 6) 
were cultured in RPMI-1640 (Gibco) supplemented with 20% FBS, 2 mM L-glutamine 
(Invitrogen), 12 mM HEPES (Invitrogen), 0.1 mM NEAA (Invitrogen), 1 mM sodium pyruvate 
(Invitrogen), 1% Pen/Strep, 50 μM 2-mercaptoethanol (Invitrogen) and 0.2 U/ml Novolin R-
insulin (Novo Nordisk).  The virus encoding the LH28z CAR was cultured in PLAT-E cells from 
Cell Biolabs Inc. in DMEM supplemented with 10% FBS and 1% Pen/Strep.  All cells used for 
the generation of the CAR constructs were used within 3 passages in vitro and 0.05% trypsin 
(Invitrogen) was used for digestion between passages.  
 
Vector construct. 7/15 and Th/Tc17 CARs contain the scFv of LH28z construct generated from 
the 7.16.4 antibody.  Whole RNA from the 7.16.4 hybridoma was isolated (RNEasy Kit, Qiagen) 
and made into cDNA (M-MLV Reverse Transcriptase kit, Invitrogen).  Antibody heavy and light 
chains were cloned with IgH or IgL primer mix (iRepertoire Inc.) and sequenced by Sanger 
sequencing (Genewiz).  CAR cDNAs were cloned into a construct containing murine CD8 
transmembrane domain and intracellular domain from murine CD28 or 4-1BB and CD3ξ 
(LH28z, LHBBz).  The CAR construct was then cloned into MSGV plasmid and driven by 5’ 




Viral construct preparation and transduction. Plasmids encoding CAR (LH28z) and pCL-
Eco retrovirus packaging vector (Novus) were co-transfected into PLAT-E cells using 
lipofectamine 2000 (Invitrogen).  Supernatant from LH28z-transfected PLAT-E cells was 
collected after 48 hours and stored at -800C.  For T cell transduction, LH28z or LHBBz or 
LH28z/LHBBz virus were plated onto a retronectin-coated plate (Takara) and incubated at 320C 
for 2h followed by the additional of activated T cells.  The co-culture was spun at 1200 x g for 
90 minutes and then stored at 370C overnight. 
 
T cell activation and culture. For 7/15 CAR T cells, splenocytes from 8-14w old female 
FVB/NJ mice (Jackson Labs) were harvested and activated using plate bound anti-CD3 (145-
2C11, Invitrogen) and anti-CD28 mAb (37.51, Invitrogen) and cultured in RPMI-1640 
supplemented with 10% FBS, 2 mM L-glutamine, 12 mM HEPES, 0.1 mM NEAA, 1 mM 
sodium pyruvate, 1% Pen/Strep, 50 μM 2-ME, along with the addition of 1 μg/ml IL-7 and IL-15 
(Peprotech).  48 hours later T cells were transduced with retrovirus and cultured for an additional 
3 days with IL-7 and IL-15.  For Th/Tc17 CAR T cells, naïve CD4+ and CD8+ T cells were 
isolated from the spleen of 8-14 week old female FVB/NJ mice (Jackson Labs) using murine 
naive CD4/CD8 T Cell Isolation Kit (Miltenyi) according to the manufacturer’s instructions.  T 
cells were activated using plate bound anti-CD3 and anti-CD28 mAb (Invitrogen).  For the first 
week, the culture was maintained as described above with the addition of TGF-β1 (2 ng/ml), IL-
1β (10 ng/ml), TNF (20 ng/ml), IL-6 (30 ng/ml) (Peprotech), anti-IFNγ	(R4-6A2, 10 μg/ml, 
Bioxcell) and anti-IL-2 (JES6-5H4, 10 μg/ml, Bioxcell) (Th17 cytokine cocktail).  Two days 
post-activation, T cells were transduced with retrovirus and kept in culture with Th17 cytokine 
cocktail for the rest of the week.  During the second week, cultured T cells were re-activated 
 
 90 
using plate bound anti-CD3 and anti-CD28 mAb and maintained in Th17 cytokine cocktail plus 
IL-23 (15 ng/ml) (Peprotech).    
 
Murine tumor model. 8-12 week old female FVB-Neu mice (Jackson Labs) were used under a 
protocol approved by University of North Carolina Institutional Animal Care and Use 
Committee.  For tumor inoculation, mice were intradermally injected with 5x104 NT2 tumor 
cells into an axillary mammary gland.  21 days later (day 0), 1.5x106 CD4+ and 1.5x106 CD8+ 
CAR T cells were injected intravenously.  Tumors were measured twice weekly with calipers 
and the tumor area calculated as length x width.  The change of tumor area was determined by 
subtracting the tumor area before CAR T injection with the value on the day of the measurement.  
Per institutional guidelines, tumor-bearing mice were sacrificed when the tumor area reached 
200 mm2 or loss of more than 20% of total body weight.  For tumor-bearing animals receiving 
combination therapy, animals underwent lymphodepletion with 5 Gy of whole body irradiation 
(X-RAD 320, Precision X-Ray) one day prior to CAR T injection.  In the morning of day 0 mice 
were injected with 500 μg of DMXAA (Tocris) distal to the site of tumor growth with CAR T 
cells injected in the afternoon.  Starting 1 day after CAR T infusion, anti-PD-1 (J43, 200 
μg/mouse), anti-Gr-1 (RB6-8C5, 300 μg/mouse), and anti-IFN-γ (R4-6A2, 250 μg/mouse) mAb 
were injected intraperitoneally into respective recipients.   
 
In vivo tumor infiltrating immune cells isolation. At indicated time points, tumors were 
bluntly resected and cut into small pieces and processed into a single-cell suspension using 
gentleMACS™ Dissociator (Miltenyi).  Lymphocyte enrichment was achieved by isolating cells 
at the interface of 44% Percoll (Sigma-Aldrich) in media and Lympholyte-M (Cedarlane).  
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Isolated immune cells were stained as described below.  The lymphocyte fraction was not 
enriched in experiments where absolute cell number was determined. 
 
In vivo tumor infiltrating immune cells isolation for single cell RNA sequencing analysis. 
At day 7 or day 10 after CAR-T therapy, tumors were bluntly resected and cut into small pieces 
and digested using Tumor Dissociation Kit, mouse (Miltenyi) in gentleMACS™ Dissociator 
(Miltenyi) according to manufacturer’s instruction. After digestion, dead and dying cells were 
magnetically separated using a Dead Cell Removal Kit (Miltenyi), after which immune cells 
were magnetically enriched using CD45 (TIL) MicroBeads (Miltenyi). Single cells were 
partitioned using a Chromium Controller (10x Genomics), and gene expression sequencing 
libraries were generated using Chromium Single Cell 3′Library & Gel Bead Kit v3 (10x 
Genomics). The libraries were pooled and sequenced using an Illumina NovaSeq 6000 
(Illumina). Raw base call files were demultiplexed with Cell Ranger 3.1.0 (10x Genomics) and 
bcl2fastq Conversion Software v2.20.0 (Illumina).  
 
Single cell RNA sequencing result analysis. Single cell results from Cell Ranger output was 
analyzed using Partek flow workstation (https://www.partek.com/application-page/single-cell-
gene-expression/).  In detail, single cell result from each sample of Cell Ranger output was 
filtered using single cell (QA/QC) filter to exclude doublets/multiplets, cells expressing genes 
<30 genes per cell and dead cells.  Processed results were normalized using recommended 
method, including log normalization of gene expression and scaled to count per million.  
Following results were filtered out by feature (gene) that were not expressed in 99% of samples. 
Then the replicate samples were pooled and clustered with an unsupervised method based on 
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PCA using the first 16 principle component. Clustered plots were visualized by t-SNE plot, 
where cells were clustered using shared nearest neighbor (SNN). Populations was determined by 
expression of key markers, including Cd3e (T cells), Adgre1 (macrophage) and Itgam and/or 
Itgax (myeloid cells), and T cells were further clustered by expression of Cd8 and Cd44 
(activated CD8 T cells), lack of Cd44 (naïve T cells), Cd4 Cd44 (activated CD4 T cells) and Cd4 
Foxp3 (Treg). For comparison, samples from each treatment group was pooled by the mean 
expression to simulate bulk RNA-seq, and compared using GSA analysis directly. Gene hits that 
reached P<0.05 with more than 2 or less than -2 fold expression difference was reported and 
shown as a heat map for pooled samples (macrophage and myeloid cells) or Q<0.05 with 2 or -2 
fold expression difference for non-pooled samples (T cells). Further detailed analysis steps can 
be found on Partek flow page 
(https://documentation.partek.com/pages/viewpage.action?pageId=12943422) and parameter 
setting was set as default unless indicated.  
 
Flow cytometry. Anti-Neu CAR T cells were detected using recombinant Neu/Her2.Fc fusion 
protein conjugated with PE (Neu-PE) (Creative Biomart).  Antibodies used in in vitro assays 
included anti-CD45-FITC/e450 (30-F11, Invitrogen), anti-IFN-γ-APC (XMG1.2, Invitrogen), 
anti-TNF-PE-Cy7 (MP6-XT22, Invitrogen) and anti-IL-17A-PE (eBio17B7, Invitrogen).  
Tumor-infiltrating immune cells were detected and analyzed with anti-CD45-FITC, anti-CD3-
e450 (17A2, Invitrogen), anti-CD4-BV510 (GK1.5, Biolegend), anti-CD8-APC-Cy7 (53-6.7 BD 
Biosciences), anti-CD44-PerCP5.5 (IM7, Invitrogen), anti-CD62L-APC (MEL-14, Invitrogen), 
anti-CD11b-BV711 (M1/70, Invitrogen), anti-F4/80-BV605 (BM8, Invitrogen), anti-Gr-1-
Percp5.5 (RB6-8C5, Invitrogen), anti-PD-1-PE-Cy7 (J43, Invitrogen), anti-CD127-BV421 
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(A7R34, Biolegend), anti-KLGR1-BV605 (2F1, BD Bioscience).  For in vivo intracellular 
protein staining, anti-Foxp3-PerCP5.5 (FJK-16S. Invitrogen), anti-Ki67-APC (SOLA15, 
Invitrogen) were used.  Dead cells were excluded with Fixable Viability Stain 700 (BD 
Biosciences) and Fc receptors were blocked with Fc block (BD Biosciences).  Cell number was 
determined using Count Bright Beads (Invitrogen).  Data were collected using a BD LSR-
Fortessa or BD Canto cytometer (BD Biosciences).  Data were analyzed with FlowJo software 
(Treestar). 
 
Flow cytometry-based T cell cytolytic assay. For co-culture killing assays, 106 NT2 tumor cells 
were labeled with 5 μM CFSE (Invitrogen) and plated in culture media for 24 hours.  CAR-T, 
mock transfected T cells or no T cells were added the next day at the indicated ratios and co-
cultured in T cell media without cytokines for three days.  Supernatant and trypsinized cells were 
collected and stained with 7-AAD (BD Biosciences) and anti-CD45 (30-F11, Invitrogen).  
Killing was measured by flow cytometry after gating on CFSE+, 7-AAD- and CD45- tumor cells 
and normalized to groups without T cell addition.  For killing curve, NT2 tumor cells were 
labeled with CFSE and plated at 105 cells/well in a 48 well plate.  CAR T cells, mock T cells or 
no T cells at the indicated ratios were added 12 hours later.  Co-cultures were maintained in T 
cell media without cytokine for 18 hours and cell killing was measured as described above.  
Percent tumor lysis was calculated by subtracting the number of live tumor cells from 100% and 
dividing by the total number of live tumor cells in the group with no T cells added.  
 
Cytokine release assay. 5x105 3T3 or 3T3-Neu cells were treated with trypsin and processed 
into a single cell suspension prior to culture with CAR T or mock T cells at indicated ratios in T 
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cell media without additional cytokine.  5 μg/ml of Brefeldin A (BD Biosciences) was added 
after the first hour co-culture.  Cells were stimulated for 5 hours and then pelleted for 
extracellular staining with anti-CD45, followed by fixation and permeabilization using Fix/Perm 
Kit (BD Biosciences) according to the manufacturer’s instructions.  Anti-IFN-γ, anti-TNF and 
anti-IL-17A were used for intracellular cytokine staining and detected by flow cytometry.  
 
Real-time PCR array. Whole tumor RNA was isolated using the RNEasy Kit (Qiagen) and 
reverse transcribed using RT2 First Strand Kit (Qiagen).  RT-qPCR was performed according to 
the manufacturer’s instruction with the RT² Profiler™ PCR Array Mouse Th17 Response 
(PAMM-073ZE-4, Qiagen) and performed on the QuantStudio 6K (Applied Biosystems Inc.). Ct 
values were determined by ABI software and data analysis was performed using the web-based 
RT2 Profiler PCR Array Data Analysis version 3.5 (Qiagen).  Fold change was normalized to a 














CHAPTER III. B CELLS AND T FOLLICULAR HELPER CELLS MEDIATE 
RESPONSE TO CHECKPOINT INHIBITORS IN HIGH MUTATION BURDEN MOUSE 
MODELS OF BREAST CANCER1
 
Introduction 
Immune checkpoint inhibitors (ICI) have improved patient outcomes in human cancers [237, 
238]. In many solid tumors, tumor mutation burden (TMB), and as a result of high TMB, neo-
antigen load are biomarkers for therapeutic benefit. For example, in colorectal cancers, 
mismatch-repair status predicted clinical benefit for the anti-PD1 antibody pembrolizumab[238]. 
In non-small cell lung cancer, a mutation signature linked to smoking predicted anti-PD1 
efficacy [239]. In melanoma, TMB and neoantigen load predict patient response to anti-CTLA-4 
therapy [240]. The presence of CD8+ T Cells[241] and expression of immune checkpoint genes 
such as the PD1 ligand (PD-L1) [242] and CTLA-4[243] also predict ICI efficacy. These data 
indicate that predicting response to ICI is multi-factorial and requires additional studies. 
 
In triple negative breast cancer (TNBC), immune cells identified by pathology (i.e. TILs) or 
by genomic signatures, indicate a favorable prognosis[244, 245] and chemotherapy efficacy is 
more likely in tumors with immune infiltrates [246, 247]. In addition to immune infiltration, 
TNBCs tend to harbor higher TMB amongst breast cancers. Recently, atezolizumab (an anti-
 
1This chapter contains a manuscript that has been published by cell. I am listed as a second author in this 
manuscript. I performed experiments for figure 4,6,7 and figure 11,12,14,15. I provided suggestion during the 
writing of the manuscript, participated in the revision of the manuscript and performed additional experiments 
after peer review. The original citation is: Hollern DP, Xu N, Thennavan A, et al. B Cells and T Follicular Helper Cells 




PDL1 antibody) plus nab-paclitaxel was shown to prolong progression-free survival in TNBC 
patients with PD-L1 positive tumors[248]. With this success and FDA approval, ICI response 
rates still range from 10-20% [249] and atezolizumab’s impact on TNBC overall survival is 
modest. Given lessons from other cancer types, we hypothesized that TMB and immune cell 
infiltration could be important factors in response to ICI for TNBC.  
  
In breast cancer, APOBEC3B enzyme activity is linked to mutagenesis of tumor genomes 
[250]. APOBEC3B is a cytidine deaminase and upon activity creates a basic sites that lead to 
mutations [251] and potentially neoantigens. Since mutation load predicts ICI response in other 
cancers [239, 240] and APOBEC3B activity corresponds with higher TMB in breast cancer 
[250], we created two separate genetically engineered mouse models (GEMM) of mammary 
cancers with overexpression of murine APOBEC3. Similarly, we used short-wave ultra-violet 
radiation to create additional high TMB GEMMs. We refer to these lines with intentionally 
increased total mutation burden as “mutagenized lines” and the non-mutated version of each line 
as its “parental line”.  Using these and other mouse models of TNBC in a pre-clinical trial of 
anti-PD1 and anti-CTLA4 therapy, we identify factors that mediate response to ICI including an 
important role for CD4+ T follicular helper cells (Tfh), B cells and the generation of antibody by 









Mouse Models and Genomic Signatures of Immune Cells.  
To study the response to ICI and identify predictive biomarkers, we turned to a genetically 
controlled model system, namely a rich resource of credentialed mouse models of TNBC [252-
254]. Figure 3.1 shows the key mRNA features for 290 specimens from multiple GEMMs. 
Within Tp53-/- and K14-Cre;Tp53f/f; Brca1f/f models, we selected transplantable sublines to 
establish a cohort for anti-PD1 and anti-CTLA4 combination therapy (aPD1/aCTLA4 = ICI; 7 
models used for initial ICI testing). Our work here focused on experimentation predominately in 
two different GEMMs: Tp53-/- tumor syngeneic transplant derived cell line (T11), and a cell line 
from a K14-Cre;Tp53f/f; Brca1f/f tumor (KPB25L). Other treated GEMMs are listed in Table 1. 
These mouse models of TNBC represent multiple subtypes (i.e. basal-like and claudin-low [252, 
255]) and show expression of signatures for CD4+ T cells, CD8+ T cells, B cells, and 
immunoglobulin G (IgG)(Figure 3.1). Diverse expression of immune checkpoint genes 
Pdcd1,Cd274 (Pd-l1), and Ctla4 was also noted in the 7 syngeneic transplantable murine lines 
used for testing ICI therapy.  
  
Testing of GEMM of Mammary Cancer with Immune Checkpoint inhibitors.  
Initial testing with aPD1/aCTLA4 therapy in TNBC GEMMs showed no response in 6/7 
tumor lines (Table 1, Figure 3.8A). Resistant GEMMs had a low TMB (Figure 3.8B) and a low 
predicted neoantigen burden (Figure 3.8C). Murine tumors had lower TMBs than typically found 
in human breast cancer, and considerably lower than ICI responsive human NSCLC and 
melanomas (Figure 3.8D). The lone (moderately) sensitive model was a BRCA1 deficient tumor 
line (KPB25L) which had higher relative TMB. Thus, we posited that to accurately reflect the 
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ICI response clinically, we needed to develop additional models that reflect the higher TMB of 
human cancers.  Because Apobec3 is linked to mutagenesis of breast cancer[250], and immune 
cell infiltrates [256-258], we hypothesized that Apobec3 could elevate the mutation load and 
number of predicted neoantigens, possibly sensitizing a previously resistant GEMM tumor to ICI 
therapy. Similarly, we hypothesized exposure to ultra violet (UV) radiation in could lock in new 
mutations to create high TMB models and improve ICI sensitivity. Indeed, Apobec3 over-
expression (T11-Apobec, KPB25L-Apobec, Figure 3.2A) and UV exposure (T11-UV, 
KPB25Luv, Figure 3.2B) markedly increased TMB as compared to the matched time-in-culture 
parental cell lines (T11, KPB25L). As expected, having a higher TMB also led to a higher 
predicted neoantigen load in MHC haplotype compatible lines (Figure 3.8C). 
 
In support of the TMB/neoantigen hypothesis of ICI responsiveness, the parental lines showed 
little sensitivity to anti-PD-1/anti-CTLA-4 therapy (Figure 3.2B) while the mutagenized lines 
had robust responses (Figure 3.2C, Figure 3.8E). The response data for all sensitive and resistant 
lines is shown in Figure 3.8. Table 1 and Table S1 lists hazard ratios for every survival endpoint 
in this report.  We also tested single agent anti-PD-1 and anti-CTLA-4 and noted while 
sometimes effective, single ICIs where inferior to combinations (Figure 3.8F). Testing isotype 
controls confirmed that response to therapy was not driven by the presence of exogenous IgG2a 
or IgG2b antibodies (Figure 3.8G), consistent with the lack of any therapeutic effect in resistant 
lines. As controls, Apobec3 overexpression and UV-based mutagenesis strategies did not impact 
proliferation in vitro (Figure 3.9). As a whole, these results signify TMB as a key marker for ICI 




Genomic Analysis of ICI Treated GEMM tumors.  
To test for additional predictors of response to ICI therapy, we examined pretreatment tumors 
(5mm in diameter) from sensitive and resistant models with mRNA-seq. Published mRNA 
signatures for CD4+ T cells[259], CD8+ T cells[260], B cells[244], and IgG [260] each 
correlated with response (Figure 3.2D). Levels of immune checkpoint genes Pdcd1 and Ctla4 
(Figure 3.2E), as well as interferon-gamma (serum and tumor, Figure 3.3C), were also 
significantly higher in sensitive tumors. Thus, we hypothesized that our mRNA-seq data may 
enable the development of new mRNA-based biomarkers. We therefore performed supervised 
analyses to derive signatures differentiating sensitive from resistant tumors. Given that 
functionally related genes often covary, we used hierarchical clustering and SigClust [261] to 
identify metagenes of statistical significance and probable biological meaning(Figure 3.3A). This 
identified a large cluster of immune cell genes (immune activity cluster) and a smaller node of B 
cell genes, IgGs, and T cell genes (Figure 3.10A) that is henceforth referred to as the B cell / T 
cell co-cluster.  
 
Human Patient Studies.  
To test the clinical value of these two new genomic signatures, we used published data from 
multiple human clinical studies. This included two melanoma datasets of patients treated with 
ICI [240, 262], three human breast cancer datasets from clinical trials of neoadjuvant 
chemotherapy [263-265], and one human breast cancer dataset that is a clinical trial of 
neoadjuvant trastuzumab + paclitaxel [266]. In each dataset the B cell / T cell co-cluster was 
significantly higher in pretreatment samples from patients that responded to therapy (Figure 
3.3B-G). Similar results were noted for the immune activity cluster (Figure 3.10B-G), however, 
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one exception was seen in the human melanoma dataset that used single cell profiling of CD45+ 
cells, where the immune activity cluster was not predictive, but the B cell / T cell co-cluster was. 
Given that equal numbers of CD45+ cells were profiled in responder and non-responder groups, 
similar expression of the generic immune activity cluster was expected. Thus, when examining 
even numbers of total immune cells, higher representation of B cell populations seems to predict 
response in human breast and melanoma tumors. 
  
Immune Cell Response to Therapy.  
To test whether these immune cell features are also activated by ICI therapy, we examined 
tumors after 7 days with or without ICI therapy using mRNA-seq. No significant changes were 
seen in immune signatures for resistant tumors. In sensitive lines treated with ICI, mRNA-seq 
again identified significant elevation in CD4+ T cells, CD8+ T cells, B cells, and IgG signatures 
(Figure 3.4A). Flow cytometry analysis (see methods Figure 3.15 for gating) confirmed T cell 
signatures and revealed expanded CD8+ and CD4+ effector memory T cells with therapy in 
sensitive models (Figure 3.4B). Flow cytometry also verified B cell signatures, with anti-
PD1/anti-CTLA4 treated tumors presenting a striking increase in activated B cells (Figure 
3.4C,D). Strong concordance between mRNA-seq and flow cytometry was also seen within each 
tumor model (Figure 3.11A-C). The IgG signature predicted the potential for B cell class-
switching and antibody responses. To confirm this prediction, we first used IHC. 
 
Indeed, IHC showed that ICI increased the number of IgG-positive cells within the tumor 
(Figure 3.4E). To test secretory antibody activity, we examined serum IgG binding to cells kept 
in vitro. Here, we noted a significant increase in IgG binding against KPB25Luv cells in ICI 
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treated mice (Figure 3.4F), with specificity marked by low off target binding (Figure 3.4G). 
Additional tests implied a possible IgG target(s) specific to the mutagenized line, as well as a 
shared target(s) with the parent line (Figure 3.11D). Treatment also increased serum IgG specific 
to tumor cells in the T11-Apobec model (Figure 3.4H). Finally, ICI did not substantially increase 
T cells in T11 parental tumors (Figure 3.11E). High CD8 to T regulatory cell (T regs) ratios were 
exclusive to mutagenized tumors (Figure 3.11F), suggesting mutations/neoantigens as key to the 
release of immune-suppression and a shift towards a productive anti-tumor response featuring 
activated T cells and B cells.  
 
Single Cell mRNA-seq.  
To precisely define the responding T cell and B cell subsets, we examined KPB25Luv (Figure 
3.5) and T11-Apobec (Figure 3.12) tumors after 7 days with or without ICI using single cell 
RNA-seq (scRNA-seq). Untreated tumors had an abundance of tumor cells, neutrophils, and 
macrophages, with a variety of other cell types present at lower frequencies (Figure 3.5A; 
3.12A). With aPD1/aCTLA4 therapy, prominent changes in the distribution of cell types 
identified were noted. In particular, tumor cells, neutrophils, macrophages were reduced while T 
cells and B cells were expanded (Figure 3.5A,B; 3.12A,B). In addition, a plasma cell cluster was 
identified and unique to treated tumors. Changes in these cell types were also reflected in 
supervised analyses comparing tumors with and without therapy (Figure 3.5C; 3.12C).   
 
In both GEMMs tested, effector memory CD8+ T cells were expanded by therapy. 
Accordingly, scRNA-seq showed significantly higher abundance of cells with Cd8a expression 
(Figure 3.5D; 3.12D). Significance testing of ICI treated CD8+ clusters revealed proliferation 
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and cytotoxic genes as increased in CD8+ T cell subsets (Figure 3.5E; 3.12E). Among cells with 
cytotoxic gene expression profiles, cells with high expression of checkpoint/exhaustion markers 
Eomes, Pdcd1, Ctla4, Lag3, and Tim3 were frequent(Figure 3.5G; 3.12G)[267]. We also noted 
CD8+ subsets that were unique to KPB25Luv tumors, with one having high expression of Eomes 
and another with high Ccr10 mRNA (Figure 3.5E-G). The Ccr10 high CD8+ T cells were also 
marked by expression of Cxcr3 and genes involved in cell migration, which is indicative of T 
cells trafficking to sites of inflammation[268, 269]. High EOMES and PD1 with low T-BET 
(TBX21) is known to mark terminal exhaustion and minimal capacity to respond to ICI[270]. 
Yet, the Eomes high CD8+ T cell cluster in KPB25Luv tumors lacked high Pdcd1 expression and 
had moderate Tbx21 levels. Together, these data show the CD8+ T cells to contain proliferating 
and cytotoxic effector memory cells.  
 
Cells expressing Cd4 mRNA were significantly increased with ICI therapy (Figure 3.5H, 
3.12H). Examining treated sensitive tumors, differentially expressed genes amongst CD4+ 
clusters identified T cells with high expression of proliferation genes (Figure 3.5I, 3.12I). This 
analysis also identified a large group of Tregs mixed with naïve-like subsets in T11-Apobec. In 
contrast, Tregs were distinct from other CD4+ subsets (Figure 3.5A) in the KPB25Luv model. 
Marker analysis also identified significant genes for a cluster of CD4+ cells resembling T 
follicular helper cells (Tfh; Figure 3.5I and 3.12I). This included well known markers such as 
Cxcr5, Cd154 (Cd40l), Pdcd1,Maf, and Il21 [271]. These Tfh-associated genes showed a clear 
distinction between the Naïve and Tfh-like clusters in KPB25Luv (Figure 3.5I-K). Similar results 
were found in T11-Apobec, adding that Tfh-like cells were also present in the proliferating 
group. With Pdcd1, many of the Tfh-like cells also had high expression of Ctla4. Collectively, 
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these data depict the dominant effector memory subset of CD4+ T cells to be T follicular helper 
cells.   
 
Markers for B cells were also associated with ICI therapy in scRNA-seq (Figure 3.5L; 3.12L) 
and depicted various stages of B cell activation in treated sensitive tumors (Figure 3.5 and 3.12 
M-O) . For example in KPB25Luv tumors, B cells were separated on the B cell receptor (BCR) 
isotype.  Non-class switched B cells had high expression of MHC class II genes and other 
activation markers. Class-switched B cells were marked by high expression of proliferation 
genes, Aicda, and Ighg1 (and low Ighd); thus, these B cells resemble those class-switched B cells 
undergoing somatic hypermutation. While this cluster was not detected in T11-Apobec, probing 
for these genes identified these cell types amongst the B cells present in this tumor model. Both 
models showed a distinct cluster of cells with gene expression profiles matching that of plasma 
cells. These cells were marked by high expression of IgG (Ighg1, Ighg3), which indicates class 
switching and the dominant antibody types induced by ICI.  
 
TCR/BCR Clonality  
To understand the selectivity of the T cell and B cell response, we used 5’ RACE-like 
sequencing to measure BCR and TCR (T cell receptor) clonality in ICI treated KPB25Luv 
(Figure 3.5P) and T11-Apobec (Figure 3.12P) tumors. Perhaps related to differences noted by 
scRNA-seq, T cells in T11-Apobec were more clonally restricted than KPB25Luv. In fact, the 
top three clones in T11-Apobec (Shannon entropy= 4.22) accounted for 40% of TCR-alpha 
expression compared to 14% in KPB25Luv (Shannon entropy = 5.58) tumors; TCR-beta 
sequences matched these trends. Assessing BCR diversity, both models were clonal. The top 
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clone of the heavy chain (BCR-H) alone made up 41% of sequences in KPB25Luv (Shannon 
entropy=2.05) and 54% of BCR-H sequences in T11-Apobec (Shannon entropy= 2.18). Light 
chain mRNA also showed a high degree of clonal restriction (BCR lambda, Shannon entropy 
KPB25Luv = 0.68; T11-Apobec = 1.75). Collectively, these data show significant evidence of 
immune adaptive cell clonal selection. 
 
Role of B cells and T cells in Response to ICI in murine models.  
The B cell/T Cell co-cluster signature predicted ICI response in human cancers and both B 
cells and T cells showed robust expansion following therapy. Thus, it was critical to test whether 
these cell types were essential to ICI efficacy in our in vivo models. Hence, we individually 
depleted CD4+ T cells, CD8+ T cells, or B cells using antibodies (Figure 3.13) during anti-
PD1/anti-CTLA4 therapy. In each case, depletion of these populations (i.e. CD4+, CD8+, CD19+, 
CD20+) significantly reduced the therapeutic response to anti-PD1/anti-CTLA4 therapy as 
assessed by survival (Figure 3.6A,C) and short term response (i.e. tumor volume changes (Figure 
3.6B,D). Most prominent effects were observed in the CD4+ T cell depleted mice and B cell 
inhibited/depleted mice (CD19 or CD20 respectively), where therapeutic benefit was completely 
ablated. 
 
B cells are known to present antigens to T cells[272, 273], prompting us to test the impact of B 
cell activity on T cells. Interestingly, both CD8+ and CD4+ T cells were reduced by B cell 
inhibition (Figure 3.6E). In CD8+ subsets, the effector and effector memory T cells were 
reduced. In the CD4+ T cells, effector memory and central memory subsets were diminished by 
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B cell inhibition. Together, these data indicate the generation of T cell memory is in part 
dependent on the function of B cells.   
 
Our B cell/T cell co-cluster also suggested that B cell activity may be similarly dependent on 
T cells. Indeed, CD4+ T cells are known regulators of B cell activity[274]. To formally test this, 
we first tested if CD4+ T cell depletion impacted B cell infiltration and activation during ICI 
therapy by flow cytometry. ICI treated tumors depleted for CD4+ T cells resembled non-treated 
tumors (Figure 3.7A), showing minimal B cell infiltration in the tumor (Figure 3.7B). As such 
we sought to identify which CD4+ subset was involved in the mechanism of B cell activation. To 
predict the CD4+ cell type activating B cells, we used the bulk mRNA-seq and scRNA-seq data. 
Published signatures for Th1 (Figure 3.14A) and Th2 (Figure 3.14B) subsets did not correlate 
with B cell signatures nor show elevation with therapy in mRNA-seq data in sensitive models. 
Similarly, Th1, Th2, and Th17 cytokines were rarely expressed the scRNA-seq transcriptome 
data suggesting that these cells are not commonly found in ICI treated tumors (Figure 3.14C,D). 
However, published signatures for T follicular helper cells strongly correlated (p<0.0001) with B 
cell signatures in mRNA-seq of ICI sensitive tumors (day 7, Figure 3.7C) and were significantly 
elevated upon aPD1/aCTLA4 therapy (Figure 3.7D). Similar results were found for the Tfh 
cytokine IL-21 (if protein, Il21 if gene) (Figure 3.7E,F). This is consistent with scRNA-seq data 
(Figure 3.5 and 3.12 I-K), showing increased expression of IL21 and a large cluster of cells with 
Tfh-like expression profiles present with ICI therapy. 
 
To test if B cell activation by ICI therapy was reliant on Tfh cells, we used antibodies against 
IL21 to neutralize Tfh activity [275]. IL21 blockade during aPD1/aCTLA4 therapy significantly 
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reduced B cell activity in both KPB25Luv and T11-Apobec tumors (Figure 3.7G, Figure 
3.14E,F). Given that IL21 is known to support class switching and plasma cell generation, we 
also examined IgG staining by IHC. This revealed that blocking IL21 during ICI therapy sharply 
reduced the number of IgG+ cells (Figure 3.7H, 3.14G). These data indicate a critical role for the 
activity of Tfh cells in the generation of antibody after dual ICI.  TNBC are often infiltrated with 
regulatory T cells (Tregs) which may be critical to inhibiting the adaptive immune response. As 
the function of Tregs is somewhat dependent on regulatory CTLA-4 signaling [276] we wondered 
whether blocking Treg activity may explain the additive effect of combining aPD1 and aCTLA4 
on B cell activation (Figure 3.11A,B). Thus, we used a mouse model where FOXP3+ cells (Tregs) 
can be specifically and temporally ablated by diphtheria toxin  [100] to test their impact on B cell 
activation. As suspected, ablation of FOXP3+ cells increased the presence of activated B cells 
(Figure 3.14H). Together, these data imply that the optimal B cell activity and therapeutic 
benefits coming from aPD1/aCTLA4 therapy correlated with concurrent Treg inhibition and Tfh 
activation. To test the importance of Tfh / IL21 activity for ICI benefit, we examined response of 
mice given aPD1/aCTLA4 therapy with IL21 blockade. This markedly diminished the anti-tumor 
response (Figure 3.14 I,J) and survival in KPB25Luv (Figure 3.7I) and T11-Apobec (Figure 
3.7J) tumors. As a whole, these data indicate Tfh cells to be critical to ICI efficacy by activating 
B cells to amplify the anti-tumor immune response.  
 
B cell activation by ICI therapy also led to the generation of class-switched plasma cells 
(IgHg1 and IgHg3; Figure 3.5 and 3.12 M-O), and tumor specific serum IgG increased following 
therapy. Moreover, IgG genes were a central part of our highly predictive B cell/T cell signature. 
This implied that production of IgG against tumor cells was important in mediating response to 
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ICI. To test this, we utilized a novel mouse model (IgMi; [277] that is immune-intact where B 
cells can be activated but are incapable of antibody secretion (verified in Figure 3.7K, 3.14K). 
Remarkably, the loss of antibody secretion during ICI therapy diminished the initial anti-tumor 
response (Figure 3.7L) and survival (Figure 3.7M) in T11-Apobec bearing mice. As IgMi mice 
are not available on a FvB background we used neutralizing anti-CD16 mAb to evaluate the role 
of secretory Ig in the KPB25Luv model [278], (Figure 3.14L,M). This also led to diminished 
responses to ICI therapy when assessed by overall survival (Figure 3.7N). These data for the first 
time indicate a critical role for antibody secretion in the function of ICI therapy.   
  
Discussion 
Identifying predictive biomarkers for human cancer patients is critically important for 
improvements in immunotherapy, and are the foundation of precision medicine. GEMM of 
human cancers are often used to investigate the mechanistic impact of specific genetic 
alterations, but in general, have yielded few clinically relevant biomarkers. The lack of public 
genomic data on ICI-treated human TNBC limited our human-to-mouse TNBC comparisons. 
Thus to seek translational evidence, we tested our possible biomarker for ICI therapy response 
on multiple clinical datasets covering a number of different therapeutic settings, and cancer 
types.  
 
This study provides a robust genomic data set, and novel syngeneic murine tumor resource, for 
further investigations into the immune microenvironment using a reproducible and genetically 
controlled animal model system. In particular, we have created a new set of transplantable TNBC 
mouse model tumors that have high TMB and are sensitive to ICI therapies. It was necessary to 
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develop these new “mutagenized” models for studying immunotherapy in TNBC as the majority 
of GEMM mammary tumor models were resistant and had TMB much lower than typically 
present in human breast tumors. As stated, these mutagenized GEMMs are uniquely immune 
activated and therefore will be ideal for future studies of immune cell dynamics and testing novel 
immunotherapies. In addition, we provide a unique resource of mRNA-seq and scRNA-seq data 
with FACS validated changes in immune features.  
 
Our ICI responsive “mutagenized” models came from genomically credentialed Tp53-/- [279] 
and K14-Cre;Tp53f/f; Brca1f/f [254] GEMMs that parallel human TNBC in somatic mutations, 
copy number changes, and gene expression profiles[253, 254, 280]. While mutation sharing in 
TNBCs is low amongst human breast cancer patients [281], save for a few drivers such as TP53 
and BRCA1, we did aim to mimic human breast cancer mutagenesis with our use of our 
BRCA1-deficient and APOBEC3 overexpression models. While UV-induced high TMB does 
not mimic the typical means for breast cancer mutagenesis, it is not evident in the clinical data 
that the process leading to increased TMB is as critical to ICI response as the presence of high 
TMB. Indeed, smoking, UV, Apobec, and homologous recombination deficiency mutation 
signatures were tested across KEYNOTE trial patients and showed no value over TMB alone in 
the ability to predict ICI benefit [282]. In agreement, the means to obtain high TMB did not 
relate to response in our GEMMs; namely APOBEC3 or UV induced high TMB, and this created 
higher sensitivity in both GEMMs. Yet, more studies are needed to clarify if mutational process 




While our two GEMMs had many similarities, we also noted differences between the various 
mutagenized lines corresponding to the parent model (T11 vs KPB25L), which may be linked to 
contrasts in their TNBC subtypes (claudin-low vs basal-like). In particular, KPB25Luv and T11-
Apobec models differed in their responsiveness to single agent ICI. In KPB25Luv tumors, 
individual aPD1 or aCTLA4 were equally effective in activating B cells and the anti-tumor 
immune response. However, in T11-Apobec, aCTLA4 was clearly more effective in eliciting B 
cell activation and therapeutic response. Given that CTLA-4 signaling is critical to the function 
of Tregs[276], we believe this to be related to the critical role of Tregs in suppressing the immune 
response which is intrinsic to T11 tumors via tumor cell CXCL12 secretion [100], This appears 
to be a general feature found in the claudin-low subtype. Indeed, genetic ablation of Tregs in T11-
Apobec was sufficient to induce increased B cell activation (Figure 3.14H). Variances in these 
models were also noted for CD8+ subsets and T cell clonality. Collectively, these differences in 
GEMMs add resource value, where individual models can be selected for growth rate, high or 
low ICI sensitivity, or composition of the microenvironment.  
 
Demonstrating the utility of the resources presented here, we have used these models to 
identify a new component of response to ICI therapy involving B cells and Tfh cells. 
Importantly, our findings here are distinct from prior findings detailing PD1 activity in B cells 
[283, 284]. For example, Thibult et al described aPD1 antibodies directly activating B cells that 
had high PD1 expression. This mechanism was shown to be T cell independent and exclusive to 
peripheral B cell subsets. In addition, the authors noted that they did not observe any impact by 
aPD1 on production of class-switched antibody. In the Wang et al study, the authors show that 
PD1 high B cells functionally suppress T cell activity and suggest these B cells as an unique B 
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regulatory cell subset. In contrast to the above studies, the B cell subsets in our tumor models did 
not show expression of Pdcd1 or express markers of B regulatory cells. Further, B cell activation 
by ICI was dependent upon Tfh cell function and resembled those occurring in germinal center B 
cells. Finally, B cell activation by ICI in our models was tied to increased class-switched 
antibody (IgG) production and activation of T cell subsets as indicated by diminished numbers of 
memory T cells following B cell inhibition. Thus, our study reveals a distinct mechanism B cell 
activation while further uncovering the necessity of B cell and Tfh cell subsets in mediating ICI-
induced anti-tumor responses. 
 
Our findings also add context to prior studies showing B cells as prognostic in many cancers 
[285-287]. Here we extend prognosis to therapeutic response with a new predictive gene 
signature. Building on these predictions, our study demonstrates B cells to be essential and 
multifunctional in ICI driven antitumor responses via secreting antibody and helping T cell 
responses. The impact of B cell inhibition upon T cells is likely due to antigen presentation, as 
both central and effector memory CD4+ subsets were impacted by inhibiting B cell function. 
This reduced CD4+ T cell activity potentially explains the reduction in CD8+ T cells, which rely 
on CD4+ cells for activation and proliferation. Given the reduced efficacy of ICI after depletion 
of T cell subsets, antigen presentation to amplify immune responses is likely a key function of B 
cells.    
 
In addition to support of T cells, antibody generation by B cells was also key to ICI response 
in our GEMMs. Secreted IgG can elicit cytotoxicity by several mechanisms such as complement 
or cellular cytotoxicity mediated by Fc-receptor activation [288]. These functions likely explain 
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the loss of ICI efficacy we observed when using an Ig secretory deficient mouse model, or by 
blocking antibody activity using anti-CD16. The clonal restriction observed in BCR/IgG 
repertoire profiling, and serum IgG binding assays, imply the antibodies induced by ICI to be 
specific to model antigens. Together, these results depicting B cell mediation of antitumor 
responses through T cell activation and antibody generation presents B cells (as well as Tfh 
cells) as an attractive cellular target to be leveraged to improve ICI therapy effectiveness. 
 
Collectively, this study uncovers B cells and Tfh T cells as direct mediators of ICI response in 
our mouse models, and possibly in humans as well. Of note, scRNA-seq predicted a role for 
IL21 in B cell activation. While scRNA-seq may not prove which cytokines/receptors mediate a 
biological process, our follow up studies verified that ICI induction of IL21 and Tfh cells 
activated B cells and class switching.  Indeed, our analysis suggest these mechanisms may also 
extend to chemotherapy in TNBC patients, and to trastuzumab response in HER2+ breast cancer 
patients. Moreover, our group has formerly noted that B cells are predictive of trastuzumab 
response[266]. Taken together, these findings suggest the importance of the immune system 
across multiple distinct classes of anti-cancer agents, and cancer types, and where the active and 
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Figure 3.1- Intrinsic tumor and immune cell gene expression features in mouse mammary 
tumor models. Gene expression patterns of tumor and immune cell features. The triangles mark 
the position of major tumor models in the heatmaps. Black bars mark tumor lines from each 
model. Blue bars to the side note models in the treatment study. Below this, blue bars show 
samples getting anti-PD1/anti-CTLA4 therapy. The heatmaps show median expression values for 
subtype and immune cell signatures. The lower heatmap is expression values of immune 







Figure 3.2- Intentional elevation of tumor mutation burden sensitizes tumors to anti-
PD1/anti-CTLA4 combination therapy. (A) Left: Total somatic mutation burden in ectopic 
Apobec3 overexpressing lines and parental control lines. Right: somatic mutation burden from 
parental lines and lines exposed to short-wave ultra violet radiation. (B) Survival and 10 day 
acute response to anti-PD1/anti-CTLA4 immune checkpoint therapy in mice bearing tumors 
from parental T11 cell line and KPB25L cell lines. (C) Survival and acute response in T11-
Apobec and KPB25Luv lines. (D) Immune cell gene expression signature expression levels. (E) 
Immune checkpoint gene mRNA expression levels. (F) Left, interferon gamma signature 
expression levels. Right, serum interferon gamma as measured by ELISA. In boxplots, bars mark 
the average and standard deviation. The p-values mark are two-tailed from unmatched T-tests. In 
Kaplan-Meier plots, p-values are from Log-rank (Mantel-Cox) tests. Signature levels are 


















Figure 3.3- Signature testing on human studies. (A) Signature development pipeline. The 
immune activity signature is noted by the blue bar near the heatmap. The B cell/T cell co-cluster 
is marked by the purple bar and featured. (B) Boxplot for the B cell/T cell co-cluster in 
pretreatment samples from a human melanoma study of anti-CTLA4 therapy[240]. (C) Boxplot 
of the B cell/T cell co-cluster in pretreatment samples from a human melanoma study of anti-
PD1/ anti-CTLA4 therapy [262]. (D) Boxplot of the B cell/T cell co-cluster in pretreatment 
breast cancer samples from CALGB40601, trastuzumab arm [266]. (E) Boxplot of the B cell/T 
cell co-cluster in pretreatment samples from the human breast cancer dataset GSE32646, P-FEC 
= neoadjuvant paclitaxel followed by 5-fluorouracil/epirubicin/cyclophosphamide[263]. (F) 
Boxplot of the B cell/T cell co-cluster in pretreatment samples from the human breast cancer 
iSPY clinical trial; A/C/T arm = Doxorubicin hydrochloride and cyclophosphamide, followed by 
treatment with paclitaxel[265]. (G) Boxplot of the B cell/T cell co-cluster in pretreatment 
samples from the TNBC NCT 01560663 clinical trial[264]. Boxplots mark the mean and 
standard deviation. All panels except C, the p-values show two-tailed p-value from standard T-






Figure 3.4- Features of response to anti-PD1/anti-CTLA4  therapy in murine tumors. (A) 
RNA-seq signatures for sensitive tumors at 7 days (5mm= day 0/ treatment initiation) without or 
with anti-PD1/anti-CTLA4 therapy. (B) Flow cytometry results for CD8+ cells and CD4+ using 
memory markers (Cd44, Cd62L). (C) Flow cytometry of tumor infiltrating B cells with or 
without ICI therapy. On the right shows staining for B cells gated for activation markers. (D) 
Quantification of flow cytometry for activated B cells (B220+, Cd19+ or Cd20+, MHC II +, 
Cd80+ or Cd86+). (E) IHC staining for IgG-kappa chain in KPB25Luv tumors. (F) IgG binding 
assay showing serum-IgG binding (Fitc+) to KPB25Luv cells. (G) Quantification of Fitc+ cells in 
IgG binding assay for KP25Luv cells and off-target binding. (H) Quantification of Fitc+ IgG 
binding assay for T11-Apobec cells following reabsorption on off-target cells. In boxplots, bars 
signify the mean and standard deviation. The p-values are two-tailed from unmatched T-tests. 






Figure 3.5- Single cell RNA-seq of KPB25Luv tumors with or without anti-PD1/anti-
CTLA4 therapy. (A) TSNE analysis of cells that passed quality checks in KPB25Luv tumors. 
Cells/clusters are color coded by the major cell type found.(B) The distribution of cell types 
between treated and non-treated tumor cells. (C) Heatmap of mRNA variance between treated 
and non-treated tumor cells. (D) Violin plot of Cd8a mRNA levels. (E) Heatmap of significant 
genes (plus Pdcd1, Ctla4) in clusters of ICI treated CD8+ T cells. (F) Classification of ICI treated 
CD8+ T cell clusters. Classes are coded to the heatmap in E. (G) Feature plot showing 
expression of key genes across CD8+ T cell clusters. (H)  Violin plot of Cd4 mRNA levels. (I) 
Heatmap of significant genes(plus Ctla4) in clusters of ICI treated CD4+ T cells (n=20) (J) 
Classification of ICI treated CD4+ T cell clusters. Classes are coded to the heatmap in I. (K) 
Feature plot showing expression of key genes across CD4+ T cell clusters. (L) Violin plot of 
Cd20 mRNA levels.(M) Heatmap of significant genes in clusters of ICI treated B cells (n=20). 
(N) Classification of ICI treated B cell clusters. Classes are coded to the heatmap in M. (O) 
Feature plot showing expression of key markers in B cell clusters. (P) Results of 5’ TCR/BCR 
sequencing. In bar-plots, read counts for each clone is shown along with the calculated Shannon 
entropy (where higher values indicate high diversity/low clonality). Above each bar, the percent 
of all reads occupied by a clone(s). Heatmap values are depicted in the legend. Violin plots mark 






Figure 3.6- Immune cell depletion of key immune cell populations during immune 
checkpoint therapy. (A) Survival for mice given anti-PD1/anti-CTLA4 therapy with anti-Cd4 
or anti-Cd8 antibodies (B) 21 day acute response for mice given anti-PD1/anti-CTLA4 with anti-
Cd4 or anti-Cd8 antibodies. (C) Survival for mice given anti-PD1/anti-CTLA4  therapy with 
anti-Cd19 or anti-Cd20 antibodies (D) 21 day acute response for mice given anti-PD1/anti-
CTLA4 with anti-Cd19 or anti-Cd20 antibodies. (E) Flow cytometry results for T cell subsets 
after 7days of aPD1/aCTLA4 therapy with/without anti-CD19 based B cell inhibition.  In 
Kaplan-Meier plots, p-value show results of Log-rank (Mantel-Cox) tests. Boxplots show the 






Figure 3.7- Testing B Cell Activation and IgG Functionality during immune checkpoint 
therapy.  
(A) Flow cytometry for B cells in KPB25Luv tumors after 7 days of ICI and CD4+ T cell 
depletion. (B) Quantification of results from A. (C) X-Y plot of IgG and CIBERSORT Tfh T cell 
signatures in mRNA-seq of sensitive tumors at day 7. (D) Boxplot of CIBERSORT Tfh T cell 
signature levels in sensitive tumors (mRNA-seq) at day 7. (E) X-Y plot of IgG signature and Il21 
mRNA in mRNA-seq of sensitive tumors at day 7. (F) Boxplot of Il21 mRNA levels in sensitive 
tumors (mRNA-seq) at day 7. (G) Flow cytometry results for activated B cells in T11-Apobec & 
KPB25Luv tumors during Tfh/IL21 blockade. (H) IHC staining for IgG-kappa chain in 
KPB25Luv tumors during Tfh/IL21 blockade. (I) Survival for T11-Apobec bearing mice during 
ICI therapy and Tfh/IL21 blockade. (J) Survival for KPB25Luv bearing mice during ICI therapy 
and Tfh/IL21 blockade. (K) Western blot for serum IgG in Igmi and Balbc mice with T11-
Apobec tumors. The blue bars mark Igmi mouse sera, purple note Balbc sera. (L) 21 day acute 
response in Igmi and Balbc control mice with T11-Apobec tumors. (M) Survival of Igmi mice 
withT11-Apobec tumors and treated with anti-PD1/anti-CTLA4  therapy in contrast to Balbc 
controls. (N) Survival in KPB25Luv tumor bearing mice treated with ICI therapy or ICI therapy 
with CD16/32 blockade . In Kaplan-Meier plots, p-values are from Log-rank (Mantel-Cox) tests. 
Boxplots show the mean and standard deviation. The p-values are two-tailed from standard T-
tests. In X-Y plots, p-values were determined by linear regression analysis.  The asterisks denote 













Figure 3.8- Somatic mutation burden and response to immune checkpoint therapy in 
mouse models of triple negative breast cancer. Related to Figure 2. (A) Top, overall survival 
of non-treated tumors and treated tumors on anti-PD1/anti-CTLA4 therapy and lower panel 
showing 10-day acute response to anti-PD1/anti-CTLA4 therapy demonstrated models that are 
resistant to immune checkpoint therapy. (B) Somatic mutation burden as called by strelka in our 
mouse model cohort, with samples being color coded for response as depicted. (C) Neoantigen 
burden as predicted by pVac-Seq; strong binders were determined by best predicted binding 
threshold <500mM and weak binders by predicted <2500mM binding threshold. (D) Tumor 
mutation burden in resistant tumors and human cancers from the depicted TCGA study cohorts.  
(E) Top, overall survival of non-treated and treated tumors on anti-PD1/anti-CTLA4  therapy and 
lower, 10-day acute response to anti-PD1/anti-CTLA4  therapy demonstrated KPB25L-Apobec 
and T11-UV as models that are sensitive to immune checkpoint therapy. (F) Single agent testing 
of anti-Pd1 or anti-Ctla4 in comparison to anti-PD1/anti-CTLA4 combination therapy, with 
overall survival on top and 10-day acute response showed on the lower. (G) Testing isotype 
control antibodies in the KPB25L and T11-Apobec models for anti-Pd1 and anti-Ctla4 shows no 
impact on top, overall survival, and lower, acute response. In Kaplan-Meier plots, p-value mark 
results of Log-rank (Mantel-Cox) test. In box and whiskers dot plots, the bar signify the average 
and standard deviation from average. The p-values represent two-tailed p-value from standard 






Figure 3.9- In vitro characterization of mouse tumor-derived cell lines mutagenized by 
Apobec3 or by exposure to short-wave ultra violet radiation. Related to Figure 2.  (A) 
Apobec3 isoform2 over-expression in KPB25L-Apobec as compared to KPB25L parent (note 
the counts that isoform appropriately span/overlap exons 4 and 6 were identified using IGV 
sashimi plots and reported here). (B) Testing a proliferation signature[260] for median 
expression in Log2 normalized, uncentered, gene expression demonstrates no difference in 
proliferation features in KPB25L, KPB25L-Apobec, and KPB25Luv gene expression. (C) Cell 
counting experiment to measure proliferation in vitro to compare KPB25L parent, KPB25Luv 
(UV mutagenized), and KPB25L-Apobec. (D) Apobec3 isoform2 over-expression as compared 
to T11 parent (note the counts that isoform appropriately span/overlap exons 4 and 6 were 
identified using IGV sashimi plots and reported here). (E) Testing a proliferation signature[260] 
for median expression in Log2 normalized, uncentered, gene expression demonstrates no 
difference in proliferation features in T11 parent, T11-Apobec, and T11-uv gene expression. (F) 
Cell counting experiment to measure proliferation in vitro to compare T11 parent, T11-uv (UV 






Figure 3.10- Supervised analysis of anti-PD1/anti-CTLA4 therapy sensitive and resistant 
mouse mammary tumors. Related to Figure 3. (A) An expression heatmap showing values of 
B cell/T cell co-cluster signature genes across RNA-seq data of sorted immune cells. Across the 
top, sample names as described on http://rstats.immgen.org/MyGeneSet_New/index.html. Below 
this, the color bar depicts the position of major immune cell types, as keyed on the right hand 
side. Immediately below, B cell and T cell subsets are depicted as color-coded. The heatmap 
depicts high expression to low expression as illustrated by the color bar. Heatmaps, clustering, 
and results generated using http://rstats.immgen.org/MyGeneSet_New/index.html.  (B) Boxplot 
for expression of the immune activity cluster in pretreatment samples from a human melanoma 
study of anti-CTLA4 therapy [240]. (C) Boxplot for the immune activity cluster in pretreatment 
samples from a human melanoma study of anti-PD1/ anti-CTLA4 therapy [262]. (D) Boxplot for 
expression of the immune activity cluster in pretreatment breast cancer samples from 
CALGB40601, trastuzumab arm [266]. (E) Boxplot for expression of the immune activity cluster 
in pretreatment samples from the human breast cancer dataset GSE32646, excluding Her2+ 
samples; P-FEC = neoadjuvant paclitaxel followed by 5-
fluorouracil/epirubicin/cyclophosphamide[263]. (F) Boxplot for expression of the immune 
activity cluster in pretreatment samples from the human breast cancer iSPY clinical trial; A/C/T 
arm = Doxorubicin hydrochloride (Adriamycin) and cyclophosphamide, followed by treatment 
with paclitaxel[265]. (G) Boxplot for expression of the immune activity cluster in pretreatment 
samples from the TNBC NCT 01560663 clinical trial[264]. In boxplots, bars represent the 
average and standard deviation. The p-values represent two-tailed p-value from standard 
unmatched T-tests; exception in panel C where Mann-Whitney tests where used due to non-






Figure 3.11- Validation of immune cell signatures and demonstration of key immune 
features for individual tumor cell lines. Related to Figure 4. (A) Gene expression signatures 
and flow cytometry features for T cells and B cells in tumors of the T11-Apobec tumor bearing 
mice without or with anti-PD1/anti-CTLA4 (or single agent) therapy. (B) Gene expression 
signatures and flow cytometry features for T cells and B cells in tumors of mice bearing 
KPB25Luv tumor model without or with anti-PD1/anti-CTLA4 (or single agent) therapy. (C) 
Gene expression signatures and flow cytometry features for T cells in mice bearing the T11-uv 
tumor model without or with anti-PD1/anti-CTLA4 therapy. (D) IgG binding assay using serum 
from ICI treated KPB25Luv bearing mice. Lines depict matched sera testing on parent and 
mutagenized cells. (E) Flow cytometry comparing the number of CD8+ T cells with effector 
memory status in tumors of mice receiving the parent T11 line or T11-Apobec without or with 
anti-PD1/anti-CTLA4 therapy. (F) A comparison of the CD8+ T cells as a ratio to CD4+ Foxp3+ 
T cells in individual tumor lines without or with anti-PD1/anti-CTLA4 therapy. All panels depict 
tumors isolated following 7 days past the therapeutic start point of a 5mm diameter tumor. In bar 
plots, the bar represents the average and standard deviation from average. The p-values represent 






Figure 3.12- Single cell RNA-seq of T11-Apobec tumors with or without anti-PD1/anti-
CTLA4 therapy. Related to Figure 5.  (A) TSNE analysis of all cells that passed quality 
control in untreated and aPD1/aCTLA4 treated T11-Apobec tumors. Cells are color coded 
according to dominant cell type (identified by gene expression profiles) found in each cluster.(B) 
The numerical distribution of cell types between treated and non-treated tumor cells. (C) 
Heatmap depicting supervised analysis comparing treated and non-treated tumor cells. (D) Violin 
plot of Cd8a mRNA levels in cells of treated and non-treated tumor cells. (E) Heatmap for 
results of Seurat marker analysis of significant genes between clusters of CD8+ T cells (as 
identified in A), shown are significant genes along with checkpoint Pdcd1 and Ctla4 mRNA 
(n=20). (F) Classification of CD8+ T cell clusters based on gene expression profiles. Note the 
color coding is also mapped above the heatmap in E. (G) Feature plot showing expression of key 
markers across CD8+ T cell clusters. (H)  Violin plot depicting Cd4 mRNA levels in cells of 
treated and non-treated tumor cells. (I) Heatmap depicting results of Seurat marker analysis of 
significant genes between clusters of CD4+ T cells (as identified in A), shown are significant 
genes along with checkpoint Pdcd1 and Ctla4 mRNA (n=20) (J) Classification of CD8+ T cell 
clusters based on gene expression profiles. Color coding is also mapped to the heatmap in I. (K) 
Feature plot showing expression of key markers across CD4+ T cell clusters. (L) Violin plot of 
Cd20 mRNA levels in cells of treated and non-treated tumor cells.(M) Heatmap for results of 
Seurat marker analysis of significant genes between clusters of B cells (as identified in A; n=20). 
(N) Classification of B cell clusters based on gene expression profiles. Color coding is also 
mapped to the heatmap in M. (O) Feature plot showing expression of key markers across B cell 
clusters. (P) Results of 5’ TCR/BCR sequencing. For each boxplot the number counts detected 
for each clone, as identified by MIXCR, is shown along with the calculated Shannon entropy 
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(where higher values indicate high diversity/low clonality). Above each bar, indicates the percent 
of all reads occupied by a clone(s). Note the fourth bar groups all clones not represented by the 
top 3 clones. All heatmap values can be found according the legend. All violin plots depict the 
















Figure 3.13- Flow cytometry analysis of targeted immune cell depletion in tumors and 
spleens in tumor bearing mice receiving anti-PD1/anti-CTLA4 therapy. Related to Figure 
6. (A) Flow cytometry plots of CD4+ T cell depletion at tumor and spleen in tumor bearing mice 
receiving anti-PD1/anti-CTLA4 therapy. (B) Flow cytometry plots of CD8+ T cell depletion at 
tumor and spleen in tumor bearing mice receiving anti-PD1/anti-CTLA4 therapy. (C) Flow 
cytometry plots of CD19 inhibition at tumor and spleen in tumor bearing mice receiving anti-
PD1/anti-CTLA4 therapy. (D) Flow cytometry plots of CD20+ B cell depletion at tumor and 






Figure 3.14- Testing B Cell Activation and IgG Functionality during immune checkpoint 
therapy. Related to Figure 7.  (A) Left: X-Y plot depicting relationship between a IgG 
signature and Th1 T cell signature in sensitive tumors (mRNA-seq) at day 7 with or without 
therapy. Right: Boxplot of expression of a T helper 1 signature in sensitive tumors (mRNA-seq) 
at day 7 with or without therapy. (B) Left: X-Y plot depicting relationship between the IgG 
signature and a T helper 2 cells in sensitive tumors (mRNA-seq) at day 7 with or without 
therapy. Right: Boxplot of expression of a T helper 2 signature in sensitive tumors (mRNA-seq) 
at day 7 with or without therapy. (C) Feature plot of T helper 17, 1, or 2 cytokines in KPB25Luv 
tumor CD4+ T cell clusters. (D) Feature plot of T helper 17, 1, or 2 cytokines in T11-Apobec 
tumor CD4+ T cell clusters. (E) Quantification of flow cytometry for activated B cells (B220+, 
Cd19+, MHC II +, Cd80+ or Cd86+) in KPB25Luv tumors given aPD1/aCTLA4 therapy with or 
without IL21 blockade. (F) Quantification of flow cytometry for activated B cells (B220+, 
Cd20+, MHC II +, Cd80+ or Cd86+) in T11-Apobec tumors given aPD1/aCTLA4 therapy with 
or without IL21 blockade. (G) IHC staining for IgG-kappa chain in untreated,aPD1/aCTLA4 
treated, or IL21blocked aPD1/CTLA4 treated T11-Apobec tumors. (H) Left: Flow cytometry 
plot demonstrating diphtheria toxin depletion of Foxp3+ cells exclusively in T11-Apobec tumors 
implanted into the Foxp3-DTR GEMM.  Right top: Quantification of Tregs in WT and Foxp3-
DTR GEMMs (bearing T11-Apobec) given diphtheria toxin. Right bottom: flow cytometry 
quantification of activated B cells in Foxp3-DTR GEMMs given diphtheria toxin (DT) to deplete 
Tregs. (I) 21 day acute response for KPB25Luv bearing mice given ICI or ICI with IL21 blockade. 
(J) 21 day acute response for T11-Apobec bearing mice given ICI or ICI with IL21 blockade. (K) 
Top: IHC for CD3, B220, or CD20 on day 7 T11-Apobec tumors implanted into Igmi mice 
demonstrates these mice to be intact for B cells and T cells. Bottom: Western blot analysis of 
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serum IgM for Igmi mice (blue bars) or Balbc mice (purple bars) bearing T11-Apobec tumors. 
(L) Flow cytometry results for anti-CD16/32-FITC binding to splenocytes in mice either treated 
with anti-PD1/anti-CTLA4 combination therapy or anti-CD16/32 (shortened as anti-CD16) with 
anti-PD1/anti-CTLA4 . (M) Flow cytometry results for anti-CD16/32-FITC binding to cells in 
tumors of mice either treated with anti-PD1/anti-CTLA4 combination therapy or anti-CD16/32 
(shortened as anti-CD16) with anti-PD1/anti-CTLA4 . In X-Y plots, p-values were determined 
by linear regression analysis.  In box and whiskers dot plots, the bar represents the average and 




All animal work was conducted according to IACUC guidelines. All mice were allowed to 
mature to 12 weeks prior to injection. All tumor studies used female mice.  FVB and Balbc mice 
were ordered from Jackson Laboratories. Tumor transplants were syngeneic; KPB25L parental 
and mutagenized lines were orthotopically injected in FVB recipients and TP53-/- models (see 
Table 1) were orthotopically injected into Balbc recipients. To determine endogenous IgG 
functionality, mice genetically engineered to be deficient in Ig secretion (Igmi mice) were used 
with T11-Apobec tumors[277]. Mice were bred to homozygosity; genotyping primers: 
5’GAGACGAGGGGGAAGACATTTG3’,5’CCTTCCTCCTACCCTACA AGCC3’. Injections 
were done as single cell suspensions of approximately 100,000 cells in Matrigel to the number 
four mammary gland. KPB25L, KPB25Luv, KPB25L-Apobec, T11, T11-UV, and T11-Apobec 
exist as cell lines. Parental lines are derived from transplantable tumors, which are present in the 
Figure 1 cluster analysis. Other models are tumor transplant lines and were digested with the 
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Miltenyi tumor dissociation kit to establish cell suspensions (130-096-730). Mice were examined 
2-3 times weekly for tumor outgrowth and upon tumor diameter of 5mm, mice were randomly 
assigned to treatment or control groups. Caliper measurement continued at a 2-3 per week 
frequency until end-stage (tumor diameter = 20mm).  
 
Antibody Regimens 
Antibody was delivered using 100ul volumes and injected intraperitoneally bi-weekly for the 
following: anti-CTLA4 (125 ug, bioxcel BE0164), anti-PD1 (10mg/kg, bioxcel BE0146), anti-
CD19 (400ug, bioxcel BE0150), anti-CD8 (500ug, bioxcel BE0004), anti-CD4 (500ug, bioxcel 
BE0003), and anti-CD16/32 (500ug, bioxcel, BE0307), anti-IL21 ( 100ug, ThermoFisher, 16-
7211-82) . Mice received one tail vein injection of anti-CD20 (Ultra-LEAF Purified anti-mouse 
CD20, item 152104, reported depletion of 30 or more days) and then given biweekly doses of the 
anti-PD1/anti-CTLA4 combination therapy. Depletion was confirmed by flow-cytometry in the 
context of combination anti-PD1/anti-CTLA4 treatment for 7 days. 
 
In vitro cell line studies 
T11 cell lines and mutagenized versions were culture in Gibco RPMI media supplemented 
with 5% fetal bovine serum and 1X penn-strep. KPB25L cell lines and mutagenized versions 
were cultured in Gibco HUMEC media with supplement. Media was supplemented with 5% fetal 
bovine serum and 1X penn-strep. To generate Apobec3 overexpressing lines, we purchased a 
vector that overexpresses the mouse Apobec3 ORF under the control of the EF1A promoter from 
vectorbuilder (VB170110-1098xwd). This isoform lacks exon 5, thus allowing Apobec3 
overexpression to be determined by examining read alignments spanning exon 4 and exon 6 
using sashimi plots on IGV. Cells were stably transfected using FUGENE. To allow for the 
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accumulation of mutations, KPB25L-Apobec cells were cultured for 1 month prior to whole 
exome sequencing and experimental studies (in vivo and in vitro). Similarly, T11-Apobec cells 
were cultured for two months prior to whole exome sequencing and experimentation. The 
matching parental lines (T11, 2 months ; KPB25L, 1 month) were kept in culture for the same 
amount of time prior to sequencing to control for other mutation sources (i.e.- p53 loss, BRCA1 
loss). For mutagenization by ultra-violet light, exposure was received by placing cells cultured in 
10cm plate (lid removed) underneath a germicidal UV lamp that emits 253.7 nm lightwaves and 
runs at 100mw per cm2 at maximum to 40 mw per cm2 at minimum. Exposure was done in 30 
second increments. Total exposure time for KPB25Luv was 1 min and 30 seconds and 5 minutes 
for T11-UV. Cells were allowed to recover to 70-90% confluency and then cultured for 10-14 
days prior further experimentation. To measure cell proliferation, we performed a cell counting 
experiment in triplicate. On day 0, cells were seeded and then cells were counted the next 3 days 
using trypan blue stain and countess cell counter.  
 
Flow cytometry 
Tumors were digested into single suspensions using the Miltenyi tumor dissociation kit (130-
096-730) and Miltenyi gentleMACs dissociator. Spleen was placed in DMEM for gentleMACS 
dissociation.   Cells were washed three times and resuspended in PBS diluted live/dead staining 
dye (Fixable Viability Stain 700, BD) for 35 minutes on ice followed by washing with PBS. Fc 
Block (clone 2.4G2; Bioxcell) diluted with staining buffer (PBS with 10% FCS) was then used 
for blocking for 20 min on ice. Fluorochrome labeled antibodies diluted with staining buffer 
were added and staining was continued for 40 min on ice. After a washing step, cells were 
fixed/stored in a 1 % PFA solution until analysis. When staining for T cells, stained cells were 
then permeabilized for FoxP3 staining using eBioscience FoxP3 staining kit according to 
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manufacturer’s instructions and stained with anti-Foxp3 antibody. Fluorochrome labeled 
antibodies are listed in the methods table. T cells staining antibodies were: anti-CD45, CD3, 
CD4, CD8, CD62L, CD44, Foxp3. The fluorochrome labeled antibodies for B cells staining 
were: anti-CD45, CD19, CD20, B220, MHCII, CD80, CD86. Flow cytometry sample acquisition 
was performed on a LSRFortessa (BD), and analysis was performed using FlowJo software 
(TreeStar). The gating strategy is as illustrated in the supplemental methods figure 1. Cell 





Gated cell number= 
Events of gated cells 








Figure 3.15 Flow cytometry gating strategy. (A) Gating strategy for CD20+ Activated B-cells as 
shown in the T11-Apobec model. (B) Gating strategy for CD19+ Activated B-cells as shown in 
the KPB25Luv model. (C) Gating strategy for T-cells (CD4+ or CD8+) to examine memory 
markers.(D) Key for to interpret memory markers profiles in T-cells.  
 
ELISA for IFNy detection 
An Elisa was performed according to manufacturer instructions using the Mouse IFN-γ ELISA 
Kit II (Cat: 558258, BD Biolegend) to compare T11 parental and T11-Apobec serum from non-
treated mice harboring these respective tumors.   ELISA plates were scanned on Synergy2 
Microplate Reader (Biotek Instruments Inc). Standards and samples absorbance and optical 





Immunohistochemistry used paraffin embedded tumors from mice that received treatment for 
7 days. The untreated control samples were matched time points from mice bearing tumors that 
had reached 5mm and collected 7 days later. All immunohistochemistry and embedding were 
conducted by the UNC Animal Histopathology Core. The IgG staining used a Rabbit anti-mouse 
monoclonal [RM103] to IgG-Kappa light chain (ab190484). The anti-CD20 stain used ab64088. 
The anti-B220 staining used ab64100. The anti-CD3 staining used ab5690.  Antigen retrieval 
used Ventana’s CC1 (pH 8.5), for 40 minutes @ 95 degrees Celsius and given a block (Rodent 
Decloaker 10X, Biocare, BM#RD913L) for 1 hour, followed by a peroxidase block for 12 
minutes. Next, primary antibody diluent (1:700) was added for 1 hour at room temperature using 
Discovery AB Diluent (760-108), followed by a post-peroxidase block for 12 minutes. 
Secondary antibody was added (Discovery OmniMap anti Rabbit HRP, 760-4311, Ready to Use) 
for 32 minutes at room temperature. The samples were treated with DAB, Hematoxylin II for 12 
minutes, and then Bluing Reagent for 4 minutes. Slide staining used Ventana’s Discovery Ultra 
Automated IHC staining system. 
 
IgG-Binding Assay 
The IgG binding assay was based upon an established protocol[289]. Tumor bearing mice 
were euthanized following 7 days of therapy (or time matched in non-treated control). Whole 
blood was collected by cardiac puncture, blood was allowed to coagulate, and tubes were spun 
for 10 minutes at 4 degrees Celsius. The supernatant was collected to provide a source of serum 
for IgG binding tests. Cells were washed three times using centrifugation and PBS and 
resuspended in 100 μL PBS buffer with the addition of 2 μL of serum. Incubation was one on ice 
for 45 minutes. On target testing used serum that came from a KPB25Luv tumor bearing mouse 
 
 148 
on KPB25Luv cells from culture or serum from T11-apobec bearing mouse on T11-Apobec cells 
from tissue culture. Off-target binding was assessed by cross reactivity with opposite 
combinations of the aforementioned cells. Since T11-Apobec cells showed high cross-reactivity 
a pre-absorption protocol was followed to remove autoantibodies from the assay. Pre-absorption 
was done by incubating serum with the T11 parental cell line for 45 minutes on ice. Cells were 
then centrifuged and the supernatant collected and then incubated with T11-apobec cells for 45 
minutes on ice. Background was assessed using the antibody. To detect IgG binding to cells, a 
FITC-tagged anti-mouse IgG (Thermofisher Scientific) was used. Background was assessed by 
using an isotype control IgG antibody.  
 
Western blot 
Mouse serum was harvested from tumor bearing Igmi and Balbc mice by cardiac puncture. In 
addition, serum was obtained from non-tumor bearing mice.  Serum protein was quantified using 
DC™ Protein Assay (Bio-Rad, Hercules CA) and all samples were diluted to equal concentration 
using water. Samples were separate by electrophoresis on 4-15% Tris-Glycine polyacrylamide 
gels (Bio-Rad), transferred to Hybond® PVDF membrane (MilliporeSigma, St. Louis MO), 
blocked for 1 hour at room temperature in 5%BSA (MilliporeSigma) in TBS with 0.05% Tween-
20. The membrane was incubated with either IgG1 HRP-conjugated (OBT1508P) or IgM MU 
CHAIN HRP-conjugated (5276-2504) antibody (Bio-Rad) for 2 hours while rocking at room 
temperature. The membrane was washed three times in TBS with 0.05% Tween-20 and exposed 
to SuperSignal chemiluminescent substrate (ThermoScientific Scientific, Waltham MA). The 






mRNA was isolated using the Qiagen RNeasy kit according to manufacturer protocol. mRNA 
quality was assessed using the Agilent Bioanalyzer and libraries for mRNA-seq made using total 
RNA and the Illumina TruSeq mRNA sample preparation kit. Paired end (2x50bp) sequencing 
was performed on the Illumina HiSeq 2000/2500 sequencer at the UNC High Throughput 
Sequencing Facility. Resulting fastq files were aligned to the mouse mm10 reference genome 
using the STAR aligner algorithm[290]. Resulting BAM files were sorted and indexed using 
Samtools and quality control was performed using Picard. Transcript read counts were 
determined was performed using Salmon[291]. Genes with no reads across any of the samples 
were removed. Salmon gene-level counts upper quartile normalized[292]. Genes with an average 
expression less than 10 were filtered from the dataset. Genes were log2 transformed using 
Cluster 3.0 and zeros were preserved for signature analysis. Data was then median centered and 
column standardized to establish the matrix in working form for statistical analyses. Hierarchical 
clustering was done using Cluster 3.0[293] and viewed in Java Tree View. Supervised gene 
expression analyses were performed using Significance Analysis of Microarrays [294] and an 
FDR of 5%. Gene expression signatures were calculated as the median expression of all the 
genes in the signature as published[260]. In signatures analysis, mouse genes were converted to 
human using BioMart. Univariate and multivariate analyses were performed using standardized 
signature scores in R-studio using logistic regression. Boxplots and KM plots were generated in 
graph pad prism. Sashimi plots demonstrating Apobec3 overexpression were done using IGV. 
All murine RNAseq data, totaling 290 samples, have been deposited into GEO under the series 
ID of  GSE124821, GSE118164 (MMMTV-Wnt tumors[295]), the CDH1/PIK3Ca tumors were 
published and included as RNA-seq data in this study [296], and raw sequence files in SRA 
under PRJNA506275.  
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Single Cell RNA-Seq 
Single cell suspensions were generated using the Miltenyi mouse tumor dissociation kit and a 
gentleMACS tissue dissociator.  Single cell suspensions were input to a 10x Genomics 
Chromium machine to establish single-cell gel beads in emulsion (GEMs) for directed retrieval 
of approximately 5000-10000 cells. Single-cell RNA-Seq libraries were primed using the 
following Single Cell 3’ Reagent Kits v2: Chromium™ Single Cell 3’ Library & Gel Bead Kit 
v2, PN-120237; Single Cell 3’ Chip Kit v2 PN-120236 and i7 Multiplex Kit PN-120262" (10x 
Genomics). Protocols were performed as directed in the Single Cell 3’ Reagent Kits v2 User 
Guide (Manual Part # CG00052 Rev A). Libraries were sequenced on an Illumina HiSeq 4000 as 
2 × 150 paired-end reads. The Cell Ranger Single Cell Software Suite, version 3.0.2 was used for 
de-multiplexing, barcode ad UMI processing, and single-cell 3′ gene counting. Specific details 
and instructions to run Cell Ranger can be found at: https://support.10xgenomics.com/single-
cell-gene-expression/software/pipelines/latest/what-is-cell-ranger). Reads were mapped to the 
mm10 genome.  
 
Cell ranger output and single cell RNA-seq data were analyzed using the R-package Seurat 
version 2.3.4. Here quality control parameters were utilized to filter dead-cells, doublets, and 
cells without the minimal number of expressed genes. Preprocessing for clustering and marker 
gene analysis was as follows. Raw UMI counts were normalized using log-normalization. 
Variable genes were identified using the standard deviation from the mean (using only non-zero 
values). Data were scaled and centered by regressing on library size and mitochondrial mRNA 
counts. Principle component analysis (PCA) was performed using variable genes. For TSNE 
analysis, clusters were identified using shared nearest neighbor (SNN) and reduction was 
performed based on PCA using the first 20 principle components.  Marker genes defining each 
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cluster were identified using Seurat’s FindAllMarkers function, which employs a Wilcoxon rank 
sum test to determine significant genes. These marker genes were used to assign cluster identity 
to individual cell types. In order to establish identity the top 200 genes were analyzed on 
established gene expression data for immune cells which can be obtained at 
http://rstats.immgen.org/DataPage/ [297]. In addition, cell clusters and markers were analyzed 
using the CellMarker database[298]: http://bio-bigdata.hrbmu.edu.cn/CellMarker/index.jsp, 
published signatures[259, 299, 300], and existing literature [271, 275, 301]. The single cell 
RNAseq data are available at the Gene Expression Omnibus: GSE136206. 
 
5’ TCR/BCR Sequencing and Repertoire Analysis 
Whole tumor mRNA coming from T11-apobec and KPB25Luv models treated for 7 days with 
ICI therapy was used as input for sequencing using each SMARTer Mouse TCR a/b Profiling Kit 
and SMARTer Mouse BCR IgG H/K/L Profiling Kit. First strand DNA-synthesis, amplification, 
and library generation followed protocol listed in the user manual. Following library selection 
additional cleanup utilized pippin prep and selection of fragments 400-900 bp. Paired-end, (2 x 
300 bp) libraries were sequenced on the Illumina miSEQ next generation sequencer. Following 
demultiplexing, the resulting fastq files were analyzed using MIXCR[302], version 2.1.9-6. Top 
chain specific clone counts were extracted from resulting clones files and designated as those 
most expressed/highest numbers of counts detected. MIXCR determined clonotypes and their 
relative abundance were used to calculate shannon entropy[303-305], a diversity index where 
lower entropy scores relate to low diversity/clonal restriction. Shannon entropy was calculated 





External Gene Expression Data Analysis 
Microarray data from Neoadjuvant chemotherapy treated breast tumors was downloaded from 
GEO as GSE32646[263], Her2+ samples were excluded. Microarray data for the ISPY data was 
downloaded from the UNC microarray database and is also available as GSE22226 [265]. 
Samples were limited to those in the A/C/T arm, normal-like samples were removed.  Data was 
median centered and column standardized prior to signatures analysis. Gene expression RNA-
Seq data from the clinical trial CALG40601 was downloaded from GEO as GSE116335[266]. 
Samples from the trastuzumab arm only were analyzed. The RNA-seq data from the melanoma 
clinical trial of ipilimumab was downloaded from DbGAP phs000452.v2.p1[240]. RNA-seq data 
for NCT01560663 is published [264].  Fastq files were aligned to hg38.d1 genomes using 
STAR[290]. Resulting BAM files were sorted and indexed using Samtools and quality control 
was performed using Picard. Transcript read counts were determined was performed using 
Salmon[291, 306]. For RNA-Seq datasets, genes with no reads across any of the samples were 
removed. Salmon gene-level counts upper quartile normalized. Genes with an average 
expression less than 10 were filtered from the dataset. Genes were log2 transformed in Cluster 
3.0[293] and zeros were preserved for signature analysis. Data was the median centered and 
column standardized. CALGB40601 data was limited to pretreatment samples from the 
Trastuzumab arms only. PAM50 subtypes were used from the publication[266]. RNA-seq data 
for sorted immune cell types were queried using the online tool 
http://rstats.immgen.org/MyGeneSet_New/index.html[297]. Heatmaps were generated using the 
online tool and by selection of the depicted immune cell populations.  
 
For the single-cell RNA-seq melanoma dataset (GSE120575[262] ), levels of genes were 
quantified as Transcripts Per Million (TPM). For each cell, the gene expression measurement 
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was normalized by its total expression, multiplied by a scale-factor 10,000, and log-transformed. 
The collapsed gene signature score down to each sample was computed as follows: first, we took 
a sum of the normalized TPM values for each gene in the signature over all the cells in a given 
sample, then we calculated the median gene expression signature score for each sample. 
 
Whole Exome Sequencing 
For whole exome sequencing of mouse tumor, genomic DNA was isolated using a Qiagen 
DNeasy blood and tissue kit (cat: 69506). As controls, we isolated DNA from whole-mouse 
mammary glands from Balbc and FVB mice.  Libraries were constructed using the Agilent Sure 
Select XT kit with 1 ug of genomic DNA according to the manufacturer's protocol. DNA 
libraries were selected and amplified using the Agilent SureSelect Mouse All Exon kit. Final 
library size selection used approximately 300 bp fragments.  Quality of libraries and captured 
exomes were measured using the Agilent Tapestation DNA 1000 and High Sensitivity D1000. 
Paired end (2 x100 bp) sequencing was done using Illumina HiSeq 2000/2500 sequencer at the 
UNC High Throughput Sequencing Facility. Sequences from fastq files were aligned to the 
mm10 using BWA mem[307]. Biobambam was used to process BAM files[308] and Picard was 
used for quality assessment. Strelka was used to call mutations and generate VCF files[309]. 
Variant filtering used mouse mammary gland sequencing from the appropriate genetic 
background. Somatic mutations were considered provided the variants were not detected in 
unexpected regions (ie- introns), or had evidence for being “germline” (shared in models of a 
known common background). In addition, subjective filtering was performed using IGV (for 
example, low-level detection of potential variant in the normal control).  Neoantigen predictions 
were done using pvac-seq and followed published guidelines[310]. All raw DNA sequence fastq 




CHAPTER IV. FUTURE DIRECTIONS 
Immunotherapy has advanced the field of tumor therapy and is considered the “fifth pillar” of 
cancer therapy. However, despite the efficacy in treating a portion of patients, a larger subset of 
patient displays a limited response to immunotherapy. The goal of my research is to gain further 
understanding as to why some individuals do not respond to immunotherapy and to modify 
current immunotherapies to enhance the response rate to immunotherapy.  
 
My work identified known and unknown barriers to immunotherapy for breast cancer. Further, 
my work proposed and tested approaches to enhance immunotherapy for breast cancer. These 
studies not only advanced our understanding of breast cancer immunotherapy but also provided 
new avenues to enhance the efficacy of CAR-T cell therapy and immune checkpoint therapy 
towards breast cancer. However, further works remains to be done to better elucidate the 
mechanism of those immunotherapies and to apply these findings in the clinic.  
 
My studies revealed a synergistic effect of the STING agonist DMXAA to enhance the 
therapeutic efficacy of Th/Tc17 CAR-T cells against breast cancer through the modification of 
the TME by DXMAA. One main concern is the ability to translate this research into the clinic as 
DMXAA fails to activate human STING in clinical trials. As a result, future work needs to be 
focused on examining the efficacy of other STING agonists in augmenting the activity of 
Th/Tc17 CAR-T in human clinical trials. For example, ML RR-S2 CDA is a STING agonist that 
activates all human STING alleles as well as murine STING[162, 311]. Based on this, the 
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combination of ML RR-S2 CDA along with Th/Tc17 CAR-T cell therapy has the potential as a 
cancer therapeutic in patients. Furthermore, my studies indicate that complete breast tumor 
remission depends on the ablation of MDSCs. However, in the clinic, the depletion of MDSCs is 
challenging, and consequently, future studies on approaches to restrict human MDSC activity in 
the TME is critical for the elimination of breast cancer in patients. For example, the use of All-
Trans Retinoic Acid (ATRA) has been shown to polarize suppressive myeloid cells into a pro-
inflammatory phenotype in animal models and clinical trials[312], and the reduction of MDSCs 
by ATRA also correlated with enhanced T cell activity in carcinoma patients. Alternatively, the 
blockade of MDSC trafficking into the TME would also be an attractive strategy. This could be 
achieved by the neutralizing chemokines such as CCL2 or CXCL2[313, 314], which have been 
shown to be critical for the trafficking of MDSCs into the TME. The remission of solid tumors 
by Th/Tc17 CAR-T cell therapy requires multiple treatments, a STING agonist, anti-PD-1 mAb 
and MDSC depletion, which are difficult to achieve in human patients. Thus, it is important to 
optimize the combinatorial approaches for in vivo efficacy. This can be achieved by the revival 
of ex-vivo cultured CAR-T cells by diABZI compound 3 for their ability to produce cGAS to 
stimulate STING in the TME [315]or through knockdown of CXCL2 by CRISPR/Cas in CAR-T 
cells to block the recruitment of MDSCs into the TME.   
 
Additionally, my research only examined the function of a STING agonist in breast cancer. 
Therefore, it is unclear whether the use of a STING agonist can enhance Th/Tc17 CAR-T 
efficacy in other solid tumors. STING pathways exist across different solid tumor types, 
including melanoma and lung cancer[316]; therefore, a STING agonist in combination with 
CAR-T cell therapy has the potential to be applied to other solid tumors, but this requires testing.         
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My work also identified a critical role for antibody-secreting B cells in response to ICI 
therapy. Although the study provides novel insight into the mechanism of ICI therapy in breast 
cancer, many questions remain unanswered. 1) What factors contribute to the recruitment of Tfh 
cells into the TME since Tfh cells are mainly found in lymphoid structures? Recent studies have 
found that the formation of tertiary structures in the TME is linked with a positive response to 
ICI therapy[216, 217]. It would be of interest to determine whether the presence of Tfh cells in 
the TME of our mutagenized tumor model is also involved in tertiary structure formation. 2) 
What target(s) do the antibodies recognize? It has been proposed that increased tumor mutations 
produce more neoantigens that can then be recognized by T and B cells; however, the 
identification of these neoantigens remains challenging. The development of algorithms to 
predict neoantigens in the tumor genome provides a useful tool for the discovery of neoantigens. 
Alternatively, using sc-RNAseq to decipher the receptors of T or B cells that underwent 
expansion in the TME also has the potential to uncover tumor targets. The identification of 
neoantigens in mutated tumors has the potential to reveal novel biomarkers on tumor cells that 
can be targeted by immunotherapy.  
 
In the future, tumor immunotherapy will undergo a personalized therapy approach due to the 
heterogeneous nature of tumors across patients. In addition, the complicated mechanisms of 
tumor development indicate that a combinatorial therapeutic strategy for tumor treatment with 
sustained efficacy is needed. As a result, the understanding and development of novel 
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